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Foreword 
The MIT-Portugal PhD program in Bioengineering Systems comprises four 
years. The first one consists in a six-month period of class attendance in four 
Portuguese universities, followed by two lab rotations of 9 weeks each. The 
remaining three years are dedicated to the PhD project. The present thesis 
dissertation is the result of three years of research at the Animal Cell 
Technology Unit of ITQB–NOVA / iBET (Oeiras, Portugal) under the 
supervision of Prof. Paula Alves and Dr. Inês Isidro. The work presented in 
Chapter IV results from a one-year co-op in the Upstream Process 
Development group at Voyager Therapeutics, under the supervision of Dr. 
Peter Slade. Voyager Therapeutics is a gene therapy company developing 
treatments for central nervous system diseases based in Cambridge, MA 
(USA). 
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Abstract 
Since the first publication introducing the concept in 1972, gene therapy has 
had a series of success stories and setbacks. However, the recent rise of 
awareness, public interest, promising results in clinical trials and recent 
market approvals indicate that gene therapy has come to stay. Currently there 
is a growing interest from the biopharmaceutical industry in gene and cell 
therapy, mostly using viral vectors.  
Adeno-associated virus (AAV) are one of the most used vectors in gene 
therapy clinical trials, already culminating in three recent approvals of 
AAV-based gene therapies: Glybera in 2012, the first approved gene therapy 
in Europe, and Luxturna and Zolgensma in the US in 2017 and 2019, 
respectively. Their attractiveness stems from their apparent lack of 
pathogenicity; sustainable episomal gene expression; ability to transduce 
both quiescent and dividing cells from a myriad of tissues; and physical 
resistance to withstand the manufacturing process.  
To cope with the actual high vector dose requirements, there is a high 
demand for efficient and scalable recombinant AAV (rAAV) manufacturing 
platforms, from which the insect cell - baculovirus expression vector system 
(IC-BEVS) stands out. The IC-BEVS combines the high recombinant protein 
expression capabilities of the baculovirus vector with the GMP-amenable 
characteristics of insect cells: suspension growth to high cell densities with 
well-defined culture media without the need of serum supplementation. This 
combination resulted in multiple products already approved for human and 
veterinary use. However, being a lytic system, recombinant AAV production 
comes to an end when the baculovirus induces host cell lysis, which also 
contributes to the release of intracellular proteases to the culture media, 
which can severely impact the quality of the produced vectors. Altogether, 
xv 
 
 
this makes the time of harvest one of the most important process 
parameters, followed by the variables related with the infection step, the 
multiplicity of infection and the cell concentration at seeding and at infection. 
Consequently, the bioprocess with insect cell-baculovirus system can 
inherently benefit from the implementation of real-time monitoring tools to 
accurately estimate the best infection and harvest timing. 
This thesis aimed at developing and implementing real-time monitoring tools 
for critical process variables in the insect cell-baculovirus system, specifically 
for rAAV production. Furthermore, the possibility to detect in real-time rAAV 
production kinetics was also investigated. 
In Chapter I these topics are introduced, and a revision of the most important 
achievements published in the literature is discussed.  
In Chapter II, the use of fluorescence spectroscopy as a soft sensor for 
monitoring rAAV production, cell concentration and viability is assessed. 
Artificial neural network models were developed, complemented with a 
genetic algorithm-based approach for spectra pre-treatment which 
significantly increased fluorescence spectra signal-to-noise ratio and 
positively impacted prediction models. Fluorescence spectroscopy proved to 
be a powerful tool for bioprocess monitoring, due to its straightforward 
implementation and the substantial information it provides from rapid culture 
medium measurements.  
In Chapter III, the objective was to detect rAAV-associated changes in 
cultured insect cells, using digital holographic imaging. A commercially 
available online automatic sampling system (iLine F, Ovizio Imaging 
Systems) was applied to insect cell culture, in growth and production batches, 
in order to clearly isolate image attributes associated with rAAV production. 
Model interpretability and robustness was assured by combining multiple 
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linear regression with parameter selection using forward stepwise regression, 
resulting in the identification of cell attributes associated with rAAV 
production, cell concentration and culture viability. This approach confirms 
the feasibility of digital holographic imaging to trace the biological state of the 
cell at each infection stage, and for real-time monitoring of rAAV titer and 
overall culture progression in lytic systems, making it a valuable tool to 
support the time of harvest decision.  
In Chapter IV the influence of rAAV production and baculovirus replication in 
the dielectric potential of the cell was investigated using dielectric 
spectroscopy. Due to the high amount of intracellular activity in the cell during 
the viral vector production process, a highly variable range of different culture 
conditions was covered in order to build a robust monitoring platform. With 
that aim, the system was challenged with purposely low rAAV-titer batches 
and transgene-devoid baculoviruses. Models for in-process prediction of cell 
concentration, viability and specific rAAV production were developed. 
Moreover, dielectric spectroscopy applicability as a process analytical tool 
was demonstrated, by accurately predicting infection time more than 24 hours 
in advance using the continuously monitored permittivity of the culture. The 
work presented in this chapter was performed in Voyager Therapeutics, a 
Boston-based gene therapy company focused on central nervous system 
disorders.  
The main drive behind the work performed in Chapters II to IV was the 
Process Analytical Technology (PAT) initiative, a guidance for the 
pharmaceutical manufacturing industry with three main pillars: product 
analysis, monitoring and control. The first pillar, product analysis, is heavily 
focused in de-risking the manufacturing process by increasing process 
understanding, identifying the product critical quality attributes (CQAs) and 
the critical process parameters (CPPs) affecting it. The second pillar stems 
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from the need to monitor in real-time the identified quality-related 
characteristics. The focus of this thesis was in these two first pillars. Chapter 
V addresses the third pillar: the implementation of a control strategy to correct 
product quality deviations. An overview of the most used bioprocessing 
control strategies is provided, encompassing both classic and advanced 
control strategies. 
 In Chapter VI, the main achievements obtained in the previous chapters are 
discussed in a broad context, and future perspectives are addressed.  
Overall, this thesis explores the suitability of three different spectroscopic 
techniques or image-based tools for quantitative real-time monitoring of rAAV 
production and viable cell concentration in the insect cell – baculovirus 
system. The quantitative models developed allow the monitoring of critical 
process variables, decision of the harvest time and are applicable to the 
establishment of controlled feeding strategies. The tools and methodologies 
presented in this thesis can be applied for real-time monitoring of other rAAV 
serotypes, other biopharmaceuticals produced in the IC-BEVS and potentially 
for other viral vector production processes. Consequently, in the scope of the 
PAT initiative, we envision this thesis significantly contributes for increasing 
rAAV production process understanding and towards implementation of 
real-time monitoring tools for monitoring rAAV production in insect cells. 
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Resumo 
Desde a primeira publicação científica que introduziu o conceito de terapia 
génica, em 1972, que esta tem tido sucessivas histórias de sucessos e de 
insucessos. No entanto, o aumento recente da sua notoriedade, os avanços 
em ensaios clínicos com resultados promissores, o aumento do interesse 
público e do número de produtos aprovados parecem indicar que a terapia 
génica veio para ficar. Atualmente, há um interesse crescente por parte da 
comunidade científica e de empresas em terapias génicas e celulares, 
usando, na grande maioria dos casos, vetores virais. 
O Vírus Adeno-Associado (VAA) tem sido cada vez mais usado para ensaios 
clínicos de terapia génica, o que culminou com a aprovação de três terapias 
baseados neste vírus: Glybera, em 2012, a primeira aprovada na Europa, e 
Luxturna e Zolgensma, aprovados nos Estados Unidos da América em 2017 
e 2019, respetivamente. As principais vantagens destes vetores são a sua 
aparente não-patogenicidade; a sua capacidade de induzir uma expressão 
genética duradoura e de transduzir tanto células quiescentes como células 
em divisão celular, e isto numa enorme variedade de tecidos; e a sua 
resistência física, que lhes permite resistir ao processo de produção e 
purificação.  
O número crescente de ensaios clínicos de terapia génica resultou numa 
demanda alta por plataformas de produção de VAA eficientes e escaláveis, 
das quais se destaca o sistema de expressão baculovirus-célula de inseto 
(SEB-CI). Este sistema combina a alta capacidade de expressão de 
proteínas recombinantes do baculovirus com as características adequadas 
às Boas Práticas de Fabrico (BPF) das células de inseto: estas são capazes 
de crescer em suspensão, atingindo concentrações celulares elevadas sem 
o uso excessivo de recursos para o seu crescimento e sem a necessidade 
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de suplementação de soro. Esta combinação resultou em diversos produtos 
aprovados para uso humano e veterinário. No entanto, sendo um sistema 
lítico, a produção de VAA recombinante acaba quando o baculovirus induz 
apoptose na célula infetada. A lise celular induzida pelo baculovirus contribui 
ainda para a libertação de proteases intracelulares para o sobrenadante da 
cultura celular, que podem afetar a qualidade dos vetores virais produzidos. 
Assim, o momento em que se termina a cultura para recolha dos vetores 
virais produzidos é uma das mais importantes variáveis neste processo, 
assim como a altura da infeção, a multiplicidade de infeção e a concentração 
celular ao inocular e infetar a cultura. Por este motivo, o sistema de 
expressão baculovirus-célula de inseto claramente beneficia da 
implementação de ferramentas de monitorização em tempo real para estimar 
com precisão a melhor altura para infetar e recolher a cultura celular.  
O objetivo principal desta tese é desenvolver e implementar ferramentas de 
monitorização em tempo real para variáveis críticas do bioprocesso no 
sistema de expressão baculovirus-célula de inseto, especificamente para a 
produção de VAA. Para além disso, também foi estudada a possibilidade de 
detetar em tempo real a cinética de produção do VAA.  
No capítulo I, são apresentados estes tópicos e é feita uma revisão dos 
trabalhos mais importantes já publicados na literatura  
No capítulo II, foi avaliado o uso de espectroscopia de fluorescência como 
um sensor indireto para monitorizar o título de VAA, concentração celular e 
viabilidade. Foram desenvolvidas redes neuronais artificiais, 
complementadas com uma abordagem baseada num algoritmo genético 
para o pré-processamento dos espectros de fluorescência. A abordagem 
desenvolvida para o pré-processamento aumentou significativamente o rácio 
sinal/ruído e teve um impacto positivo nos modelos de previsão. A 
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espectroscopia de fluorescência provou ser uma ferramenta poderosa para 
monitorização de bioprocessos, devido à sua fácil implementação e à 
quantidade substancial de informação que providencia a partir de medições 
rápidas do sobrenadante da cultura celular.  
No capítulo III, o objetivo foi detetar, nas células de inseto em cultura, 
alterações morfológicas associadas à produção de VAA, usando microscopia 
holográfica digital. Foi aplicado um sistema comercial de amostragem 
automática (iLine F, Ovizio imaging systems) a culturas em reator de células 
de inseto infetadas e não infetadas, para isolar características da imagem 
associadas à produção de VAA. As características associadas às variáveis 
a monitorizar foram determinadas usando regressão gradual para a frente 
combinada com regressão linear múltipla, culminando com a identificação 
das características da célula associadas à produção de VAA, concentração 
celular e viabilidade da cultura. Esta abordagem confirma que é possível usar 
microscopia holográfica digital para a deteção do estado biológico da célula 
a cada fase da infeção, e para monitorização em tempo real do título de VAA 
e da progressão da cultura em sistemas líticos. Assim, esta é uma ferramenta 
valiosa para determinar o tempo de recolha da cultura celular.  
No capítulo IV, foi investigada a influência da produção de VAA e da 
replicação do baculovirus no potencial dielétrico da célula, utilizando 
espectroscopia dielétrica. Devido à elevada atividade intracelular da célula 
durante o processo de produção, e de modo a construir uma plataforma de 
monitorização robusta, incluímos diferentes condições de cultura, 
adicionando culturas de reatores com títulos de VAA propositadamente 
baixos e com infeção por baculovirus sem transgene. Com esta estratégia, 
foram desenvolvidos modelos para prever, durante o processo, a 
concentração celular, viabilidade e produção de VAA por célula. Foi também 
demonstrada a aplicabilidade da espectroscopia dielétrica como Tecnologia 
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Analítica de Processo (TAP), com previsões precisas do tempo de infeção 
mais de 24 horas antes, usando as medições contínuas da permitividade da 
cultura. O trabalho apresentado neste capítulo foi realizado na Voyager 
Therapeutics, uma empresa de terapia génica sediada em Boston focada no 
tratamento de doenças do sistema nervoso central.  
A principal motivação por detrás do trabalho desenvolvido nos capítulos II a 
IV foi a iniciativa Tecnologia Analítica de Processo (TAP), um guia criado pela 
Food and Drug Administration (FDA) dos Estados Unidos da América (EUA) 
para a indústria farmacêutica, assente em três pilares principais: análise, 
monitorização e controlo do produto. A análise do produto foca-se em 
diminuir o risco do processo de produção através do aumento de 
conhecimento sobre o processo, identificando os Atributos Críticos da 
Qualidade (ACQ) do produto assim como os Parâmetros Críticos do 
Processo (PCC) que os afetam. O segundo pilar tem origem na necessidade 
de monitorizar em tempo real as características do produto identificadas 
como relacionadas com a qualidade deste. O trabalho desenvolvido nesta 
tese incidiu sobretudo nestes dois primeiros pilares.  
O capítulo V aborda o terceiro pilar referido: a implementação de uma 
estratégia de controlo para corrigir desvios ao perfil de qualidade do produto. 
É apresentada uma visão geral das estratégias de controlo mais usadas para 
bioprocessos que inclui abordagens clássicas e avançadas.  
No capítulo VI, são discutidos de modo geral os principais resultados obtidos 
nos capítulos anteriores. É também feita uma reflexão sobre as perspetivas 
futuras nesta área.  
Assim, esta tese explora o uso de três métodos diferentes, baseadas em 
espectroscopia ou em análise de imagem, para a quantificação em 
tempo-real da produção de VAA e da concentração de células viáveis no 
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sistema de expressão baculovirus-célula de inseto. Os modelos quantitativos 
desenvolvidos permitem monitorizar os Parâmetros Críticos do Processo e 
decidir o momento de recolha da cultura celular, e são aplicáveis para 
estabelecer estratégias controladas de suplementação de nutrientes. As 
ferramentas e metodologias apresentadas podem ser aplicadas na 
monitorização em tempo real de outros serotipos de VAA, outros 
biofarmacêuticos produzidos no SEB-CI e, potencialmente, outros processos 
de produção de vetores virais. Deste modo, e no âmbito da iniciativa TAP, 
acreditamos estar a contribuir significativamente para aumentar o 
conhecimento do processo de produção do VAA e para a implementação de 
ferramentas de monitorização em tempo real da produção de VAA nas 
células de inseto.  
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Introduction 
 
1. Motivation: The need for real-time monitoring tools for viral 
vector manufacturing 
The interest for the gene therapy field has resurged since the approval of 
Glybera™, in 2012. The promise of a lifetime treatment for debilitating genetic 
conditions that dramatically reduce the life expectancy of patients currently 
attracts the interest of several pharmaceutical companies and shareholders. 
The World Health Organization (WHO) estimates the existence of 10000 
monogenic diseases, with an incidence at birth of 0.4-0.5 % (Venugopal et 
al., 2018; World Health Organization, 2019). However, gene therapy has 
potential for treating a whole range of genetic diseases, affecting an estimate 
of 330 million people worldwide, of which approximately half are children 
(Goswami et al., 2019). This represents an estimated forecasted global 
market for gene therapies of USD 11000 million over the next 10 years 
(Goswami et al., 2019). 
The significant investment to study and optimize new viral vectors, new 
delivery methods and strategies to specifically transduce target cells and 
improve manufacturing processes translates into a prohibitive cost for the 
approved gene therapies. As these therapies start entering the 
commercialization stage, manufacturing the large quantity of vectors 
necessary in a cost-effective way cannot be achieved only by scaling-up the 
process but needs to be combined with the development of scalable, 
compliant and standardized manufacturing processes. Moreover, in the 
Process Analytical Technology (PAT) initiative (FDA, 2004), the regulatory 
entities recommend the identification and continuous in-process monitoring 
of the product quality characteristics, as well as the product itself, in order to 
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assure product quality at every stage of the manufacturing process. However, 
the currently developed methods available for bioprocess monitoring were 
mostly developed for protein-based products, and methods for online 
monitoring of viral vectors are still lacking (Petiot et al., 2016). 
In the scope of the PAT initiative, the work presented in this thesis is focused 
on the implementation of real-time monitoring tools coupled with advanced 
pre-treatment and modeling techniques for viral vector manufacturing and 
increasing AAV vector production process understanding. 
 
2. Gene therapy: the next mAb revolution? 
2.1. Historical perspective 
Gene therapy is defined as a therapeutic strategy consisting in transferring 
DNA to patient cells, with the aim of correcting or replacing a defective gene 
or gene product (Shahryari et al., 2019). The initial concept of gene therapy, 
the idea to correct defective genes replacing them with their fully functional 
version, can be traced back to 1972 (Neufeld et al., 1972). The first successful 
clinical trial occurred 18 years afterwards: in 1990, Ashanti DeSilva, a patient 
suffering from ADA-SCID, was successfully treated with an adenoviral vector, 
remaining a success story to this day (Wirth et al., 2013). In the same decade, 
several trials were followed, culminating with the infamous ornithine 
transcarbamylase deficiency clinical trial: in 1999, a very high adenovirus 
vector dose administration induced multiorgan failure in Jesse Gelsinger, 
resulting in his death (Wirth et al., 2013). This event originated a setback in 
gene therapy clinical trials, with a consequent focus in improving the safety 
of viral vectors. 
Slowly, the field resurged, with the first approved viral-vector based gene 
therapy taking place in China in 2003, an adenovirus vector for head and neck 
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cancer treatment (Wirth et al., 2013). In Europe, the first approved gene 
therapy viral vector was Glybera™, in 2012, for the treatment of lipoprotein 
lipase deficiency (Wirth et al., 2013). The approval of Luxturna™ in the USA 
in 2017, for the treatment of Leber's congenital amaurosis, and Zolgensma® 
in 2019, for Spinal Muscular Atrophy, marks the definitive establishment of 
the gene therapy field (Keeler and Flotte, 2019).  
2.2. Approved products  
Currently, there are 19 gene therapy products approved and currently in the 
market (Shahryari et al., 2019), 2 of them based on direct AAV vector delivery: 
Zolgensma® and Luxturna™ (Figure I.1). Glybera™, an AAV1-based 
therapy, set the first milestone in AAV-mediated gene therapy, being the first 
gene therapy product approved in the western world in 2012. Glybera™ was 
withdrawn from the market in 2017, due to low market demand, despite its 
effectiveness (Goswami et al., 2019). The current view for the gene therapy 
field is optimistic, with 70-90 approved products expected by 2025. This 
projection is based on the current rate of Investigational New Drug (IND) 
applications to the FDA for gene therapy (800 in 2018 and over 1000 in 2019) 
(Puri, 2019). 
Due to the market risk, the complexity and the cost of the manufacturing 
process, gene therapies are among the most expensive drugs in the market, 
which raises concerns on the affordability and profitability of such treatments: 
when it was launched, Glybera™ had a price tag of over €1 M; Luxturna™ 
has a cost of USD 770 M for both eyes while Zolgensma®, currently the most 
expensive gene therapy drug, has a price tag of USD 2.125 M. This has led 
companies to develop alternative payments schemes, based on pay 
per-performance annuities and outcome-based rebates (Goswami et al., 
2019; Shahryari et al., 2019). 
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Figure I.1 – Overview of the current gene therapy products approved and currently in the market (Glybera™ was withdrawn from the market in 
2017). For each product, we list the therapeutic indication, the manufacturing company, the dosing and pricing and the markets where the drug 
is approved. The upper right corner indicates the type of product, while the lower left corner depicts the production system. Adapted from 
(Goswami et al., 2019; Kim et al., 2004; Nemunaitis et al., 2000; Shahryari et al., 2019 and from the corresponding product leaflet in the FDA 
or EMA websites (accessed on February 2019)). *Oncorine dose and price is indication dependent. **Kymriah™ dose decreases to 
0.2-5 × 106 cells/kg for patients less than 50 kg. Missing production systems are proprietary information. AAV – Adeno-Associated Virus; 
Adenosine deaminase severe combined immunodeficiency; AdV5 – Adenovirus type 5; ASO – Antisense oligonucleotide; 
CAR-T - Chimeric Antigen Receptor; E. coli – Escherichia coli; HSV – Herpes Simplex Virus; IC-BEVS – Insect cell – baculovirus expression 
vector system; siRNA – small interfering RNA. 
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2.3. Delivery and therapeutic strategies 
2.3.1. Viral and non-viral delivery 
“There are only three problems in gene therapy: delivery, delivery and 
delivery (…)” (I.M. Verma in TIME, 1999; Jan 11). Despite the research and 
efforts put in viral or cell line development and improvement of manufacturing 
conditions, to be successful as a therapy the genetic load must be delivered 
to the target cells. With that aim, both viral and non-viral strategies have been 
developed (Figure I.2). 
Non-viral based strategies have the advantage of being easier to prepare and 
relatively safer than viral-vector approaches, and include the use of 
alternatives such as plasmid DNA, liposomes and polymer-based 
approaches (reviewed in Yin et al., 2014). However, viral vectors have the 
advantage of their higher transduction potential, since they rely on the natural 
capacity of viral vectors to infect and express their genetic material in the 
target cell.  
Cucchiarini et al. published in 2016 a comprehensive review of the current 
challenges associated with gene therapy delivery, such as physical barriers, 
immune response, vector capacity, internalization and transgene expression 
(Cucchiarini, 2016). 
2.3.2. Therapeutic strategies 
According to the European Medicines Agency (EMA), gene therapy 
comprises several strategies to “regulate, repair, replace, add or delete 
genetic sequences” in humans (Shorthose, 2017). The chosen strategy is 
thus dependent on the root cause of the genetic condition (Wang et al., 2019): 
loss of gene function, gain of toxic mutations or defective protein 
overexpression or gene modulation (Figure I.3). The challenges associated 
with each of these strategies and examples of ongoing clinical trials using 
them are reviewed elsewhere (Wang et al., 2019). 
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Figure I.2 - Comparison of the main advantages and shortcomings in non-viral and viral-based 
strategies for gene therapy. Adapted from (Cucchiarini, 2016). Abbreviations: VP – viral 
particles; HSV – Herpes simplex virus; rAAV – recombinant adeno-associated virus vectors. 
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Figure I.3 – Overview of the current gene therapy strategies. A) Gene replacement – addition 
of the correct copy of the defective gene to correct for loss of function mutations. This is the 
strategy employed for recessive monogenic diseases, such as most eye conditions, 
hemophilia, Duchenne muscular dystrophy or spinal muscular atrophy. B) Gene 
knockdown - Delivery of interference RNA or use of gene-editing strategies to reduce the 
expression of the faulty protein. Examples include monogenic diseases (Huntington), 
tauopathies, such as Alzheimer, or Friedreich Ataxia. C) Genome editing – Using strategies 
such as CRISPR/Cas9 or zinc finger nucleases to edit the mutation causing the disease. D) 
Genome modification or gene addition - introduction of DNA sequences to correct a mutation 
or provide a therapeutic or suicide gene, such as the Aromatic L-amino acid decarboxylase 
gene in Parkinson Disease or suicide genes for cancer therapy. E) Fine-tuning of the protein 
expression levels by non-coding RNA modulation, as used for instance for heart failure. 
Adapted from (Planul and Dalkara, 2017; Valdmanis and Kay, 2017; Wang et al., 2019).   
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3. The Adeno-Associated Virus (AAV) 
3.1. Biology  
The adeno-associated virus (AAV) is a small (20-25 nm), icosahedral, 
non-enveloped, single-stranded DNA (ssDNA) virus belonging to the 
Parvoviridae family. Its genus name, Dependoparvovirus, indicates their 
dependency on the viral machinery of helper viruses (usually adenovirus or 
herpes-simplex virus) to replicate in the host cell (Wang et al., 2019). AAV 
were first detected as a contamination in adenovirus preparations, hence their 
name (Wang et al., 2019). Currently there are over 108 AAV variants 
identified, derived from 12 serotypes (Colella et al., 2018). Each serotype has 
capsid amino acid variations which change their affinity to cellular receptors, 
and as such their tropism to different cell types, tissues or species (compiled 
in Keeler and Flotte, 2019 and Saraiva et al., 2016). Despite these 
inter-serotype differences, recently a new cellular receptor was identified as 
critical for infection of all AAV serotypes, and accordingly renamed as 
“universal” AAV receptor (Pillay et al., 2016). 
AAV infection starts with attachment of the virus to the cellular receptors, 
followed by the virus internalization by endocytosis (Nonnenmacher and 
Weber, 2012). After being released from the endosome into the cytoplasm, 
the vector is imported into the cell nucleus via the nuclear pore complex, 
eventually reaching the nucleoplasm, where the viral genome is released by 
capsid uncoating and the ssDNA is copied into a double stranded DNA. 
(Brown et al., 2017; Nonnenmacher and Weber, 2012). In the absence of a 
helper virus, the viral DNA either stays in its episomal form, in the case of 
viral vectors, or is inserted into the host cell chromosome, in the case of wild 
type virus (specifically, region AAVS1 in chromosome 19 for human cells) 
(Keeler and Flotte, 2019). 
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The AAV DNA consists of a 4.7 kbp linear single stranded genome, which 
encodes the necessary viral proteins for capsid expression (cap) and genome 
replication (rep). These are coded in two open-reading frames, one for cap 
and the other for rep genes (Hentzschel et al., 2016). The cap gene confers 
the AAV serotype, and encodes for the three capsid proteins (VP1, VP2 and 
VP3, with 87, 73 and 62 kDa respectively) (Cecchini et al., 2008). The rep 
gene encodes for the 4 replication proteins, two large proteins (Rep78 and 
Rep68) and two small ones (Rep52 and Rep40) (Dubielzig et al., 1999). The 
recently discovered Assembly-Activating Protein (AAP) is encoded 
out-of-frame in the VP2 gene sequence, and it has important chaperone 
functions for capsid assembly for most serotypes (Große et al., 2017). AAV 
genomic material is flanked by Inverted Terminal Repeats (ITRs), palindromic 
DNA sequences with approximate 140 bp which are essential to provide the 
encapsidation signal for the cellular machinery (Savy et al., 2017).  
3.2. AAV as a vector for gene therapy  
 AAVs are subject to extensive research in both academia and industrial 
setting and are one of the most used viral vectors for gene therapy clinical 
trials (Figure I.4). Reasons for their widespread use are their apparent lack of 
pathogenicity in humans and the ability to transduce a variety of cell types, 
while allowing sustained episomal gene expression in replicating and 
quiescent cells. Finally, recombinant AAVs are resilient, rendering them 
resistant to industry manufacturing and purification strategies (Naso et al., 
2017; Negrete and Kotin, 2009). Some serotypes, such as AAV9, can cross 
the blood brain barrier, which allows systemic, intravenous administration of 
vectors targeting the central nervous system, as is the case of Zolgensma®. 
The main bottlenecks of AAV-based gene therapy (Figure I.2) have been 
addressed with several interesting strategies:  
• Transgene capacity - rAAV possess a very low therapeutic gene 
capacity (4.7 kbp). While some authors report the slight increase of the rAAV 
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capacity using molecular biology strategies, such as eliminating VP2 (Grieger 
and Samulski, 2005), the most used strategies to circumvent the low 
transgene capacity is dividing large genes into dual rAAV vectors 
(Chamberlain et al., 2016; Mcclements and Maclaren, 2017). 
• Existence of pre-existing antibodies and immunogenicity – The 
seroprevalence of neutralizing antibodies for rAAV depends on the serotype. 
Taking as an example rAAV-2, neutralizing antibodies were detected on 
average in 45 % of subjects (Louis Jeune et al., 2013); additionally, the 
similarity between serotypes originates cross reactivity between the 
corresponding neutralizing antibodies, which was verified in more than 50 % 
of subjects for any dual serotype combination (Louis Jeune et al., 2013). For 
multiple dose treatments, the possible generation of rAAV neutralizing 
antibodies prevents subsequent vector administration. Strategies to prevent 
rAAV administration-related immune responses (reviewed in Mingozzi and 
High, 2017) include reduction of the neutralizing antibodies titers pre-vector 
administration, alternative routes of administration, switching the rAAV 
serotype or combining AAV vector transduction with non-viral delivery based 
on exosome vesicles (Meliani et al., 2017; Orefice et al., 2019). This last 
approach can potentially ameliorate vector uptake by target cells and reduce 
the associated immune response (reviewed in György and Maguire, 2017). 
• Slow onset of transgene expression – In the absence of a helper virus, 
conversion of rAAV ssDNA into dsDNA has been shown to be a rate-limiting 
step (Berry and Asokan, 2017). Self-complementary AAV vectors (scAAV) 
have been developed to shorten the time between vector transduction and 
transgene expression by eliminating the time for synthesis of the 
complementary DNA strand. This was achieved by packaging the therapeutic 
transgene and its complementary DNA strand as the vector payload. 
However, this approach further reduces the transgene capacity by half 
(Snyder and Moullier, 2011).   
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3.2.1. Clinical trials using rAAV as delivery vector 
The current landscape of rAAV-based gene therapy is marked by the 
existence of several companies and a high number of clinical trials under 
development (219 as of January 2019), targeting a range of eye, blood, 
muscle, metabolic and central nervous system disorders. The major 
indications currently being addressed in clinical trials are hemophilia 
(BioMarin, UniQure, Spark Therapeutics, Pfizer), retinal diseases (Spark 
Therapeutics, NightStar Therapeutics, Gensight Biologics), metabolic 
diseases (Adverum), Parkinson and other central nervous system disorders 
(PTC Therapeutics, Voyager Therapeutics) and muscular diseases 
(Audentes Therapeutics) (Shahryari et al., 2019). rAAV-based gene therapy 
is relatively safe, with rare reports of serious adverse events, mostly related 
with elevation of liver enzymes and immune responses against transduced 
liver cells, which can be overcome with transient immunosuppression (Kotin 
and Snyder, 2017). 
Currently, rAAV represents 8 % of the gene therapy clinical trials, largely 
focused in monogenic diseases as target indication (Figure I.4), but with 
cancer as the next major therapeutic application (Reul et al., 2019; reviewed 
in Santiago-Ortiz and Schaffer, 2016) followed by neurological disorders 
(reviewed in Hudry and Vandenberghe, 2019), ocular diseases and 
cardiovascular diseases (reviewed in Bera and Sen, 2017). 
 A comprehensive list of the currently active rAAV clinical trials and the 
corresponding serotype, target tissue and condition is provided elsewhere 
(Wang et al., 2019). 
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Figure I.4 - Clinical trials using adeno-associated virus (AAV). The data is from 
http://www.abedia.com/wiley/, accessed on January 2019. A) rAAV clinical trials by therapeutic 
application (n=219). B) Distribution of the clinical trials by vector / non-viral delivery methods 
(n=3081). C) Distribution by clinical trial phase (total=215). 
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3.3. Comparison of rAAV production systems 
The attractiveness of rAAV for gene therapy led to the development and 
improvement of several biological production systems. The current state of 
the art shows the different production systems have comparable cell specific 
rAAV productivities (Merten, 2016). As such, the choice of the production 
system is dependent of factors such as the vector quantity needed. For 
instance, for phase I clinical trials or specific administration sites or routes, 
where small vector doses are needed, transfection-based systems can be 
used. For later clinical trial stages and for IV administration, the use of more 
scalable systems is needed (Merten, 2016; Rininger et al., 2019). 
This section will detail each rAAV production system, their strengths and 
limitations and recent improvements. There are four biological systems 
considered established for production of AAV vectors, which are detailed in 
the following sections and compiled in Table I.1. Additionally, Section 3.3.5 
briefly addresses the use of new production systems. 
3.3.1. Transfection of HEK293 cell lines 
This system relies on triple transfection of HEK293 cells, with one plasmid 
containing the rep and cap genes, the other one containing the ITR-flanked 
transgene and the helper plasmid containing the necessary adenoviral genes. 
A two-plasmid variation has been developed, in which the helper plasmid is 
combined with the one containing the rep and cap functions. This system is 
widely used due to the easiness to design the plasmids and the optimization 
of the transfection process in these cells throughout the years (Merten, 2016). 
It is mostly used for screening of new rAAV constructs due to the method 
simplicity, availability of GMP-grade plasmids and no intellectual property on 
the manufacturing protocols (Clément, 2019). 
These cells are grown in adherent conditions, which poses a constraint for 
large scale production of the viral vectors. Production in cell stacks or 
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fixed-bed bioreactors slightly alleviates this issue, although the space 
requirements are still a concern. The use of suspension and serum 
free-adapted cells is also reported, in scales of up to 20 L using the WAVE 
bioreactor system (Chahal et al., 2014; Grieger et al., 2016; Powers et al., 
2016) . 
3.3.2. Stable producer mammalian cell lines 
This system is based on the use of packaging and producer cells which stably 
express the rep and cap genes and the ITR-flanked gene of interest (Merten, 
2016). In general, either HeLa or A549 cells are preferred due to their 
easiness to grow in suspension and maintain stably integrated copies of the 
cytotoxic rep protein (Merten, 2016; Thorne et al., 2009). In order to produce 
the recombinant AAV vectors, infection with a helper virus is necessary to 
provide the helper functions required for rAAV replication. Adenovirus is often 
chosen as helper vector, since it is easy to produce and to demonstrate viral 
clearance after the purification process (Thorne et al., 2009). This system 
generates more than 105 rAAV viral genomes (vg) per cell (Merten, 2016; 
Sharon and Kamen, 2017), however with the concomitant production of 
infectious adenovirus, which need to be removed from the final product. This 
can be partially addressed by using replication deficient or cold-attenuated 
adenovirus, although with a decrease on the rAAV titers achieved (Merten, 
2016; Sharon and Kamen, 2017). The main limitation of this system is the fact 
that a stable cell clone must be generated for every serotype / therapeutic 
application (Wang et al., 2019). The use of suspension-adapted producer cell 
lines has been described in scales up to 2000L (Clément and Grieger, 2016). 
3.3.3. Infection with Herpes Simplex Virus (HSV) 
The helper functions required for rAAV replication can be provided by the 
Herpes Simplex Virus. This system relies on co-infection of HEK239 or BHK 
cells adapted to grow in suspension with two recombinant herpes simplex 
vectors, one coding for the therapeutic transgene flanked by AAV ITRs and 
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the other one providing the rep and cap sequences (Galibert and Merten, 
2011). Production scales up to 100 L have been reported (Clément, 2019). 
Interestingly, when using BHK cells, the decreased virus replication cycle has 
allowed to harvest rAAV as soon as 24 hpi (Thomas et al., 2009). This system 
has the potential to generate HSV vectors with immunogenic potential, which 
need to be removed from the final product. Additionally, a high multiplicity of 
infection (MOI) of HSV vectors is required for rAAV production, and 
consequently HSV is produced in suspension culture or fixed bed bioreactors 
(Knop and Harrell, 2008; Merten, 2016). 
3.3.4. Insect Cell – Baculovirus expression vector system  
Similarly to the HSV system, the use of the baculovirus system to produce 
rAAV in insect cells requires two baculovirus: one coding for the AAV rep and 
cap functions and the other one providing the transgene flanked by the AAV 
ITRs (Smith et al., 2009). The main advantage of this system is its scalability, 
with scales up to 400 L being reported, yielding 2.7×1014 vg/L (Cecchini et 
al., 2011; Kotin and Snyder, 2017). 
It is worth referring that Glybera™ was produced using the insect cell 
baculovirus system. Further details on rAAV production in this system are 
provided in Section 4.3.  
3.3.5. Novel modalities to produce rAAV  
The aim to increase cell specific productivity or decrease manufacturing costs 
led to the development of new rAAV production systems. This section intends 
to list the current existing alternatives, rather than provide a detailed 
description of each of the systems: 
• Use of CAP® cells, by Cevec Pharmaceuticals – Using a human cell 
line able to grow in suspension, serum- and animal-free conditions, 
Cevec reports the production of rAAV using both stable cells and 
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transient systems. The reported volumetric titers are comparable to 
existing systems, up to a 10 L scale (Cevec Pharmaceuticals, 2019; 
Hein et al., 2018). 
• Other mammalian-based systems include the use of i) vaccinia virus 
infection of HEK293 cells, producing superabundant VP1 vectors with 
increased transduction in vivo (Wang et al., 2017); ii) a novel identified 
AAV helper virus, the bocavirus, which resulted in rAAV titers twice as 
high as the two-plasmid HEK transfection system (Wang et al., 2018);  
• Production in Saccharomyces cerevisiae, however the recombinant 
AAV possessed lower infectivity and full capsid ratio than in the 
IC-BEVS (Aponte-Ubillus et al., 2018; Barajas et al., 2017); 
• Production of AAV2 VP3 protein in E. coli, followed by cell-free capsid 
assembly of Virus-like particles (VLPs) (Le et al., 2019). Further 
developments are required to encapsidate genomic material into the 
VLPs and achieve infectious titers similar to the established systems. 
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Table I.1 - Comparison of several biological systems used for rAAV production. Scale indicated represents the higher reported to date. Adapted 
from (Aponte-ubillus et al., 2017; Clément, 2019; Clément and Grieger, 2016; Kondratov et al., 2017; Merten, 2016; Wang et al., 2019, 2011).  
 
System Description Strengths Limitations Companies  
Specific productivities 
(vg and IP) 
Selected references 
HEK293 
transfection 
Double or triple 
transfection of 
HEK 293 
High vector potency; 
Versatility; Cost; Scales up to 
20 L; No need to maintain 
viral stocks; Track record; 
Simplicity; Human origin 
Scalability; Plasmids contain 
bacterial backbone; concerns 
regarding rcAAV formation 
Spark; AskBio; 
Neurologix; 
Abeona; Audentes. 
1.3×104 – 9.4×105 vg/cell 
102-103 TU/cell 
(Blessing et al., 2019; 
Chahal et al., 2014; 
Grieger et al., 2016; 
Powers et al., 2016) 
Herpes 
Simplex 
Infection  
Co-infection of 
BHK cells with 
two HSV1 
Scalable up to 100 L; high 
rAAV vector potency 
Large amounts of HSV vector 
necessary; Viral removal 
needed 
Dimension; 
SolidBio 
7×104 – 1.5×105 vg/cell 
6×103 - 1×104 
(Adamson-Small et al., 
2017, 2016; Clément et 
al., 2009; Knop and 
Harrell, 2008; Thomas et 
al., 2009) 
Stable 
Mammalian 
cells 
AdV infection 
of stable HeLa 
cells; 
Human origin 
High ratio of full capsids and 
rAAV vector potency; High 
specific titer  
Flexibility; Viral removal 
needed; Scalability; need of 
antibiotic and clone selection.  
AGTC 
5×104 – 1.3×105 vg/cell 
3×102 – 2×103 IP/cell 
 
(Chen et al., 2014; Martin 
et al., 2013; Thorne et 
al., 2009) 
IC-BEVS 
Co-infection of 
insect cells 
with two 
baculovirus 
Suspension; Scalable up to 
400 L; High cell density and 
vol. productivities achieved; 
reduced encapsidation of 
foreign DNA; Absence of 
mammalian-derived products 
Low rAAV potency; Molecular 
biology strategies for vector 
improvement; Baculovirus 
genetic instability; Suboptimal 
VP ratios; Viral removal needed  
Voyager; UniQure; 
Adverum; Abeona; 
Virovek; 
Lacerta 
104-105 vg/cell; 5×105 for 
stable cells 
102 IP/cell  
 
(Cecchini et al., 2011; 
Kotin and Snyder, 2017) 
Stable cells: (Joshi et al., 
2019; Mietzsch et al., 
2017, 2014) 
rcAAV – replication competent AAV; HEK – human embryonic kidney 293 cell line; BHK – baby hamster kidney cell line; HSV1 – Herpes Simplex Virus 1; AdV – Adenovirus;  
HeLa - Cancer cell line derived from Henrietta Lacks; vg – vector genomes; TU – transducing units; IP – infectious particles; vol - volumetric  
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3.4. Manufacturing and purification challenges 
3.4.1. AAV vector quality attributes 
The main concern regarding recombinant AAV production is the balance 
between the vector quantities achieved and their quality. The rAAV quality 
attributes are the ability to infect and transduce the target cell, the ratio of 
empty to full particles obtained and the encapsidation of undesirable DNA 
material (Schnödt and Büning, 2017). There is however a common issue in 
the field, which is the standardization of analytical methods for rAAV quality 
attributes quantification. As reported in the works by Lock et al., and Ayuso 
et al., standardization of rAAV2 and 8 characterization assays is indeed a 
challenge. These authors produced and purified an rAAV2 and 8 vector lot, 
and characterized it in different labs, using the same protocols and reagents. 
Despite the standardization efforts, the titration results for the vector total, 
filled, infectious and transducing capsids were remarkably different between 
the different labs (Ayuso et al., 2014; Lock et al., 2010). This has profound 
implications for characterization of the produced vector by any institution or 
company, but also for comparison studies between different production 
systems, with discrepancies in the reported values for empty to full ratios and 
infectivity titers achieved by the different production systems (Kondratov et 
al., 2017; Merten, 2016; Rumachik et al., 2019). In particular for the vector 
potency assay, in which biological variability is inherently present, the final 
infectious titers are dependent on many factors, such as the method used to 
assess transduction (detection of transduced cell by flow cytometry, protein 
expression or qPCR) or the cell line used for titration. 
The other important quality attribute of rAAV vectors is commonly referred as 
the ratio of empty to full particles. However, in reality there are three vector 
“species”: capsids with the correct encapsidated DNA; empty capsids; and 
capsids with incorrect encapsidated DNA (which includes truncated ssDNA 
and host cell DNA) (Savy et al., 2017; Schnödt and Büning, 2017). The 
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majority of incorrectly encapsidated material originates from the vector 
backbone (Penaud-Budloo et al., 2018, 2017), and although in low 
percentage, it has immunogenic potential and is considered a major safety 
concern, being one of the six major product quality concerns identified during 
Glybera™ licensing assessment (Wright, 2014; Penaud-Budloo et al., 2017). 
As such, currently the presence of the host cell DNA and partial filled 
sequences is a concern for rAAV manufacturers (Wright, 2014). Although 
strongly dependent of the production system (for instance, the IC-BEVS has 
the lowest percentage of vector with incorrect genomes), some approaches 
have been developed to reduce foreign DNA encapsidation, such as 
increasing the length of the packaged transgene, closer to the AAV natural 
packaging capacity (Penaud-Budloo et al., 2017) and modification of the ITR 
or rep constructs (Noordman Y, Lubelski J, Bakker, 2016; Savy et al., 2017). 
Approaches to increase the percentage of full capsids have mainly been 
achieved by improvement of the vector molecular design (Kondratov et al., 
2017), increasing culture temperature after infection (Aucoin et al., 2007) and 
altering the ITRs structures (Savy et al., 2017). 
3.4.2. Upstream challenges 
The main challenges in the upstream process for rAAV production are 
scalability of the process and stability of the vector during the production 
process (Merten, 2016).  
Scalability of the bioprocess is a concern as therapies advance in the clinical 
trials phase as large doses are needed. As an example, for AAV therapies 
the dosage can be as low as 1012 vector per patient, for eye indications, but 
three orders of magnitude higher when systemic administration is needed 
(Rininger et al., 2019). Although for some indications or Phase 1 trials the use 
of adherent platforms can be used (e.g. cell factories, roller bottles or fixed 
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bed bioreactors), when larger vector amounts are needed the use of 
bioreactor systems is necessary (Rininger et al., 2019).  
The loss of vector infectivity during the culture is mostly related with rAAV 
autoproteolytic degradation or external protease activity (Mitchell and 
Samulski, 2013). The influence of pH and protease activity on rAAV infectivity 
is reviewed in (Salganik et al., 2012). Strategies to address this issue rely on 
continuous vector harvest from the culture media (Benskey et al., 2016; 
Grieger et al., 2016) or addressing the root causes of the vector loss of 
potency, as demonstrated by Galibert and coworkers. The authors identified 
the role of baculovirus protease cathepsin on the degradation of rAAV 
vectors, and report a two to four-fold increase in the vector potency when 
cathepsin was deleted from the baculovirus construct (Galibert et al., 2018).  
Interestingly, this protease-dependent activity has been used for 
development of myocardial infarction treatments, relying on the elevated 
protease presence in diseased environments to activate an AAV-based 
provector (Guenther et al., 2019). 
3.4.3. Downstream process challenges 
The aim of the downstream process in rAAV manufacturing is to remove 
process and product-associated impurities while maintaining the vector 
quality characteristics. Process-related impurities include host cell proteins 
and DNA and the residual plasmids or helper virus used during the production 
step, potential causes of geno- or immunotoxicity or even posing infectious 
risk, as in the case of adenovirus or HSV. Product-associated impurities 
include capsids with undesirable genetic material (Aponte-ubillus et al., 2017; 
Wright, 2014).  
A typical rAAV downstream process consists in cell lysis, followed by 
clarification and purification. For the cell lysis step both detergent lysis and 
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freeze-thaw are reported, although the first is preferred due to its scalability. 
A nuclease addition step may be added during or after lysis, as well as a 
concentration step such as tangential flow filtration. For the purification step, 
chromatography techniques are preferred, usually relying on affinity or 
ion-exchange (Clément and Grieger, 2016; Florencio et al., 2015).  
The choice of the downstream process depends on the upstream conditions, 
such as cell type and culture volume to process, but it is also dependent on 
the vector serotype and possibly the vector transgene (Clément and Grieger, 
2016; Virag et al., 2009). The different biophysical and chemical properties of 
the diverse rAAV capsids led to the development of commercially available 
affinity resins specific for each serotype (Clément and Grieger, 2016). The 
current challenges for rAAV manufacturing being addressed are the scalable 
separation of empty and full particles based on ion-exchange 
chromatography (Lock et al., 2012; Qu et al., 2007) and the development of 
“universal”, serotype-independent purification strategies for rAAV purification 
based on chromatography (Nass et al., 2018) or three-phase partitioning (Yu 
et al., 2020).  
 
4. The Insect Cell-Baculovirus Expression Vector System  
4.1. Introduction 
The insect cell – baculovirus expression vector system (IC-BEVS) combines 
the versatility and robustness of insect cells as production host cells and the 
suitability of the baculovirus as a potent and safe expression vector. 
Baculovirus is an enveloped insect cell virus, with a circular double stranded 
DNA (dsDNA) (80 to 180 kbp) which has been completely sequenced (Ferrelli 
et al., 2010). Initially studied for their application as insecticide, baculovirus 
potential as a vector for gene therapy soon emerged, mostly due to their 
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non-pathogenicity and high recombinant protein production yield (Yee et al., 
2018). Nowadays, baculovirus-based systems have proved to be a good 
production system for difficult-to-express proteins from all organisms 
(Drugmand et al., 2012). The most studied and widely used baculovirus 
vector is based in the Autographa californica multicapsid 
nucleopolyhedrovirus (AcMNPV).  
Insect cells, the other component of the IC-BEVS, are a robust production 
system also due to their scale-up and GMP-amenable characteristics: 
high-cell densities cultivation with modest growth requirements, in serum-free 
media, at 27 °C, without the need of CO2 as a buffer for pH control. Insects 
cells can provide human-like post-translational modifications, have a proven 
track record for production of virus-like particles (VLPs) and viral vectors and 
produce lower lactate and ammonia than mammalian-based systems due to 
their higher TCA cycle utilization (Aponte-ubillus et al., 2017; Monteiro, 2015; 
Penaud-Budloo et al., 2017; Yee et al., 2018).  
This combination resulted in the approval of several products for human use, 
such as Flublok®, Cervarix®, Provenge® and Glybera™ (reviewed in 
Monteiro, 2015 and Cox, 2012).  
The most used cell lines for biopharmaceutical production are derived from 
two lepidopteran organisms: Sf9 and Sf21 cell lines, derived from the fall army 
worm Spodoptera frugiperda, and HighFive cells, derived from the cabbage 
looper Trichoplusia ni (van Oers et al., 2015). Both have similar physical 
characteristics and culture requirements. Despite the higher recombinant 
protein expression of the HighFive cell line, Sf9 cells are preferred over Sf21 
and HighFive due to their higher efficiency in producing infectious baculovirus 
vectors (Drugmand et al., 2012). For a more detailed comparison of the two 
cell lines and an overview of the use of insect cells for biopharmaceutical 
production and their metabolic requirements, the works of Drugmand and 
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Monteiro are recommended (Drugmand et al., 2012; Monteiro et al., 2016, 
2014). 
Insect cells can be cultured over long-term passaging, although not without 
the occurrence of morphological and physiological changes and the decrease 
in the ability to produce infectious baculovirus (Clement, 2016). Other 
limitations of the system include the change in chromosome polyploidy during 
long-term cultivation (Drugmand et al., 2012), inability of insect cells to 
produce complex N-glycosylation (Steele et al., 2017) and the recent 
identification of Sf9 cell line contamination with a novel rhabdovirus (Ma et 
al., 2014). The latter two issues can be addressed by several 
glycoengineering approaches (compiled in Yee et al., 2018) or the 
development of rhabdovirus-free insect cell lines (Maghodia and Jarvis, 
2017). 
Still, the IC-BEVS is now one of the most used production systems for 
proteins and vaccines for animal and human use, in particular for multi-protein 
complexes, virus-like particles and rAAV production (Monteiro, 2015; van 
Oers et al., 2015). Recently, applications as a gene delivery vector for 
mammalian cells or in cancer therapy have also been reported (Asad et al., 
2017; van Oers et al., 2015).  
4.2. Baculovirus infection cycle  
The baculovirus infection starts with gp64-mediated cell entry, followed by 
internalization of the virus. A full infection cycle comprises three phases: 
early, late and very late. The early phase (0-6 hours post-infection, hpi) is 
characterized by the transcription of the initial baculovirus genes, responsible 
for the activation of promoters of later genes (Hopkins and Esposito, 2009; 
van Oers et al., 2015). Detection of these early expressed baculovirus genes 
is the basis for the development of titration cell lines (Hopkins and Esposito, 
2009). In the late infection phase (6 to 20-24 hpi), the baculovirus DNA 
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replication occurs, with the concomitant production of budded viruses, global 
shut-off of host cell synthesis and baculovirus-induced cell cycle arrest in the 
G2/M phase, resulting in the cell growth arrest observed in infected insect 
cells (Monteiro et al., 2012). The very late phase is characterized by the very 
strong p10 and polyhedrin promoter expression, which are usually associated 
with the recombinant protein expression (van Oers et al., 2015).  
In the wild-type virus, the baculovirus has a biphasic replication cycle, with 
two corresponding virions: budded virions, responsible for intra-organism 
systemic infection, and occlusion derived-virions, responsible for 
between-organisms infection (Keddie et al., 1989). The very late phase 
corresponds to the occluded virus production phase, in which very high 
expression levels of polyhedrin are produced, which will then involve the 
newly formed baculoviruses and being responsible for their stability outside 
of the insect larvae. The p10 promotor drives the expression of the P10 
protein, also expressed in very large amounts and required for the release of 
the occluded virus from the infected cell (Monteiro, 2015; van Oers et al., 
2015). The finding that both p10 and polyhedrin promoters were very strong 
promoters but their wild-type genes are not required for recombinant 
baculovirus replication in infected cells is the main drive of the development 
of the IC-BEVS (van Oers et al., 2015).  
4.3. Producing rAAV in the IC-BEVS 
The first report of the IC-BEVS for rAAV production was published by Urabe 
group (Urabe et al., 2002). This first generation of the system was based in 
infection with three baculovirus: one baculovirus encoding the rep gene, 
another encoding the cap gene and the third baculovirus delivering the 
ITR-flanked transgene. The helper genes necessary for rAAV expression are 
provided by the baculovirus itself (Adamson-Small et al., 2017). This 
approach requires a cell to be simultaneously infected by the three 
baculovirus, which is only possible at high multiplicities of infection (MOIs). 
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The second significant improvement using this system was the reduction of 
the system to two baculovirus, by combining the rep and cap baculoviruses 
into one only (Smith et al., 2009). This not only increases the probability of 
one cell to be infected by all baculovirus, but is also advantageous since there 
is one less baculovirus stock to generate, amplify, store and titrate (reviewed 
in Zitzmann et al., 2017). 
The necessity of co-infection of the same cell by both baculovirus has led to 
the development of strategies for system simplification by using one 
baculovirus only: one of the strategies is based on infection with a 
transgene-encoding baculovirus of Sf9 cells, which stably express the rep 
and cap genes. Because of Rep protein cytotoxicity, the authors developed a 
switch system and demonstrated the production of rAAV vectors with 
increased infectivity, although a separate cell line is needed to produce each 
rAAV serotype (Joshi et al., 2019; Mietzsch et al., 2015, 2014). The other 
approach relies on using a baculovirus vector which contains all the 
necessary genes for rAAV production: rep, cap and ITR-flanked gene of 
interest. The difficulty with this approach is to find unessential baculovirus 
genes and a third strong promoter, however the development of a single 
baculovirus system has been reported (Merten, 2016). 
Given that baculovirus is a lytic virus, rAAV production halts due to the 
baculovirus-induced cell lysis, which also releases the produced rAAVs to the 
culture medium (Meghrous et al., 2005). This lytic activity results in release 
of proteases into the culture supernatant, which can compromise rAAV 
quality, as introduced in Section 3.4.2. 
4.4. IC-BEVS production issues and further improvements  
The use of the IC-BEVS for recombinant protein expression always requires 
optimization of process conditions, such as the optimal cell concentration at 
infection (CCI), the MOI and the time of harvest (Lecina et al., 2006; Roldão 
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et al., 2008; Palomares and Ramírez, 2009). All these process variables, 
together with the cell line and culture medium used can impact product yield 
(Druzinec et al., 2013; Kwang et al., 2016).  
In particular for the CCI, the IC-BEVS shares with other viral-based systems 
the occurrence of the “cell density effect”, the drop in the cell specific 
productivity when cells are infected beyond a certain cell concentration 
(Bernal et al., 2009; Merten, 2016). This effect is likely related with the 
exhaustion of media components, as demonstrated by Mena et al who used 
feeding strategies for infection at high cell densities (Mena et al., 2010).  
Regarding MOI, the number of baculovirus per cell added at infection, the 
main strategies used are infection at low (<0.1) or high (>3) MOI. A high MOI 
strategy is useful to infect the majority of the cell population (synchronous 
infection) and maximize the probability that every cell is infected by all 
baculoviruses for applications where more than one baculovirus is needed 
(Roldão et al., 2007, 2008). However, this strategy induces cell growth arrest 
in the first 24 hpi (Palomares and Ramírez, 2009). The low MOI strategy relies 
on a first infection phase in which a small percentage of cells are infected. 
The remaining cells are infected in the following rounds of baculovirus 
replication. This strategy has the advantages of delaying the cell growth arrest 
phase, needing less amounts of viral stock and decrease the number of 
defective interfering baculoviruses produced (Palomares and Ramírez, 
2009). Still, one more than one baculovirus is used for the production process, 
the low MOI strategy can result in asynchronous infection of cells by both 
baculoviruses and more process optimization variables to consider, such as 
the overall MOI and the MOI for each baculovirus (Aucoin et al., 2006; Roldão 
et al., 2008).  
A rather interesting and scalable approach is the use of Baculovirus-Infected 
Insect Cells (BIICs) as the viral inoculum step. Briefly, insect cells are infected 
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with baculovirus and cryopreserved, resulting in a drastic reduction in the 
vector stock volume needed for infection even in the bioreactor scale 
(Cecchini et al., 2011; Wasilko et al., 2009). 
The fact that baculovirus is a lytic virus is also seen as a disadvantage, since 
the recombinant protein production always reaches an end when the cell 
enters the apoptotic stage. As such, strategies to prolong the productive 
lifetime of infected cells have been developed, relying either on stable 
expression of proteins involved in apoptosis inhibition (Fath-goodin et al., 
2009; Steele et al., 2017) optimization of the agitation and aeration rates of 
the culture (Cruz et al., 1998) or by developing culture strategies to decrease 
the shear stress sensed by infected cells, such as hollow-fiber bioreactors 
(Weidner et al., 2017) or the use of the WAVE bioreactor system (Cecchini et 
al., 2011). Another alternative is to decouple protein production from the 
baculovirus replication, using baculovirus vectors unable to replicate in 
infected cells (Marek et al., 2017), efficiently eliminating a contaminating 
product and in theory redirecting more resources for recombinant protein 
production. 
The most reported issues for rAAV manufacturing in the IC-BEVS are the 
altered capsid compositions and the low potency of the vectors obtained 
(Kondratov et al., 2017; Merten, 2016; Wang et al., 2011). However, recent 
improvements in the baculovirus and AAV vector design have addressed 
these issues using leaky ribosome scanning and attenuated Kozak 
sequences (Kondratov et al., 2017); modification of rep and cap sequences 
(Kohlbrenner et al., 2005); modifying the translation initiation sites for the VP 
proteins (Bosma et al., 2018) or by deletion of the baculovirus protease 
cathepsin (Galibert et al., 2018). 
With regards to the optimal CCI, published reports of rAAV production in this 
system use mostly CCI = 1×106 cells/mL (Große et al., 2017; Liu et al., 2010; 
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Penaud-Budloo et al., 2017; Savy et al., 2017) or CCI = 2×106 cells/mL 
(Negrete et al., 2007; Negrete and Kotin, 2007; Potter et al., 2014; Urabe et 
al., 2002). Depending on the scale and specific application, both low (Große 
et al., 2017; Liu et al., 2010; Penaud-Budloo et al., 2017; Savy et al., 2017) 
and high (Meghrous et al., 2005; Negrete et al., 2007; Negrete and Kotin, 
2007; Potter et al., 2014) MOI strategies are reported for rAAV production. 
 
5. Real-time monitoring of cell culture processes 
5.1. Quality by design and process analytical technology 
Quality by Design (QbD) is an initiative promoted by the pharmaceutical 
industry regulatory authorities, aiming to yield consistent product quality by 
switching the traditional product quality testing in the end of each batch into 
“building quality in the product, by design” (Rathore and Winkle, 2009; 
Carrondo et al., 2012). 
The Process Analytical Technology (PAT) (FDA, 2004) was launched in 2004 
by the USA FDA, aiming at facilitating regulatory approval of new drugs. It 
provides a series of recommendations, which can be summarized into two 
common goals: to identify the product critical quality attributes (CQAs), and 
to de-risk the manufacturing process by increasing process understanding, 
providing quantitative measurements of how changing the process 
parameters affects the overall process. In particular, PAT highlights the need 
to identify the process parameters with a significant impact in the product 
CQAs, termed the critical process parameters (CPP). This knowledge should 
be used to find the acceptable CPP ranges and define the product Design 
Space, the proven range of parameter values yielding a product with the 
desired quality characteristics (FDA, 2004; ICH, 2009; Pais et al., 2014). 
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As such, the PAT and QbD initiatives are strictly interconnected: only by 
understanding the manufacturing process and determining the CPP setpoints 
and acceptable ranges for each of the different phases of the process a 
product with consistent quality can be obtained. However, deviations from the 
desired setpoints will occur, and to assure their detection and early correction, 
the FDA recommendation is to use real-time monitoring tools to monitor the 
identified CPPs and CQAs, together with the design of control strategies to 
keep the product from deviating from the acceptable quality profile (FDA, 
2004; Pais et al., 2014). 
In the following sections, an overview of the real-time monitoring tools 
commonly used for cell culture processes is provided, with more focus 
provided to the techniques employed in this thesis.  
5.2. Real-time monitoring tools  
5.2.1. The use of real-time monitoring tools for cell culture 
processes 
Real-time monitoring tools for cell culture processes should, ideally, be 
non-invasive, non-destructive, and provide rapid and comprehensive 
information from the culture in real-time, as well as withstand the sterilization 
procedure and cellular activity and maintain stability and reliability between 
batches over long time periods (Carrondo et al., 2012; Glassey, 2013; Guerra 
et al., 2019; Rowland-Jones et al., 2017). Spectroscopic techniques possess 
the necessary characteristics mentioned above, and have thus been widely 
used for cell culture processes, with Raman (Rangan et al., 2018; Santos et 
al., 2018; Tulsyan et al., 2019; Webster et al., 2018), near infrared (NIR) 
(Mercier et al., 2016; Rowland-Jones et al., 2017; Wu et al., 2015), dielectric 
(Kroll et al., 2017; Mercier et al., 2016; Nikolay et al., 2018; Petiot et al., 2016) 
and fluorescence spectroscopy (Karakach et al., 2018; Schwab and Hesse, 
2017) being the most widely used.  
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Some of these techniques, such as Raman, NIR and fluorescence, are able 
to track metabolite dynamics in the complex cell culture media of mammalian 
cells (reviewed in Abu-Absi et al., 2014), providing real-time information 
simultaneously from different culture components. Dielectric spectroscopy on 
the other hand, relies on the detection of changes in cell physiology, providing 
information regarding the cell concentration and overall cell state (Negrete et 
al., 2007; Petiot et al., 2016; Zeiser et al., 2000). The key features, limitations 
and selected applications of these techniques for cell culture monitoring are 
compiled in Table I.2. 
A commonality present in real-time monitoring spectroscopic tools for cell 
culture is the large amount of data obtained due to the cell culture media 
complexity. Moreover, metabolite spectra in Raman and IR is spread over 
multiple peaks and bands, which may confound the results (Roberts et al., 
2018). As such, adequate pre-processing methods or data analysis 
techniques are necessary to analyze and model the data available from 
spectroscopic techniques. Indeed, data preparation is a step that should not 
be overlooked, with the possibility to “make or break” the success of a model 
development strategy (Bayer et al., 2019; Glassey, 2013; Pais et al., 2019). 
Common pre-processing steps are smoothing and baseline correction, 
particularly for spectroscopic data; and scaling and centering, applied before 
performing multivariate data analysis to account for only the time-course 
variation of the variable rather than the absolute value variations (Bayer et 
al., 2019; Glassey, 2013).  
When the variable of interest cannot be measured by the real-time monitoring 
tool but the probe measurements can be correlated with the variable of 
interest through chemometrics techniques, we are in the presence of a soft 
sensor (Kroll et al., 2017; Luttmann et al., 2012; Pais et al., 2019; Zabadaj et 
al., 2017). Soft sensors in cell culture processes rely on multivariate data 
analysis techniques for data reduction and elimination of noise in the original 
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dataset. The multivariate data analysis techniques most used for those 
purposes are partial least squares (PLS) and principal component analysis 
(PCA) (Glassey, 2013; Møller et al., 2005; Rathore et al., 2014). Both are 
projection-based techniques, in which the experimental data is decomposed 
into a new space using linear combinations of the input variables. These new 
vectors are the principal components (in the case of PCA) and the latent 
factors (for PLS).  
While PCA is an unsupervised technique, in PLS the decomposition in latent 
factors maximizes the relationship between input variables and the variables 
to predict (Rathore et al., 2014; Teixeira et al., 2009). Even when relying in 
spectroscopic methods such as Raman or IR for metabolite detection, 
calibration models are needed to correlate the spectral signals to the 
analytical measurements, and these models are often based in multivariate 
data analysis (Tulsyan et al., 2019). 
Without neglecting the usefulness of PCA and PLS for bioprocess monitoring, 
one cannot overlook the fact that these are based in linear regression, which 
limit their applicability for the non-linear nature of biological processes 
(Glassey, 2013). Recently, the advent of machine learning has also 
demonstrated its applicability for monitoring cell culture processes, as 
demonstrated by the use of artificial neural networks (Contreras-Gómez et 
al., 2017; Liu et al., 2017), support vector machines (Huang et al., 2019; 
Zavala-Ortiz et al., 2020), genetic algorithms (Pais et al., 2019; Sokolov et al., 
2017) or decision-trees (Sawatzki et al., 2018), to name a few. Details on the 
mode of action of each of the multivariate data analysis and machine learning 
techniques mentioned is out of the scope of the present thesis, and the reader 
is referred to the available literature (Glassey, 2013) on the topic. In particular 
for an extensive review of the different types of artificial neural networks and 
deep learning and its application to genomics, the work of Eraslan is 
recommended (Eraslan et al., 2019). 
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Table I.2 – Overview of the most common spectroscopic techniques used for cell culture monitoring, the measurement principles and selected 
references of their use for cell culture processes. Adapted from (Lourenço et al., 2012; Moore et al., 2019; Pais et al., 2019; Ribeiro da Cunha 
et al., 2019; Wu et al., 2015). VCC - Viable cell concentration; mAb - monoclonal antibody. 
 
Technique 
Measurement 
principles 
Key features Current limitations 
Measured metabolites 
and process variables 
Selected references 
Fluorescence 
Spectroscopy 
Fluorescence 
Detection of intracellular 
fluorophores; Very low 
detection limit (<0.1 ppm) 
and high selectivity. 
Suitable for aqueous 
media 
Applicable only to 
fluorescent metabolites; 
Temperature sensitive; 
Sensitive to sample 
turbidity 
Vitamins, co-factors and 
fluorescent amino acids 
(Bayer et al., 2019; Hakemeyer 
et al., 2013; Karakach et al., 
2018; Ohadi et al., 2015, 2014; 
Pais et al., 2019; Schwab et al., 
2016; Schwab and Hesse, 
2017; Teixeira et al., 2011a, 
2009; Zabadaj et al., 2017) 
Raman 
Spectroscopy 
Vibrational (Raman 
scattering) 
Rapid spectra acquisition. 
Robust to sample turbidity 
and aqueous media 
Temperature-sensitive; 
Overlapping of fluorescent 
signals. Limit of detection 
(25-150 ppm) 
Glucose, glutamine, 
amino acids, lactate, 
ammonia, glutamate; 
mAb titer, VCC. 
(Abu-Absi et al., 2011; Berry et 
al., 2016; Matthews et al., 2016; 
Rangan et al., 2018; Santos et 
al., 2018; Whelan et al., 2012) 
Infrared 
Spectroscopy 
(NIR, MIR, 
FTIR) 
Vibrational (infrared 
absorption) 
High selectivity (FTIR). 
Rapid measurements 
(NIR) 
Optical density probes 
(NIR) 
Poor selectivity using NIR;  
Strong signal from water 
absorption (NIR). 
Temperature sensitive 
 
Glucose, glutamine, 
amino acids, lactate, 
ammonia, glutamate; 
mAb glycosylation 
(Clavaud et al., 2013; 
Hakemeyer et al., 2013; Ribeiro 
da Cunha et al., 2019; Sandor et 
al., 2013; Wu et al., 2015; 
Zavala-Ortiz et al., 2020, 2019) 
Dielectric 
spectroscopy 
 
Dielectric potential of 
cells in an alternating 
electrical field 
Continuous monitoring; 
very sensitive for cell 
culture monitoring 
Only able to measure 
cell-related features 
Viable cell concentration; 
Cell biovolume.  
(Ansorge et al., 2011, 2007; 
Negrete and Kotin, 2007; Petiot 
et al., 2016) 
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All the above-mentioned techniques are the so-called data-driven techniques. 
However, bioprocess models are increasingly becoming hybrid-models, 
combining the “black box” approach of multivariate data analysis with 
first-principles modeling and bioprocess data to increase model predictive 
power (Bayer et al., 2019; Glassey, 2013; Guerra et al., 2019; Konakovsky et 
al., 2017; von Stosch et al., 2016). 
A label-free alternative to spectroscopic techniques is imaging-based cell 
culture monitoring, in which the cell itself is measured (Joeris, 2002; 
Kasprowicz, 2017; reviewed in Höpfner, 2010). Notably examples include the 
use of Digital Holographic Microscopy (DHM) (Janicke et al., 2017; Kamlund, 
2018; Ugele et al., 2018) and Raman microscopy, a combination of Raman 
spectroscopy, microscopy and multivariate data analysis (applications for cell 
culture reviewed in Kann et al., 2015). 
5.2.2. Real-time monitoring in the IC-BEVS 
The already presented characteristics of the IC-BEVS render it inherently 
amenable to be monitored using real-time monitoring tools. The majority of 
the literature report on the use of dielectric spectroscopy, which can be used 
not only for determination of the cell concentration (Zitzmann et al., 2018), 
but also for monitoring the progress of baculovirus infection (Ansorge et al., 
2007; Negrete et al., 2007; Petiot et al., 2016; Zeiser et al., 2000, 1999). NIR 
has also been used, in particular for measuring glucose, glutamine and 
lactate concentrations or cell concentration based in the light scattering 
properties of suspension cells (Qiu et al., 2014; Riley et al., 1997; Zitzmann 
et al., 2018). Because of the characteristic baculovirus-induced diameter 
increase, some authors report the use of imaging microscopy for monitoring 
the progress of baculovirus infection in insect cells (Janakiraman et al., 2006; 
Laasfeld et al., 2017; Palomares et al., 2001). 
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5.3. Fluorescence spectroscopy, digital holographic imaging and 
dielectric spectroscopy 
Being the techniques explored in this thesis, in the following sections we 
provide a more detailed explanation of the working principles of fluorescence 
spectroscopy, digital holographic imaging and dielectric spectroscopy, as well 
as selected references of its application for cell culture processes.  
5.3.1. Fluorescence spectroscopy  
Molecules have various states referred to as energy levels. Fluorescence 
spectroscopy is primarily concerned with electronic and vibrational states. 
Generally, the species being examined has a ground electronic state and an 
excited electronic state of higher energy. Within each of these electronic 
states there are various vibrational states. Fluorescence spectroscopy is 
based on the excitation of the species from its ground electronic state to one 
of the various vibrational states in the excited electronic state. Collisions with 
other molecules cause the excited molecule to lose vibrational energy until it 
reaches the lowest vibrational state of the excited electronic state (Figure I.5). 
When the molecule returns to the ground energy state, it releases energy in 
the form of light, which is less energetic than the excitation radiation due to 
the energy loss in the form of vibrational energy during collision with the other 
molecules. Fluorescence spectroscopy relies on the detection of these 
changes when both the excitation and emission light belong to the visible 
spectrum. 
Fluorescence spectroscopy has great sensitivity when compared with other 
vibrational-based spectroscopies. Besides, each excitation emission region 
in the spectra is associated with very few fluorescent compounds, unlike 
Raman, NIR or MIR, in which the metabolite spectra is contained over a wide 
range of frequencies. However, this spectroscopy is only suitable for 
detection of fluorescence molecules, such as some amino acids, vitamins and 
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co-factors present inside and outside the cells (Ohadi et al., 2014; Schwab et 
al., 2016; Teixeira et al., 2011a, 2009; Wolf et al., 2001). 
Fluorescence spectroscopy has been extensively used for monitoring water 
quality (reviewed in Carstea et al., 2016), and demonstrated to be a suitable 
tool for bioprocessing monitoring in bacteria (Bayer et al., 2019; Schwab et 
al., 2016), yeast (Karakach et al., 2018; Zabadaj et al., 2017) and mammalian 
cells (Ohadi et al., 2015; Ohadi, 2014; Teixeira et al., 2011b, 2009), including 
its use for monitoring critical quality attributes such as monoclonal antibody 
aggregation (Schwab & Hesse, 2017).  
 
 
 
Figure I.5 – Jablonski diagram for tryptophan, exemplifying the fluorescence spectroscopy 
principle. 
 
Application of fluorescence spectroscopy to cell culture processes relies 
mostly in two measuring modes: Two-dimensional (2D) fluorescence and 
synchronous fluorescence.  
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A 2D fluorescence map is obtained by setting the excitation wavelength and 
recording the fluorescence emission over the emission range. After obtaining 
the fluorescence intensity values for all the excitation-emission pairs for the 
fixed excitation wavelength, the next excitation wavelength is fixed and the 
whole emission spectra recorded. This process is repeated until the whole 
range of excitation-emission pairs is tested. This strategy yields very 
comprehensive datasets, at the cost of a lengthier spectra acquisition process 
and the need for spectra pre-processing to account of spectral overlap of 
different fluorescent species (Teixeira et al., 2009). 
Synchronous fluorescence is a more rapid acquisition mode, corresponding 
to a diagonal line in a 2D fluorescence map. In synchronous fluorescence, 
the difference between the emission and excitation wavelength is kept 
constant during the whole spectral acquisition, but both the excitation and 
emission wavelengths are changed simultaneously, resulting in a convolution 
of the excitation and emission spectra (Kaminski and Purcell, 1982). Besides 
the more rapid spectral acquisition, the obtained spectra are simpler and with 
improved peak resolution (Teixeira et al., 2011a). The choice of the offset to 
apply during spectra acquisition needs to be proper selected to maximize the 
obtained information using this technique. 
5.3.2. In situ microscopy and holographic imaging 
Microscopy was the first technique developed to observe cells (XVI century). 
Nowadays, real-time information regarding cell concentration and 
morphology can be obtained using in situ microscopy. This technique 
combines real-time imaging using a CCD camera immersed in the cell culture 
medium with image analysis algorithms (Druzinec et al., 2013). The working 
principle of in situ microscopes is either based in detection of backscattering 
or transmission light. Available commercial systems rely on both methods 
(Zitzmann et al., 2017) and have been applied for microcarrier-based or 
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suspension mammalian cell culture (Guez et al., 2004; Höpfner et al., 2010; 
Rudolph et al., 2008).  
A recent image-based technology for cell culture monitoring is quantitative 
phase imaging (QPI), which has been applied for detecting biological phases 
based on cell imaging measurements (Kasprowicz et al., 2017; Ugele et al., 
2018). QPI is based on quantification of the phase shift of the light after it has 
passed through the object of focus, such as cells (Kamlund, 2018; Mann et 
al., 2005). In digital holographic imaging (DHM), this light phase difference is 
encoded in a hologram which is used to construct high resolution intensity 
and quantitative phase images of the cell. The way that the light phase 
changes after interacting with the cells depends on cell factors such as 
thickness, circularity or intracellular composition (Kasprowicz et al., 2017; 
Kemper et al., 2010; Mann et al., 2005; Rapoport et al., 2011). As such, DHM 
can be used to extract important information from the cell state, and has 
proven useful for several cell-based applications: identification of 
morphological parameters distinguishing between epithelial and 
mesenchymal cells (Kamlund, 2018), detecting cell division in endothelial 
cells (Kemper et al., 2010) and developing cell proliferation (Janicke et al., 
2017) or cytotoxic assays (Kühn et al., 2013).  
5.3.3. Dielectric spectroscopy 
When an electric field is applied to viable cells, those behave like small 
capacitors and polarize with a frequency-dependent response. This is due to 
the dielectric proprieties of the lipid based-cell membrane and the presence 
of conductive solutes in the extracellular medium and in the cytoplasm 
(Druzinec et al., 2013). This charge can be detected and quantified, being 
reported as permittivity (capacitance per membrane area). This property is 
the working principle behind dielectric spectroscopy, rendering it a very useful 
technique for measuring viable cell concentration, as demonstrated for 
bacteria, yeast, plant, insect and mammalian cells (Ansorge et al., 2007; 
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Grein et al., 2018; Kroll et al., 2017; Liu et al., 2016; Negrete et al., 2007; 
Nikolay et al., 2018; Opel et al., 2010; Petiot et al., 2016; Zeiser et al., 2000, 
1999; reviewed in Justice et al., 2011) and also for monitoring multicellular 
spheroids (reviewed in Alexander et al., 2013). 
The ability of the cell to store charge and polarize is influenced by the 
frequency of the applied electrical field. In other words, low frequencies will 
result in the cell being able to fully polarize, while at very high frequencies the 
applied electric field switches too fast for the cell to be able to polarize. 
Plotting the permittivity of the culture over a range of applied electrical field 
frequencies yields the beta-dispersion curve (Figure I.6), which provides 
information regarding the cell characteristics. For instance, the 
beta-dispersion curve profile changes depending on the cell concentration, 
culture biovolume and cell shape and size distribution (Ansorge et al., 2007; 
Dabros et al., 2009; Petiot et al., 2016). 
Consequently, insights on the overall cell physiological state can be obtained 
by measuring the dielectric properties of the cell. As such, some authors have 
studied the progress of virus infection using dielectric spectroscopy for 
several recombinant vectors and host cells: baculovirus infection in insect 
cells (Ansorge et al., 2007; Petiot et al., 2016), VERO cells infected with 
rabies virus (Rourou et al., 2010) and lentiviral and influenza vector 
production in HEK293 cells (Ansorge et al., 2011; Petiot and Kamen, 2012). 
For a more in-depth study of the theory behind dielectric spectroscopy and its 
application to cell culture the works of Zitzmann and Dabros are 
recommended (Dabros et al., 2009; Zitzmann et al., 2017).  
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Figure I.6 – Representative diagram of the beta-dispersion curve. The curve can be defined 
by four parameters: the low and high frequency plateau represent the limit of the capacity of 
the cell to store electrical charges at low and high frequencies, respectively; the inflexion point 
of the curve is represented by the characteristic frequency, fc; and α quantifies the rate of 
decrease of the permittivity measurement with increasing frequencies. The difference between 
the high and low frequency plateaus is often referred as Δεmax. 
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6. Thesis scope and outline 
The overarching purpose of this PhD is the implementation of real-time 
monitoring tools for rAAV production in IC-BEVS, for real-time determination 
of critical process variables. Specifically, the focus is to monitor cell 
concentration, viability and rAAV production. Cell concentration and viability 
are two of the most significant process variables in this system, important for 
timing the infection and harvest steps and to follow the overall culture 
progress. Monitoring in real-time rAAV production kinetics is of special 
interest for the pharmaceutical manufacturing industry, allowing to identify 
non-compliant batches during production and increasing process 
understanding.  
The work of this thesis is divided in four parts: Chapters II to IV explore the 
application of three real-time monitoring tools to monitor rAAV production in 
the insect cell system. Chapter II uses fluorescence spectroscopy as a soft 
sensor to detect rAAV-induced metabolic dynamics in insect cells; the study 
is complemented with an analysis of the influence of different pre-processing 
methods for culture predictions. Chapter III assesses the suitability of digital 
holographic imaging for monitoring this system, exploiting the ability of this 
technology to detect intracellular dynamics in the monitored cells to detect 
possible rAAV-related variables. In Chapter IV, dielectric 
spectroscopy-based models are developed for monitoring and predicting not 
only cell concentration and viability profiles, but also intracellular rAAV 
production kinetics. The tools developed in these chapters generate 
predictive models for the measured critical process variables, based on the 
real-time monitoring probe outputs. These models allow to fulfill the final aim 
of real-time monitoring: to control the process, by acting on the identified 
critical variables in order to maintain them in the desired setpoint. Chapter V, 
the last part of the thesis, contains an update on the existing control strategies 
for biological processes.  
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In light of the previous chapters, Chapter VI presents a discussion on how 
each one of the explored techniques can contribute, by itself or combined with 
other real-time monitoring tools, to monitor rAAV quality characteristics and 
address the existing challenges for the field.  
Overall, this thesis contributes to increase the knowledge of rAAV production 
in the insect cell baculovirus system, while simultaneously exploring the 
application of different real-time monitoring tools to monitor viral production in 
infected cells. Hopefully, these strategies can be applicable not only to other 
rAAV serotypes, but for other viral vector manufacturing processes, 
contributing towards a process analytical technology (PAT) implementation 
for the gene therapy field. 
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Abstract 
The process analytical technology (PAT) initiative shifted the bioprocess 
development mindset towards real-time monitoring and control tools to 
measure relevant process variables online and acting accordingly when 
undesirable deviations occur. Online monitoring is especially important in lytic 
production systems in which released proteases and changes in cell 
physiology are likely to affect product quality attributes, as is the case of the 
insect cell-baculovirus expression vector system (IC-BEVS), a 
well-established system for production of viral vectors and vaccines.  
Here, we applied fluorescence spectroscopy as a real-time monitoring tool for 
recombinant adeno-associated virus (rAAV) production in the IC-BEVS. 
Fluorescence spectroscopy is simple, yet sensitive and informative. To 
overcome the strong fluorescence background of the culture medium and 
improve predictive ability, we combined artificial neural network models with 
a genetic algorithm-based approach to optimize spectra pre-processing.  
We obtained predictive models for cell viability, cell concentration and rAAV 
intra and extracellular titer with normalized root mean squared errors of 4 %, 
7 %, 16 % and 7 %, respectively, for leave-one-batch-out cross-validation.  
Our approach shows fluorescence spectroscopy allows real-time 
determination of the best time of harvest in order to maintain rAAV infectivity, 
an important quality attribute, and detection of deviations from the golden 
batch profile. Spectra acquisition takes 22 minutes for 2D-fluorescence maps, 
but less than 2 minutes for the synchronous fluorescence mode. This 
methodology can be applied to other biopharmaceuticals produced in the 
IC-BEVS, supporting the use of fluorescence spectroscopy as a versatile PAT 
tool.  
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1. Introduction 
Following the introduction of the process analytical technology (PAT) initiative 
(FDA, 2004), new process development efforts have focused on: i) a thorough 
characterization of product quality; ii) increasing process understanding; and 
iii) the use of real-time monitoring and control tools to implement robust 
bioprocesses. The use of PAT tools allows minimizing the impact of process 
variations in product quality, ensuring its consistency, cost savings and 
real-time release, ultimately easing regulatory approval of new drugs. 
Nevertheless, the potential benefits brought on by PAT are hindered by 
resistance in implementing new tools to existent bioprocesses and the 
concern that the investment in these technologies will exceed the benefits of 
their implementation (reviewed in Henriques et al., 2018; Pais et al., 2014). 
For a wide implementation of PAT, real-time monitoring solutions are needed. 
Spectroscopic methods are ideal for use as analyzers to support process 
control, enabling its use to assure product quality during production and to 
act in conformity when undesirable changes are observed (FDA, 2004; 
Teixeira et al., 2011; reviewed in Pais et al., 2014). 
Several spectroscopic techniques have been used for cell culture processes 
and virus production monitoring, with Raman (Rangan et al., 2018; Santos et 
al., 2018; Webster et al., 2018), near-infrared (Mercier et al., 2015; 
Rowland-Jones et al., 2017), dielectric (Kroll et al., 2017; Mercier et al., 2015; 
Nikolay et al., 2018; Petiot et al., 2016) and fluorescence spectroscopy 
(Karakach et al., 2018; Schwab & Hesse, 2017) being the most widely used. 
All possess characteristics desirable for PAT: spectroscopic techniques are 
non-invasive, non-destructive, and able to provide rapid information from 
several components simultaneously (Ohadi et al., 2014, 2015; 
Rowland-Jones et al., 2017; Teixeira et al., 2011, 2009), including product 
quality attributes (Chopda et al., 2017; Li et al., 2019). Both Raman and 
fluorescence have proven worthy for monitoring recombinant protein 
production and cell density in cell culture processes, due to their ability to 
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track metabolite dynamics in the complex cell culture media of mammalian 
cells (reviewed in Abu-Absi et al., 2014). Fluorescence spectroscopy has the 
advantages of a more straightforward spectra acquisition, pre-processing and 
interpretation, coupled with high sensitivity and low cost. It also can detect 
fluorophores inside and outside the cells (Ohadi et al., 2014; Schwab et al., 
2016; Teixeira et al., 2011, 2009; Wolf et al., 2001). When compared with 
dielectric spectroscopy for monitoring virus and protein production, 
fluorescence has the advantage of incorporating information from metabolite 
dynamics, rather than using changes in cell physiology (Negrete et al., 2007; 
Petiot et al., 2016; Zeiser et al., 2000). 
Fluorescence spectroscopy has proven useful to monitor cell and product 
formation, as well as metabolite consumption and production in different 
biological systems. Examples include prediction of biomass and recombinant 
protein production in E. coli (Schwab et al., 2016) and prediction of product 
titer, glucose consumption, optical density and overall culture progression in 
yeast cultures (Karakach et al., 2018; Zabadaj et al., 2017), to name a few. 
Our group and others have also shown the applicability of fluorescence 
spectroscopy to monitor viable cell concentration and recombinant protein 
titers in mammalian cell culture systems (Ohadi et al., 2014, 2015, Teixeira 
et al., 2011, 2009), or critical quality attributes such as monoclonal antibody 
aggregation (Schwab & Hesse, 2017).  
In this work, we investigate the use of fluorescence spectroscopy as a soft 
sensor to monitor recombinant adeno-associated virus (rAAV) production in 
the insect cell-baculovirus expression vector system (IC-BEVS). Soft sensors 
infer information for process variables that cannot be measured directly 
based on other measured variables. For fluorescence spectroscopy, the 
spectra reflect changes in the concentrations of fluorophores such as amino 
acids, co-factors and vitamins present in the cell culture medium, which can 
then be correlated with culture progression and viral production. As with other 
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spectroscopic techniques, fluorescence-based soft sensors require adequate 
spectra pre-processing combined with multivariate models to predict relevant 
process variables accurately (reviewed in Glassey, 2013). Chemometrics 
employs mostly linear methods, but to model the non-linear nature of 
biological systems, non-linear learning models can be used. These include 
artificial neural networks (ANN), which have a broad track record of 
applications to bioprocess monitoring (Contreras-Gómez et al., 2017; Wolf et 
al., 2001).  
Recombinant adeno-associated viruses (rAAV) are increasingly gaining 
interest as viral vectors for gene therapy. Reasons include their safety profile, 
long term transgene expression and the existence of several serotypes, 
which allow transduction of cells from different tissues (Gray et al., 2012). 
Large-scale manufacturing of rAAV is still a challenge, with several biological 
systems competing for establishment as the preferred platform for rAAV 
production. One of those systems is the IC-BEVS, which is well established 
for manufacturing of recombinant products, with several approved 
biopharmaceuticals on the market. Advantages of this system include high 
productivity, scalability and GMP-compatible characteristics (Cox, 2012; 
Merten, 2016).  
Here, we combine in-situ fluorescence spectroscopy with ANN models to 
predict relevant process variables, such as viability and product titer, in the 
IC-BEVS platform during rAAV production. As mentioned previously, in 
fluorescence spectroscopy the useful information obtained is highly 
dependent on adequate spectra pre-processing (Wolf et al., 2001). In the 
insect cell medium, this is even more relevant due to the existence of a strong 
background fluorescence signal. As such, a genetic algorithm-based 
approach was applied to maximize predictive power through optimization of 
spectra pre-processing, using different combinations of common spectra 
pre-treatments.  
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2. Materials and Methods 
2.1. Cell line and culture medium  
Spodoptera frugiperda Sf9 cells were obtained from Thermo Fisher Scientific 
(No 11496015) and routinely cultivated in 500 mL glass Erlenmeyer flasks 
with 50 mL working volume of SF900-II medium (GibcoTM), at 27 °C with an 
agitation rate of 100 rpm in an Innova 44R incubator (orbital motion diameter 
= 2.54 cm, Eppendorf). Cell concentration and viability were determined using 
a Cedex HiRes Analyzer (Roche). 
HT1080 cells (Agilent), used for titrating infectious rAAV, were maintained in 
a 37 °C humidified atmosphere incubator with 5 % CO2 in air, cultured in high 
glucose DMEM medium (GibcoTM) supplemented with 10 % Fetal Bovine 
Serum (GibcoTM). 
2.2. Viruses, infection and titration 
The recombinant Autographa californica nucleopolyhedrovirus encoding the 
GFP transgene under the control of the cytomegalovirus promoter 
(CMV-GFP) and flanked by AAV2 inverted terminal repeats (ITR) regions was 
kindly provided by Généthon and was titrated and amplified in house as 
described for the rep/cap baculovirus (below).  
The plasmid containing rAAV2 rep and cap genes was a gift from Robert Kotin 
(Addgene plasmid #65214) (Smith et al., 2009). Recombinant baculovirus 
was produced using the Bac-to-Bac® Baculovirus Expression System 
(Invitrogen), according with manufacturer instructions. Baculovirus 
amplification was performed infecting exponential growing suspension Sf9 
cells at 1×106 cells/mL at a multiplicity of infection (MOI) of 0.01 plaque 
forming units (pfu) per cell. When cell viability was between 80-85%, culture 
was harvested and centrifuged at 200 g for 10 min at 4 °C. After discarding 
the pellet, the supernatant was centrifuged at 2000 g for 20 min at 4 °C, and 
the resulting supernatant titrated and stored at 4 °C in clarified culture 
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medium, protected from light and periodically titrated in Sf9 cells using the 
MTT assay as described elsewhere (Roldão et al., 2009).  
Recombinant adeno-associated virus (rAAV) intra and extracellular titer was 
estimated separately using a commercially available sandwich ELISA kit 
(Progen Biotechnik GmbH), according to the manufacturer instructions. This 
kit detects a conformational epitope present in assembled rAAV capsids. 
Infectious rAAV titer was determined by titrating intra and extracellular 
samples using the HT1080 cell line. Briefly, 3×104 cells were infected with 
serial dilutions of rAAV virus in 200 µL DMEM+2% FBS, in 24-well plates. The 
plate was gently shaken every 30 minutes until 4 hours after infection, at the 
time a fresh DMEM+12 % FBS was added to reach a final concentration of 
DMEM+10 % FBS. Cells were harvested 42 hours post-infection, and 
infectious titer was calculated by determining the percentage of 
GFP-expressing cells in a flow cytometer (CyFlow Space, Partec).  
2.3. Bioreactor cultures and sample processing 
Four independent bioreactor runs (BR1-4) were performed using 1 L 
BIOSTAT® DCU-3 (Sartorius), equipped with two Rushton turbines. 
Temperature control (27 °C) was achieved using a water recirculation jacket 
and gas supply was provided by a ring sparger in the bottom of the vessel. 
Two additional bioreactor cultures (BR5 and 6) were performed using the 
QPlus system (Sartorius), with a working volume of 0.5 L and equivalent 
hydrodynamic characteristics to the 1 L bioreactors. Figure II.1 summarizes 
the experimental methodology: Sf9 cells were inoculated at 0.5×106 cells/mL 
and infected with rAAV2 and GFP-expressing baculoviruses the day after, 
when cell concentration reached 1×106 cells/mL. The progress of infection 
was monitored in situ for the 4 BIOSTAT® cultures using fluorescence 
spectroscopy. Sf9 infection was performed at varying MOIs (total of 0.02, 0.1 
or 10 pfu/cell, with the two baculoviruses in equal proportions). Dissolved 
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oxygen (DO) concentration was kept at 30 % by controlling the stirring rate 
(70-270 rpm) and the N2 /air ratios in a mixture of air and N2 (0.01 vvm). 
At each sampling point, cell concentration and viability were measured, and 
a clarification step was performed (200 g, 10 min, 4 °C). Supernatant was 
subjected to a further clarification step (2000 g, 20 min, 4 °C) and stored 
at -80 °C for offline analysis. Cell pellets were used for intracellular rAAV 
quantification, by extraction with TNT buffer, consisting of 20 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, 1% Triton X-100, 10 mM MgCl2 (Smith et al., 2009), 
to which a 0.5 % solution of sodium deoxycholate was added to further 
increase the release of intracellular rAAV from pelleted cells (Gray et al., 
2012). After 10 minutes of incubation at 22 °C, the suspension was 
centrifuged (2000 g, 20 min, 4 °C) and the supernatant stored at -80 °C for 
offline analysis.  
2.4. Fluorescence spectra acquisition 
Online fluorescence data was acquired in situ using a spectrofluorometer 
(Horiba Jobin Yvon Fluoromax-4) equipped with a bifurcated optical fiber 
cable. To accommodate the optical fiber, we designed and built in house a 
cylindrical stainless-steel probe which fits into a bioreactor 19 mm top port 
and accommodates a quartz lens (CVI laser optics) in the bottom, in contact 
with culture media. The bioreactors were covered with a blackout material to 
prevent interference of outside light with the fluorescence acquisition. For the 
2 Qplus bioreactors, fluorescence acquisition was performed offline in a 
Tecan Spark® 10 M microplate reader (Tecan Group Ltd), with 250-520 nm 
excitation range and 280-640 nm emission range.  
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Figure II.1 - Experimental and computational setup. Exponential growing Sf9 cells were cultured in stirred tank bioreactors and co-infected by 
two baculoviruses (encoding a CMV-GFP gene and AAV rep-cap2 genes). Fluorescence spectra were acquired online using an in-situ probe, 
connected to the fluorometer through optical fibers. Samples were collected at several culture time points to determine relevant process 
variables and fluorescence spectra were acquired in two modes (2D maps and synchronous fluorescence). These spectra were pre-processed 
to maximize predictive power, based on genetic algorithm-guided computational approach. To correlate fluorescence signals with experimental 
process variables, different prediction models were tested: PLS – partial least squares regression; N-way – multi-way PLS; ANN – artificial 
neural network regression. 
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For the 4 BIOSTAT bioreactors, 2D fluorescence maps and synchronous 
spectra were acquired online (no cell centrifugation) simultaneously to 
sampling. 2D fluorescence maps were acquired with 5 nm steps in the 
250-520 nm excitation range and 265-640 nm emission range. Synchronous 
fluorescence is a fluorescence acquisition mode in which the difference 
between excitation and emission (Δλ) is kept constant throughout the scan. 
In this work we evaluated Δλ values of 20, 80 and 140 nm, in the 250-520 nm 
excitation range, with 2 nm steps. Synchronous fluorescence data was 
concatenated and utilized as one dataset only. Slit widths were set to 2.5 nm 
for excitation and emission in the two fluorescence acquisition modes.  
In addition to acquisitions done simultaneously with sampling, fluorescence 
spectra were also acquired between two samples to increase the data 
available for model training. The reference data values for these spectra were 
estimated using MATLAB (Mathworks Inc, USA) cubic smoothing spline 
function. 
2.5. Spectra pre-processing 
Several pre-processing methods for 2D maps and synchronous fluorescence 
spectroscopy were implemented using in house MATLAB code. The choice 
of the spectra pre-processing combinations that could increase predictive 
power and increase accuracy of reference data prediction was guided by a 
genetic algorithm. The pre-treatments available to the genetic algorithm for 
2D maps and synchronous fluorescence spectra are listed in Supplementary 
Table II.1. 2D maps were converted from two- to one-dimensional arrays for 
pre-processing and algorithm training.  
Optimization of the extent of Rayleigh and Raman scattering removal was 
performed visually, by gradually increasing the excised excitation-emission 
pairs below and above the excitation wavelength of the known scatter area 
using the drEEM toolbox (Murphy et al., 2013). The chosen values (60 and 
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25 nm for 1st and 2nd order Rayleigh and 5 nm for 1st and 2nd order Raman) 
represent a compromise between extent of scatter removed without loss of 
important information. For the Qplus the obtained spectra were normalized to 
the 1 L bioreactors culture medium fluorescence spectrum.  
Each data point consists of a 2D map, 3 synchronous fluorescence scans and 
the corresponding set of reference data (cell concentration, viability, rAAV 
total concentration, rAAV intracellular percentage and rAAV titer). The 
sampling time was added to the fluorescence data. 
2.6. Artificial neural network (ANN) and partial least squares (PLS) 
predictors 
For the artificial neural networks, partial least squares and principal 
component analysis (PCA) calculations, MATLAB built-in functions and 
standard toolboxes were used. ANN models were trained using the 
Levenberg-Marquardt backpropagation algorithm. To avoid overfitting, only 
ANN structures with up to two hidden layers were considered, with a 
maximum of 4 nodes in each layer, in a total of 9 different architectures. 
Leave-one-batch-out (LOBO) cross-validation was employed by using all 
batches but one for model training and predicting the remaining batch feeding 
its fluorescence spectra to the trained model. The optimal number of latent 
variables for PLS and ANN architecture was obtained by cross-validation. 
Specifically, for PLS the number of latent variables was increased until the 
obtained models started overfitting the predicted batches (measured by the 
normalized root mean squared error of cross-validation (nRMSEcv), 
normalized to the range of the variable, Equation 1). For ANN, the nRMSEcv 
was calculated for all predicted batches for each of the 9 architectures, and 
the one presenting the lowest nRMSEcv was chosen as the optimal model.  
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𝑛𝑅𝑀𝑆𝐸𝑐𝑣 =
√
∑ (?̂? − 𝑦)2𝑛𝑠𝑎𝑚𝑝𝑙𝑒𝑠𝑖=1
𝑛𝑠𝑎𝑚𝑝𝑙𝑒𝑠
max(𝑦) − min(𝑦)
                                                  (1) 
 
In equation 1, ?̂?  represents a vector of model-predicted values and y 
represents the corresponding reference data for the validation set; nsamples 
is the total number of data points and max(y) and min(y) refer to the maximum 
and minimum values for the standardized reference data, respectively.  
The correlation coefficients of calibration and validation (R2 and Q2) were 
calculated according to equations 2 and 3, respectively using calibration 
(ncal) or validation (nval) samples. σ2 represents sample variance and 
RMSEC and RMSEV stand for root mean-squared error of the calibration and 
validation set, respectively.  
𝑅𝑀𝑆𝐸𝐶 = √
∑ (?̂? − 𝑦)2𝑛𝑐𝑎𝑙𝑖=1
𝑛𝑐𝑎𝑙
             𝑅𝑀𝑆𝐸𝑉 = √
∑ (?̂? − 𝑦)2𝑛𝑣𝑎𝑙𝑖=1
𝑛𝑣𝑎𝑙
                          (2) 
𝑅2 = 1 −
𝑅𝑀𝑆𝐸𝐶2
𝜎2
                             𝑄2 = 1 −
𝑅𝑀𝑆𝐸𝑉2
𝜎2
                                           (3) 
 
2.7. Sensitivity analysis 
A Monte Carlo sensitivity analysis was performed to find the fluorescence 
regions contributing more for the prediction of each process variable. Briefly, 
for each principal component (PC) of the 2D map obtained after 
pre-processing, 10000 new data points were generated, with random noise 
added to that PC with a normal distribution with average and standard 
deviation calculated from all PC values. The remaining values were kept 
constant and equal to the average of each PC. ANN outputs for the new data 
points were computed, and a relative standard deviation, RSD, was 
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calculated. The Monte Carlo results were converted back to the form of a 2D 
map by reversing the PCA transformation.  
 
3. Results  
3.1. Culture conditions and rAAV production 
The main purpose in this study was to correlate fluorescence spectra 
dynamics with rAAV production in Sf9 cells using the baculovirus expression 
vector system. In order to build a robust fluorescence-based monitoring 
platform, a range of culture conditions was covered (Table II.1), including low 
and high multiplicities of infection (MOI) and the use of different fluorometers 
for online and offline spectra acquisition. Overall MOIs tested ranged from 
0.02 to 10 pfu/cell, yielding between 1.4 and 13.3×1010 total rAAV 
capsids/mL. Infectious rAAV concentration was strongly correlated with total 
titer (R2=0.935), ranging from 0.8 to 7.4×107 infectious rAAV/mL. To improve 
process understanding, the intra- and extracellular rAAV capsid titer and 
infectious titer were quantified (Supplementary Figure II.1 C, D and E 
respectively), as well as cell concentration and viability (Supplementary 
Figure II.1 A and B, respectively). In order to provide the model with a wider 
training space, the experiments included common harvest times described in 
other works (day 3 and 4 post-infection) as well as an extra day of production. 
The different experimental conditions translated into a high and desirable 
experimental variability, where similar trends between cultures can be 
observed, although with significant differences in rAAV titer and quality 
profiles.  
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Table II.1 - Summary of the culture conditions, spectra acquisition mode, maximum total rAAV achieved and number of samples for each batch. 
The MOI indicated is overall MOI for the culture. The same MOI was used for each baculovirus (rep-cap2 and CMV-GFP), and as such individual 
MOI for each baculovirus is half of the presented value. Cell samples represent number of samples used to build models for prediction of viability 
and cell concentration. Product samples represent the number of samples used to build models for prediction of rAAV titer and total rAAV. 
 
Bioreactor 
number 
Fluorescence 
acquisition 
mode 
Overall 
MOI 
(pfu/cell) 
Day of 
harvest 
Maximum 
rAAV 
(1010 total 
capsids/mL) 
Maximum 
infectious 
rAAV 
(107 
infectious 
rAAV/mL) 
2D spectra SF spectra 
Cell 
samples 
Product 
samples 
Cell 
samples 
Product 
samples 
1 Online 0.02 4 1.4 0.8 27 15 27 16 
2 Online 0.1 5 13.3 6.4 33 28 33 28 
3 Online 0.1 5 12.4 7.4 34 26 52 42 
4 Online 0.1 5 4.9 2.9 35 21 33 20 
5 Offline 0.02 5 1.7 1.7 13 5 NA NA 
6 Offline 10 5 1.7 2.5 13 5 NA NA 
rAAV – recombinant adeno-associated virus; MOI – multiplicity of infection (pfu/cell); CMV-GFP - GFP transgene under the 
control of the cytomegalovirus promoter; pfu=plaque forming units; NA – not applicable.  
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3.2. Fluorescence spectra dynamics 
Despite the differences in the experimental determination of process 
variables, common trends in the temporal fluorescence profiles for all cultures 
were identified (Figure II.2). Although some fluorescence regions have a clear 
trend over culture time, either with decreasing intensity (e.g. 
excitation/emission pair 290/350 nm, corresponding to tryptophan) or 
increasing intensity (e.g. 440/530 nm, corresponding to riboflavin), overall 
most fluorescence regions associated with important co-factors and vitamins 
are difficult to correlate with process variables using univariate analysis 
methods. Nevertheless, fluorescence regions correlated with cell viability 
profiles could be identified in the spectra with the two fluorescence acquisition 
methods evaluated: 2D maps (Figure II.2 A, riboflavin region) and 
synchronous fluorescence (Figure II.2 B), highlighting the potential of this 
spectroscopy for real-time monitoring in this system.  
3.3. Fluorescence-based ANN models can predict important process 
variables 
The first approach into developing 2D fluorescence-based models for rAAV 
production was based on the four online bioreactors. When coupled with PCA 
and adequate spectra pre-processing, ANN models yielded good predictions 
that captured the correct trend of the experimental data for all relevant 
process variables (Figure II.3).  
Chapter II 
76 
 
 
Figure II.2 - Representative fluorescence spectra collected at different time points. (A) 2D 
fluorescence maps; (B) Synchronous fluorescence spectra, with Δλ of 20 nm; (C) 2D map for 
the culture media with indication of synchronous fluorescence regions used (black lines) and 
expected location for known fluorophores. 
 
The best prediction model was obtained for cell viability, with a nRMSEcv of 
4% (Figure II.3 A). The nRMSEcv was 7% for both extracellular rAAV titer 
and viable cell concentration models (Figure II.3 B and C) and 16% for total 
rAAV concentration (Figure II.3 D), which are good predictions considering 
the demanding leave-one-batch-out validation strategy used and the 
variability of the dataset. For each variable, the number and size of hidden 
layers in the ANN model was optimized (limited to 2 hidden layers and 4 
nodes per layer) and different pre-processing combinations were used, as 
indicated in Supplementary Table II.2. 
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Figure II.3 - Experimental and predicted values for four bioreactor runs using online 2D 
fluorescence maps and artificial neural network (ANN) models. (A) Cell viability; (B) 
Extracellular rAAV titer; (C) Viable cell concentration; (D) Total rAAV concentration (intra and 
extracellular rAAV). Model-predicted values for a bioreactor are based on ANN models trained 
using data from the other three bioreactors (leave-one-batch-out cross-validation). Colors 
represent different batches, open circles represent experimental data and filled circles show 
model predictions. The different ANN architectures and the spectra pre-processing used are 
described in Supplementary Table II.2. 
 
The culture time was used as an input variable, in addition to the 2D maps, 
which improved accuracy of model predictions (Supplementary Table II.3).  
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Similarly to 2D maps, synchronous fluorescence spectra can be used with 
ANN models to predict process variables (Supplementary Figure II.2). 
Nevertheless, when all culture predictions are considered, predictors based 
on 2D maps are more accurate than those based on synchronous 
fluorescence, despite the similar nRMSEcv (Table II.2), indicating the former 
contain important spectral information missing in the synchronous spectra.  
The final ANN models were benchmarked against linear partial least squares 
(PLS) regression models. The non-linearity of the system is confirmed in the 
inability of using PLS for modeling, translating into much higher nRMSEcv 
values (Table II.2).  
 
Table II.2 - Comparison of ANN and PLS regression models for different process variables, 
using 2D and synchronous fluorescence data for the four online cultures (bioreactors 1-4). 
Values represent the cross-validation error calculated using leave-one-batch-out after 
optimization of pre-processing. For ANN models, values in parentheses represent the ANN 
architecture, e.g., an ANN with two hidden layers, with 3 nodes on the first one and 2 nodes 
on the second layer would be represented as (3 2). For PLS models, values in parentheses 
represent the number of latent factors. 
 
Predicted Variable 
2D SF 
ANN PLS ANN 
Cell concentration    11%  (4 1)     19%  (2)      9%  (2) 
Viability      4%  (2)     14%  (3)      4%  (1) 
Total rAAV concentration    16%  (2 3)     28%  (1)    14%  (4) 
% Intracellular rAAV    16%  (4)     26%  (2)    14%  (3 2) 
rAAV extracellular titer      7%  (3 2)     22%  (1)      7%  (4) 
ANN – artificial neural network; PLS – partial least squares; 2D -two-dimensional 
fluorescence data; SF – synchronous fluorescence data; rAAV – recombinant 
adeno-associated virus. 
 
3.4. Assessment of model robustness and fluorescence regions 
important for prediction  
Model robustness was assessed by performing bioreactor cultures with 
variable profiles and acquiring fluorescence data in two different fluorometers 
(Table II.1). As before, ANN models with a leave-one-batch-out validation 
strategy were used and pre-processing was optimized guided by a genetic 
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algorithm. The resulting predictive models for the complete dataset 
(Figure II.4) showed similar predictive capabilities (as shown by the 
nRMSEcv) to the models using online fluorescence data only. This 
demonstrates that fluorescence data from different fluorometers can be 
combined for model training, independently of the fluorometer or culture 
condition, when combined with adequate pre-processing, tailored for each 
process variable (see also Supplementary Figure II.3).  
 
 
 
Figure II.4 - Assessment of fluorescence models robustness by combination of fluorescence 
data acquired in different fluorometers. Fluorescence spectra for bioreactors 1-4 was acquired 
online, whereas for bioreactors 5 and 6 this data was acquired offline in another fluorometer. 
(A) Cell viability; (B) rAAV extracellular titer. Colors represent different batches, open circles 
represent experimental data and filled circles show model predictions. The different artificial 
neural network (ANN) architectures used are the same as in Figure 3 A-B, respectively, and 
the spectra pre-processing combinations used are described in Supplementary Table II.2. 
 
Sensitivity analysis using Monte Carlo simulations highlights that the most 
important excitation-emission pairs are different for each predicted process 
variable (Figure II.5). The metabolites associated with each region provide 
information which can be used for process improvement. Noteworthy, the 
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sensitivity analysis results are highly associated with the PCA coefficients for 
each variable (Supplementary Figure II.4). 
 
 
 
Figure II.5 - Regions of the fluorescence spectra more meaningful for prediction based on 
Monte Carlo simulations using the artificial neural network (ANN) models from Figure 3. (A) 
Cell viability; (B) Total rAAV concentration; (C) Extracellular rAAV titer. Expected location for 
known fluorophores is indicated in black. Black lines represent synchronous fluorescence 
regions using a Δλ of 80 and 140. Monte Carlo sensitivity scores are colored according to their 
positive (red) or negative (blue) values, which arise from the principal component scores and 
the relative standard deviation (RSD) obtained for each principal component after Monte Carlo. 
 
4. Discussion 
The aim of this study was the development of a fluorescence 
spectroscopy-based approach to monitor rAAV production in IC-BEVS to 
enable PAT implementation in this system. Fluorescence spectra predictive 
power was maximized through a combination of pre-processing techniques, 
efficiently circumventing the strong fluorescence background of insect cell 
culture medium to predict rAAV production profiles and supporting the time of 
harvest decision, an important process parameter for virus-based processes 
(Grein et al., 2018; Nikolay et al., 2018).  
The best time of harvest is dependent on many different factors. These 
include not only bioprocess parameters like cell concentration at infection 
(CCI), MOI and culture medium, but also the baculovirus construct, making it 
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difficult to draw general conclusions. In previous reports (Aucoin et al., 2006, 
2007; Meghrous et al., 2005), the maximum rAAV total and infectious titer 
was obtained at 72 hpi, using a high MOI. Here, using a low MOI strategy, 
the maximum rAAV total and infectious titer were achieved at the same 
culture time. Additionally, the aforementioned reports found a plateau in 
infectious rAAV concentration after 72 hpi, whilst in this work infectious titer 
peaks at 72 hpi, and then decreases (Supplementary Figure II.1 E). The 
concentration of infectious rAAV particles is a critical determinant of the 
product quality, and as such the knowledge of the process variables that 
affect it is critical to obtain higher rAAV quality. This decrease in infectious 
rAAV titer can be explained with the decrease in cell viability upon 
baculovirus-induced cell lysis and the consequent release of proteases to the 
culture medium, to which rAAV is sensitive (Florencio et al., 2015). Therefore, 
to have a process able to monitor in real-time the decrease of viability of 
infected cells is critical to ensure rAAV infectious titers remain at their peak.  
The high complexity of the cell culture medium, together with its strong 
fluorescence signal, justifies a two-fold approach for developing fluorescence 
spectroscopy-based tools for real-time monitoring in this system: first, 
increasing the predictive power of the fluorescence spectra, by optimizing 
spectra pre-processing; second, to make use of PCA and chemometric tools 
for dimensionality reduction and correlation of relevant fluorescence regions 
with process variables.  
The first approach was guided by a genetic algorithm. Although a widely used 
computational technique for numerous applications, the use of genetic 
algorithms for optimization of fluorescence spectra pre-processing has not 
been reported before. Based on pre-processing combinations optimized for 
each model (Supplementary Table II.2), we concluded that for 2D matrices, 
dividing each excitation-emission pair by its integral and standard deviation 
for all samples was one of the most important pre-processing steps. 
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Subtracting the average of emission wavelengths and scaling by standard 
deviation of excitation wavelengths, or vice-versa, was also a pre-processing 
combination useful for model prediction, since in the same step information 
from excitation and emission wavelengths for all samples is considered. 
These are scaling approaches which minimize the effects of variability among 
different spectra acquisitions and batches. Performing a PCA reduction to 
manage the highly redundant 2D maps before training the ANN model 
(Teixeira et al., 2009; Zabadaj et al., 2017) greatly improved not only the 
prediction but also the time needed for model training. 
As a viral-dependent production process, the system under study is 
characterized by non-linear dynamics (Roldão et al., 2007), which can be 
perceived in the viable cell concentration and total rAAV titer profiles 
(Figure II.3 C and D respectively). In particular, cell concentration increases 
significantly in the beginning of the culture when the fluorescence spectra 
show less variation. Additionally, fluorescence spectra can present 
fluorophore overlapping and inner-filter effects, further increasing non-linear 
behavior (Teixeira et al., 2009). As such, the second approach was based on 
the use of non-linear modeling tools combined with chemometrics for process 
monitoring. Specifically, artificial neural networks (ANN) were tested and 
benchmarked against partial least squares (PLS) regression, a standard 
linear model for chemometrics (Teixeira et al., 2009). In PLS, the aim is to 
maximize the relationship between inputs (fluorescence spectra) and outputs 
(variables to predict). This is achieved by extracting the most relevant 
information from the input data in the form of latent variables, hence 
simultaneously offering dimensionality reduction, by transforming the N input 
variables into M orthogonal latent factors or principal components (M≤N). The 
ideal number of latent factors is determined to prevent overfitting. Unlike PLS, 
ANN can describe non-linear relationships between inputs and outputs. To 
do so, an ANN has a number of hidden layers, each with a number of nodes 
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with variable connectivity. The nodes on the input layer receive the inputs and 
apply a non-linear transformation to the data. According to the results of the 
transformation, these nodes will activate specific nodes on the subsequent 
layer until the output layer is reached. The number of hidden layers and the 
number of nodes in each layer is adjusted by testing several configurations in 
training and validation data. 
Linear models based on PLS regression did not predict well process variables 
using leave-one-batch-out (LOBO) cross-validation, a consequence of the 
system non-linearity (Table II.2). To use the 2D fluorescence maps in their 
2D format, rather than converting them in one-dimensional arrays (Teixeira 
et al., 2009), N-way PLS was also tested (Murphy et al., 2013). However, the 
results obtained were similar to PLS, and consequently PLS was preferred. 
ANN have been used previously to model non-linear interactions in 
bioprocesses, including also in the IC-BEVS (Contreras-Gómez et al., 2017; 
Wolf et al., 2001), and therefore were chosen for chemometric modeling.  
The best predictors were obtained for viability and extracellular rAAV 
concentration, variables which have an expected higher impact on 
extracellular medium composition and thus on the supernatant fluorescence. 
Viability profiles in the beginning of the culture have less accurate predictions 
(Figure II.3 A) because there is no significant release of the fluorescent 
compounds into the culture medium before cells start lysing. Model-based 
prediction of variables such as cell concentration or intracellular rAAV 
accumulation based on secretion and uptake of fluorescent metabolites is 
less direct, and highly dependent on the quality of the obtained spectra and 
the number of batches. Still, both biomass and assembled rAAV particles 
have fluorescent compounds in their composition. In fact, according to 
published data regarding AAV2 capsid composition (UniProt, 2002), 12 % of 
the assembled AAV capsid is composed of the fluorescent amino acids 
tryptophan, phenylalanine and tyrosine. One possible strategy to improve 
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prediction of cell concentration and total rAAV concentration would be to use 
two in-situ probes, combining fluorescence and dielectric spectroscopy. In 
this way, medium components information from the fluorescence probe could 
be combined with the cell concentration and cell physiology information from 
the capacitance probe, which has proven useful for insect cell culture 
(Negrete et al., 2007; Petiot et al., 2016; Zeiser et al., 2000). 
The robustness of the fluorescence-based models is confirmed by prediction 
of the rAAV titer for a bioreactor with a low production profile (Figure II.3 B 
and D, bioreactor 1), using fluorescence data from the other batches. The 
similar prediction ability when using fluorescence spectra from different 
fluorometers and from cultures with dissimilar rAAV production profiles at high 
and low MOIs (Figure II.4 and Table II.1) also sustain the claim that adequate 
pre-processing is critical for accurate predictions (Supplementary Figure II.3), 
allowing combination of data from different fluorometers. As expected, when 
adding the fluorescence spectra acquired from the different fluorometers, a 
better model was obtained when normalization to culture medium was 
performed. Taken together, this work demonstrates that fluorescence-based 
models, coupled with adequate spectra pre-processing, are robust and can 
be used to detect deviations to a standard rAAV production profile in the 
IC-BEVS.  
One disadvantage of using 2D maps is the lengthier spectra acquisition time 
(22 minutes per sample). As such, the suitability to apply synchronous 
fluorescence for this system was assessed. Synchronous fluorescence 
allows faster spectra acquisition (1.5 minutes per sample) by focusing on 
excitation-emission pairs with a fixed offset between them (Δλ) (Teixeira et 
al., 2011). The acceptable predictions obtained (Supplementary Figure II.2), 
coupled with the knowledge of the spectral regions more important for 
prediction, can make this a valid strategy to support PAT implementation in 
this system (Pais et al., 2014; Teixeira et al., 2011). However, 2D maps-based 
Monitoring of rAAV production by fluorescence spectroscopy 
85 
models yielded better predictions, since the ones based on synchronous 
fluorescence were not able to capture rAAV titer production trends for some 
batches nor provide predictions for complex variables such as rAAV total titer 
(Supplementary Figure II.2 B). Identifying the Δλ which captures a higher 
amount of relevant process information together with incorporation of more 
bioreactor data in training models will prove useful to address this issue.  
The most important fluorescence spectra regions for each process variable 
were evaluated using Monte Carlo simulations, highlighting differences for 
each of the variables under study (Figure II.5). The corresponding 
fluorophores associated to each region may provide valuable insights for 
process understanding. However, the fluorescence of a compound is highly 
dependent on culture medium composition, pH and temperature. While other 
fluorophores which also contribute to the overall spectra may exist in the 
identified regions, for simplicity the most commonly identified in culture media 
were considered.  
The predictors for cell viability are correlating the release of intracellular 
compounds (e.g. NAD(P)H, riboflavin or tyrosine) with the decrease in cell 
viability, which is also confirmed by the negative sensitivity scores 
(Figure II.5 A); indeed, NADH-dependent fluorescence has been reported to 
be used for monitoring the progress of baculovirus infection (Zeiser et al., 
1999). Fluorescence regions for these metabolites are identified in the 
sensitivity analysis as having a lower importance for the prediction than whole 
regions of the spectra which do not correspond to known fluorophores. This 
may be because the PCA reduction captured the background signal (mainly 
unchanged regions), which the model uses to establish the baseline value for 
prediction. Then, the information contained in the fluorophore regions is used 
to adjust the prediction over time for each bioreactor.  
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Because changes in cell viability are associated with release of rAAV to the 
supernatant, many of the most important excitation-emission pairs for 
extracellular rAAV prediction are common to those important for viability 
(Figure II.5 C).  
For total rAAV concentration (Figure II.5 B), interpretation of the results is not 
straightforward due to the rAAV production profile, which increases until 
72 hpi followed by a decrease and plateau throughout the remaining culture 
time (Figure II.3 D). Still, fluorescence regions corresponding to NAD(P)H, 
riboflavin, tryptophan and tyrosine also have large absolute sensitivity scores, 
which are likely related to the increased metabolic needs required for rAAV 
production and amino acid incorporation into viral particles. The fact that 
NAD(P)H regions appear as important for rAAV production can be a 
consequence of the modulation of energetic metabolism by baculovirus 
infection, independently of the transgene carried by the baculovirus (Zeiser 
et al., 1999). Another region that is also important for the model is 
approximately at 300 nm excitation and 360 nm emission wavelengths. This 
region likely corresponds to rAAV fluorescence, based on the 2D 
fluorescence map of a purified rAAV2 solution in PBS. In this solution, the 
fluorescence signal in the regions between 270-300 nm excitation and 
310-370 nm emission wavelength was higher than in the PBS control, likely 
due to fluorescence signal of the amino acids incorporated into the assembled 
rAAV capsid, whose fluorescence signal changes when integrated in a 
protein (Teixeira et al., 2009). This finding was confirmed in the work of (Fu 
et al., 2019), in which AAV empty and full capsid separation was monitored 
using a fluorescence detector with excitation wavelength of 280 nm and 
emission wavelength of 350 nm.  
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5. Conclusions  
The present study reports for the first time the use of fluorescence 
spectroscopy as a soft sensor to monitor recombinant adeno-associated virus 
(rAAV) production in the insect cell-baculovirus expression system 
(IC-BEVS). Using a combination of spectra pre-processing methods and 
artificial neural network models, prediction of important process variables 
such as cell viability, rAAV titer and intra and extra rAAV concentration was 
achieved. Monitoring the rAAV production process online allows 
determination of the best time for harvest to maintain rAAV infectivity, as well 
as detection of deviations from the expected batch profile.  
The straightforward implementation of fluorescence spectroscopy coupled 
with a suitable data analysis framework and the substantial information it 
provides from rapid culture medium measurements renders this 
spectroscopic technique a powerful tool for bioprocessing monitoring. As 
such, this demonstration of fluorescence spectroscopy for real-time 
monitoring can be applicable to other rAAV serotypes and 
biopharmaceuticals produced in the IC-BEVS.  
Overall, this demonstration of fluorescence spectroscopy as a tool for 
real-time monitoring and for improving process understanding represents one 
step further towards a process analytical technology (PAT) implementation 
for rAAV production in the IC-BEVS.  
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7. Supplementary Data 
Supplementary Table II.1 – Complete list of pre-processing steps available for the genetic algorithm, for 
2D maps and synchronous spectra.  
 
2D spectra Synchronous fluorescence 
Divide by the integral of map Divide by the integral of sample 
Subtract sample average Subtract sample average 
Divide by sample standard deviation Divide by sample standard deviation 
Normalize each sample by its maximum Divide by integral per wavelength 
Divide by integral per excitation wavelength Subtract average by wavelength 
Divide by integral per emission wavelength Divide by standard deviation of wavelength 
Subtract average by excitation wavelength Subtract or divide by culture medium spectra 
Subtract average by emission wavelength Normalize each sample by its maximum 
Divide by standard deviation of emission wavelength Moving average smoothing 
Divide by standard deviation of excitation wavelength PCA reduction 
Subtract or divide by culture medium spectra 
Subtract average and divide by standard deviation for 
excitation-emission wavelength pairs 
 
Smooth using moving average  
Remove Rayleigh scatter (1st and 2nd order)  
Remove Raman scatter (1st and 2nd order)  
Interpolate the removed scatter values using the 
remaining spectra 
 
PCA reduction  
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Supplementary Table II.2 – Optimal pre-processing combinations, number of PCA components and ANN architectures used for each model. For ANN, values 
in parentheses represent the ANN architecture, e.g., an ANN with two hidden layers, with three nodes on the first one and two nodes on the second layer would 
be represented as (3 2). R2 and Q2 were calculated according to equations 2 and 3 from main text, and indicate the correlation coefficients of calibration and 
validation, respectively. 
 
Model Figure Pre-processing combinations 
Number of PCA 
components 
(ANN 
architecture) 
R2 Q2 
Total 
data 
points 
Viability (2D data, 
4 BR) 
 
nRMSEcv=4 % 
Figure II.3 A / 
Supplementary 
Figure II.3 C 
Removed Rayleigh 1st and 2nd order scatter; subtracted 
average and divided by standard deviation of 
excitation-emission wavelength pairs; subtracted 
average of excitation wavelengths and divided by 
standard deviation of emission wavelengths; samples 
normalized by their maximum; reduced by PCA. 
2 
(2) 
0.99 0.98 129 
rAAV titer (2D 
data, 4 BR) 
 
nRMSEcv=7 % 
Figure II.3 B 
Removed Rayleigh and Raman 1st and 2nd order 
scatter; subtracted average and divided by standard 
deviation of excitation-emission wavelength pairs; 
subtracted average of excitation wavelengths and 
divided by standard deviation of emission wavelengths; 
smoothed using moving average and reduced by PCA. 
3 
(3 2) 
0.99 0.93 89 
Viable cell 
concentration (2D 
data, 4 BR) 
 
nRMSEcv=7 % 
Figure II.3 C 
Removed Rayleigh 1st and 2nd order scatter and 
Raman 1st order scatter, and interpolated removed 
values using remaining spectra; subtracted average 
and divided by standard deviation of 
excitation-emission wavelength pairs; divided each 
sample by the culture medium spectrum; subtracted 
average of emission wavelengths and divided by 
standard deviation of excitation wavelengths; reduced 
by PCA. 
2 
(4) 
0.97 0.90 129 
Total rAAV 
concentration (2D 
data, 4 BR) 
 
nRMSEcv=16 % 
Figure II.3 D 
Removed Rayleigh and Raman 1st and 2nd order 
scatter and interpolated removed values using 
remaining spectra; subtracted for each sample the 
culture medium spectrum; subtracted average and 
divided by standard deviation of excitation-emission 
wavelength pairs; divided emission wavelengths by 
their standard deviation; smoothed using moving 
average and reduced by PCA. 
4 
(2 3) 
0.97 0.82 90 
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Supplementary Table II.2 (cont.) 
Model Figure Pre-processing combinations 
Number of PCA 
components 
(ANN 
architecture) 
R2 Q2 
Total 
data 
points 
Viability (2D data, 
6 BR) 
 
nRMSEcv=4 % 
Figure II.4 A 
Removed Rayleigh and Raman 2nd order scatter and 
Rayleigh 1st order, and interpolated removed values 
using remaining spectra; divided each sample by the 
culture medium spectrum; subtracted average and 
divided by standard deviation of excitation-emission 
wavelength pairs; smoothed using moving average 
and reduced by PCA. 
9 
(2) 
0.99 0.98 155 
rAAV titer (2D 
data, 6 BR) 
 
nRMSEcv=7 % 
Figure II.4 B 
Removed Rayleigh and Raman 1st and 2nd order 
scatter, and interpolated removed values using 
remaining spectra; Subtracted the culture medium 
spectrum for each sample; subtracted the average and 
divided for standard deviation for the emission 
wavelengths; calculated the integral of the sample 
spectrum along the emission wavelength; reduced by 
PCA. 
6 
(3 2) 
0.99 0.91 98 
Viability (SF data, 
4 BR) 
 
nRMSEcv=4 % 
Supplementary 
Figure II.2 A 
Subtracted average per sample; divided each sample 
by the culture medium spectrum and by integral per 
wavelength; samples normalized by their maximum 
PCA reduction. 
4 
(1) 
0.99 0.98 145 
rAAV titer (SF 
data, 4 BR) 
 
nRMSEcv=7 % 
Supplementary 
Figure II.2 B 
Subtracted average per sample; subtracted culture 
medium spectrum from each sample; samples 
normalized by their maximum and reduced by PCA. 
5 
(4) 
0.99 0.95 104 
Viable cell 
concentration (SF 
data, 4 BR) 
 
nRMSEcv=9 % 
Supplementary 
Figure II.2 C 
Divided each sample by the culture medium spectrum, 
by the integral per wavelength and by sample standard 
deviation; samples normalized by their maximum and 
reduced by PCA. 
1 
(2) 
0.70 0.84 147 
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Supplementary Table II.2 (cont.) 
Model Figure Pre-processing combinations 
Number of PCA 
components 
(ANN 
architecture) 
R2 Q2 
Total 
data 
points 
Total rAAV 
concentration (SF 
data, 4 BR) 
 
nRMSEcv=14 % 
Supplementary 
Figure II.2 D 
Divided each sample by its integral and by culture 
medium spectrum, and reduced by PCA 
4 
(4) 
0.97 0.75 106 
PCA – principal component analysis; ANN – artificial neural network; 2D – two-dimensional fluorescence data; BR - bioreactor; 
rAAV -recombinant adeno-associated virus; SF – synchronous fluorescence data. 
 
 
 
Supplementary Table II.3 - Comparison of ANN models for different process variables with and without adding culture time as a predictor 
variable, using the 2D fluorescence data for the four online bioreactors. Values represent the cross-validation error calculated using 
leave-one-batch-out after optimization of pre-processing and ANN structure for each model. For ANN, values in parentheses represent the 
ANN architecture, e.g., an ANN with two hidden layers, with three nodes on the first one and two nodes on the second layer would be 
represented as (3 2). 
 
Predicted variable 
nRMSEcv using 
time 
(ANN architecture) 
nRMSEcv without 
using time 
(ANN architecture) 
Viable cell concentration            7 %  (4)            18 %  (4) 
Cell viability            4 %  (2)            16 %  (2 2) 
rAAV extracellular titer            7 %  (3 2)              9 %  (1) 
Total rAAV titer          16 %  (2 3)            15 %  (4) 
Intracellular rAAV fraction          16 %  (4)            21 %  (2 3) 
ANN – artificial neural network; 2D – two-dimensional fluorescence data; 
rAAV – recombinant adeno-associated virus; nRMSEcv - normalized root 
mean squared error of cross-validation. 
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Supplementary Figure II.1 - Time course profiles for the experimentally determined process variables for 
all cultures. (A) Viable cell concentration; (B) Cell viability; (C) Intracellular rAAV titer; (D) Extracellular 
rAAV titer; (E) Infectious rAAV titer (intra- and extracellular); error bars represent standard error 
propagated from measurement replicates). hpi - hours post-infection. 
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Supplementary Figure II.2 - Experimental and predicted values for four bioreactor runs using online 
synchronous fluorescence spectra and artificial neural network (ANN) models. (A) Cell viability; (B) rAAV 
extracellular titer; (C) Viable cell concentration; (D) Total rAAV concentration (intra and extracellular rAAV). 
Model-predicted values for a bioreactor are based on ANN models trained using the other three bioreactors 
data (leave-one-batch-out cross-validation). Colors represent different batches, open circles represent 
experimental data and filled circles show model predictions. The different ANN architectures and spectra 
pre-processing used are described in Supplementary Table II.2. 
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Supplementary Figure II.3 - Example of the importance of pre-processing for 2D fluorescence maps and 
ANN models. Choosing one of the optimized models (Figure II.3 A, viability prediction), we kept the optimal 
ANN architecture for that model but tested standard fluorescence spectra pre-processing before batch 
prediction. Pre-processing used are as follows: (A) PCA, 1st and 2nd order Rayleigh removal and medium 
normalization, R2=0.97, Q2=-0.62; (B) Same as before, without medium normalization, R2=0.88, Q2=0.61; 
(C) Optimal pre-processing (Supplementary Table II.2), R2=0.99, Q2=0.98. 
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Supplementary Figure II.4 - Principal components (PC) loadings for each of the 2D maps 
excitation-emission pairs: (A) and (B) - First and second PC loadings for viability; (C), (D), (E), (F) – First, 
second, third and fourth PC loadings for total rAAV concentration; (G), (H), (I) – First, second and third 
component coefficients for rAAV titer. Maps are colored according to their positive (red) or negative (blue) 
values, which arise from the principal component scores. 
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Abstract 
The insect cell-baculovirus vector system has become one of the favorite 
platforms for expression of viral vectors for vaccination and gene therapy 
purposes. Being a lytic system, it is essential to balance maximum 
recombinant product expression with harvest time, minimizing product 
exposure to detrimental proteases. With that purpose, new bioprocess 
monitoring solutions are needed to accurately estimate culture progression. 
Herein, we used online digital holographic microscopy (DHM) to monitor 
bioreactor cultures of Sf9 insect cells. Batches of baculovirus infected Sf9 
cells producing recombinant adeno-associated virus (rAAV) and non-infected 
cells were used to evaluate DHM prediction capabilities for viable cell 
concentration, culture viability and rAAV titer. Over 30 cell-related optical 
attributes were quantified using DHM, followed by a forward stepwise 
regression to select the most significant (p<0.05) parameters for each 
variable. We then applied multiple linear regression to obtain models which 
were able to predict culture variables with root mean squared errors (RMSE) 
of 7×105 cells/mL, 3% for cell viability and 2×103 rAAV/cell for 3-fold 
cross-validation.  
Overall this work shows that DHM is a valuable tool for online monitoring of 
Sf9 concentration and viability, permitting also to monitor product titer, namely 
rAAV, or culture progression in lytic systems, making it a valuable tool to 
support the time of harvest decision and for the establishment of controlled 
feeding strategies. 
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1. Introduction 
After the FDA launched the Process Analytical Technology (PAT) initiative in 
2004 (FDA, 2004), an increased effort has been put in place by the 
manufacturers of biological products to comply with PAT requirements. The 
PAT initiative is a guidance for the pharmaceutical industry for the 
development of new products and production processes, with the main focus 
on: i) increasing product and process knowledge through identification of the 
product critical quality attributes and the process parameters affecting it; and 
ii) monitoring in real-time the identified critical process parameters and the 
product quality characteristics, ensuring manufacturing robustness and an 
increased quality assurance to achieve the required levels of compliance 
(FDA, 2004; Pais et al., 2014; Petiot et al., 2016).  
Label-free methodologies are preferred, especially in biopharmaceutical 
processes, since they allow the monitoring of cell culture without adding any 
compounds which would influence cellular behavior. Most cell culture 
monitoring methods employing label-free methodologies are based on 
spectroscopic techniques, which have been widely used for cell culture 
process monitoring. Examples include the use of dielectric spectroscopy and 
turbidimetry/light scattering probes for determination of cell concentration 
(Loutfi et al., 2020; Moore et al., 2019), as well as the use of Raman (Santos 
et al., 2018; Tulsyan et al., 2020), infrared (Zavala-Ortiz et al., 2019) and 
fluorescence (Pais et al., 2019) spectroscopy, which allow quantification of 
metabolites based on direct spectra quantification, but also indirect 
determination of cell concentration and product formation based on 
chemometric analysis. 
A label-free alternative to spectroscopic techniques is imaging-based cell 
culture monitoring. Since cells are mostly transparent, these systems rely on 
several strategies to generate the needed image contrast (Kasprowicz et al., 
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2017; Mann et al., 2005). One example of a imaging technique with proven 
demonstrations for live cell imaging is Digital Holographic Microscopy (DHM) 
(Janicke et al., 2017). Briefly, DHM provides quantitative phase imaging 
(QPI), quantifying the phase shift of the light after it has passed through the 
object of focus, such as cells. This light phase difference is encoded in a 
hologram which is used to construct high resolution intensity and quantitative 
phase images of the cell, while also providing quantitative parameters related 
with light phase and intensity (Kamlund, 2018; Mann et al., 2005). The way 
light is scattered after interacting with cells depends on factors such as cell 
thickness, circularity or intracellular composition (Kasprowicz et al., 2017; 
Kemper et al., 2010; Mann et al., 2005; Rapoport et al., 2011). As such, DHM 
can be used to extract important information from the cell state, and has 
proven useful for several cell-based applications: identification of 
morphological parameters distinguishing between epithelial and 
mesenchymal cells (Kamlund, 2018), detecting cell division in endothelial 
cells (Kemper et al., 2010) and developing cell proliferation (Janicke et al., 
2017) or cytotoxic assays (Kühn et al., 2013). In particular, infected cells will 
have different intracellular structure than uninfected cells (Altschuler and Wu, 
2010; Petiot et al., 2016; Ugele et al., 2018). Furthermore, as demonstrated 
by Ugele and colleagues, DHM-based detection of the intracellular 
composition of infected erythrocytes even allowed to distinguish between 
different infection phases in the malaria P. falciparum life cycle (Ugele et al., 
2018). The ability to detect infected cells as well as cell concentration and 
viability makes DHM inherently attractive to monitor the progress of 
infection-based biopharmaceutical production systems, such as the insect 
cell-baculovirus system (Hidalgo et al., 2017). 
Insect cells are one of the preferred hosts for viral vector manufacturing for 
vaccines and gene therapy purposes, since they can be grown in suspension 
to high cell densities in serum free media (Cox, 2012; Negrete et al., 2007). 
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However, to maximize product yields it is determinant to infect cells at low cell 
concentration, to prevent the so called “cell density effect”, a drop on the 
specific productivity of the cell when infection takes place at high cell 
concentration. The optimal cell concentration for infection and the definition 
of “low” and “high” cell concentration are dependent on the cell type, culture 
medium used and recombinant product being expressed (Bernal et al., 2009; 
Sequeira et al., 2018). Moreover, baculovirus is a lytic virus, which can lead 
to the release of intracellular proteases into the culture medium, possibly 
degrading the recombinant product after it has been released into the 
medium. As such, both culture viability and cell concentration are critical 
process parameters for this system. 
Other authors have addressed ways to monitor this system using dielectric 
(Negrete et al., 2007; Petiot et al., 2016; Zeiser et al., 2000, 1999) or 
fluorescence spectroscopies (Pais et al., 2019), as well as using image-based 
technologies, in particular for measuring the progress of baculovirus infection 
(Janakiraman et al., 2006; Laasfeld et al., 2017; Palomares et al., 2001). DHM 
can go one step further, by monitoring not only the cell diameter increase 
after baculovirus infection, but also the evolution profile of several cell 
characteristics, allowing to explore the possibility to observe baculovirus or 
rAAV-induced changes in suspension insect cells in real-time. 
In this chapter, we used iLine F differential DHM microscope (DDHM) (Ovizio 
Imaging Systems SA/NV) for real-time monitoring of a Sf9 culture infected 
with baculovirus, expressing recombinant adeno-associated virus (rAAV) 
type 2. rAAV is widely used as a gene therapy viral vector, due to its lack of 
known pathogenicity, broad tissue tropism coupled with long term transgene 
expression and ability to withstand harsh manufacturing conditions (Naso et 
al., 2017). Estimation of rAAV titer in real-time is desirable in order to harvest 
when its concentration is higher. Moreover, monitoring this system in 
real-time can support the time of harvest decision, an important process 
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variable to consider giving the lytic nature of the baculovirus and 
consequential release of proteases to the medium when cells start lysing. 
Since DDHM can be used to detect infected cells, we further explored this 
capability for monitoring the AAV titer in our cultures along with the 
development of predictive models for viable cell concentration and viability. 
Using the culture-related morphologic and optical attributes quantified with 
iLine F, we used forward stepwise regression to find the attributes associated 
with viable cell concentration, viability and intra and extracellular rAAV titer. 
We validated this approach using leave one batch out (LOBO) and 3-fold 
cross-validation strategies. As such, we demonstrate DDHM can be used not 
only for monitoring Sf9 cell concentration and viability but also for assessing 
rAAV production kinetics in this biological system.  
 
2. Materials and Methods 
2.1. Cell line and culture medium 
Spodoptera frugiperda Sf9 cells were obtained from Thermo Fisher Scientific 
(No 11496015) and routinely cultivated in 500 mL glass Erlenmeyer flasks 
with 50 mL working volume of SF900-II medium (GibcoTM), at 27 °C with an 
agitation rate of 100 rpm in an Innova 44R incubator (orbital motion diameter 
= 2.54 cm, Eppendorf). Cell concentration and viability were determined using 
a Cedex HiRes Analyzer (Roche). 
2.2. AAV and baculovirus infection and titration 
The recombinant Autographa californica nucleopolyhedrovirus encoding the 
GFP transgene under the control of the cytomegalovirus promoter 
(CMV-GFP) and flanked by AAV2 inverted terminal repeats (ITR) regions was 
kindly provided by Généthon and was titrated and amplified in house as 
described for the rep/cap baculovirus (below).  
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The plasmid containing AAV2 rep and cap genes was a gift from Robert Kotin 
(Addgene plasmid #65214) (Smith et al., 2009). Recombinant baculovirus 
was produced using the Bac-to-Bac® Baculovirus Expression System 
(Invitrogen), according with manufacturer instructions. Baculovirus 
amplification was performed as described elsewhere (Pais et al., 2019).  
Recombinant adeno-associated virus (rAAV) intra and extracellular titer was 
estimated separately using a commercially available sandwich ELISA kit 
(Progen Biotechnik GmbH), according to the manufacturer instructions. This 
kit detects a conformational epitope present in assembled rAAV capsids.  
2.3. Bioreactor cultures and sample processing 
Benchtop 1 L bioreactor runs were performed in BIOSTAT® DCU-3 
(Sartorius), equipped with two Rushton turbines. Temperature control (27 °C) 
was achieved using a water recirculation jacket and gas supply was provided 
by a ring sparger in the bottom of the vessel. Dissolved oxygen (DO) 
concentration was kept at 30 % by cascade controlling the stirring rate 
(70-270 rpm) and the N2/air ratios in a mixture of air and N2 (0.01 vvm). 
Several runs were performed to establish the standard culture progression 
profile. However, due to equipment constraints, only two bioreactors were 
monitored using the iLine F system (Ovizio Imaging Systems). These 
included a growth batch, consisting of a Sf9 batch culture monitored until cell 
death due to nutrient starvation, which occurred after ten days of culture; and 
an infected batch, in which a Sf9 culture was infected with two baculovirus 
vectors to express recombinant adeno-associated virus type 2, harvested on 
day six. Both bioreactors follow similar process trends to their biological 
replicates (vide Supplementary Figure II.1 in the previous chapter, page 93). 
Sf9 cells were inoculated at 0.5×106 cells/mL for both bioreactors. The 
“infected batch” was infected 31 hours after inoculation, when viable cell 
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concentration reached 1×106 cells/mL, with a multiplicity of infection (MOI) of 
0.05 plaque forming units per cell, for each baculovirus. The two baculovirus 
strategy was used, in which one baculovirus codes for the AAV2 rep and cap 
genes and the other provides the GFP transgene flanked by the AAV ITRs. 
In the iLine F system, a single-use, autoclavable closed-loop tube is inserted 
in a standard 19 mm bioreactor top port. This sampling tube contains in the 
other end a cartridge with the imaging chamber. After sterilization, the 
sampling tube is connected to a pump motor. Cell culture is continuously 
aspirated through the sampling tube to the imaging chamber and then 
returned to the cell culture vessel. The setup is controlled using the OsOne 
software (Ovizio Imaging Systems SA/NV), which controls the sampling rate 
and image analysis by the holographic microscope. Images are acquired 
every minute, but image processing occurs in batches of 25, thus yielding a 
new timepoint every 30 minutes (the 5 remaining minutes are used for 
background elimination and attribute calculations). Image processing 
consists in (1) image focus, (2) holographic fingerprint acquisition for every 
cell present in the image, (3) computation of 66 image-related attributes for 
every cell. Supplementary Figure III.1 exemplifies the cell culture and 
hologram evolution profiles.  
Sampling for determination of reference variables was performed daily for the 
growth batch and three times per day for infected batch. At each sampling 
point, cell concentration and viability were measured using Cedex HiRes 
Analyzer (Roche). Additionally, for the infected batch a clarification step was 
performed (200 g, 10 min, 4 °C) to recover intra and extracellular rAAV. 
Supernatant was subjected to a further clarification step (2000 g, 20 min, 
4 °C) and stored at -80 °C for offline analysis. Intracellular rAAV was 
extracted from cell pellets with TNT buffer, consisting of 20 mM Tris-HCl (pH 
7.5), 150 mM NaCl, 1% Triton X-100, 10 mM MgCl2 (Smith et al., 2009), to 
which a 0.5% solution of sodium deoxycholate was added to further increase 
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the release of intracellular rAAV from pelleted cells (Gray et al., 2012). After 
10 minutes of incubation at 22 °C, the suspension was centrifuged (2000 g, 
20 min, 4 °C) and the supernatant stored at -80 °C for offline analysis.  
2.4. Modeling strategy and software 
2.4.1. Dataset 
After run completion, for each timepoint the average for each attribute was 
calculated, considering all cells present in the 25 images acquired per 
timepoint. This resulted in 499 timepoints for growth batch and 275 timepoints 
for infected batch (online data). This data was smoothed using a moving 
average of two hours, corresponding to four datapoints. The reference data 
consisted of 14 samples for growth batch and 23 samples for infection batch, 
with determination of the four reference variables (viable cell concentration, 
viability, extracellular volumetric rAAV titer and intracellular specific rAAV 
titer) for each sample. The data for modeling consisted of each one of the 
reference datapoints time-aligned with the corresponding online datapoints, 
yielding a matrix of [37 rows × 4 reference variables columns × 66 columns 
with averaged attributes]. 
All analysis and modeling were performed in JMP v14 (Statistical Analysis 
System institute). 
Potential outliers in the reference data were identified by visual inspection of 
the data time-course profile and confirmed by calculating the jackknife 
distances for each datapoint. JMP jackknife outlier identification method relies 
on estimates of the mean, standard deviation, and correlation matrix that do 
not include the observation itself. 
2.4.2. Attribute selection and stepwise regression 
OsOne calculates 66 attributes per each cell. However, due to high 
collinearity of some attributes and to prevent model over-fitting (Feng et al., 
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2009), the Pearson correlation coefficient was calculated for every attribute 
pair. For pairs with a high correlation (Pearson correlation coefficient absolute 
value >0.95), one of the attributes was excluded from further analysis. This 
process was iterated until no attributes had a correlation coefficient higher 
than 0.95 or lower than -0.95, reducing the initial 66 attributes to 30. 
For model training, JMP “Fit model” platform was used. Briefly, the selected 
30 attributes were subjected to a forward stepwise regression to find the most 
significant for the prediction of each of the reference variables. In a forward 
stepwise regression method, the most significant attribute is identified and 
added to the model, followed by identification and inclusion in the model of 
the second most significant attribute and so on. This process was stopped 
when the next term added was considered not significant (p-value>0.05).  
Since this biological system has non-linear variables, which can be observed 
on the viable cell concentration and rAAV titer profiles, after identification of 
the most significant attributes for every variable, a second model was created, 
by performing the same forward stepwise regression technique using the 
significant terms (“main effects”) and their interactions and quadratics. The 
final forward stepwise regression model (main effects only or with 
interactions) was chosen by comparison of prediction profiles and root mean 
squared error (RMSE). 
2.4.3. Model training and validation 
Multiple linear regression models were built based on the stepwise forward 
regression strategy. Two validation strategies were used to assess model 
prediction capabilities and overfitting: leave one batch out (LOBO) and 3-fold 
cross-validation (3CV). For LOBO models, the stepwise attribute selection 
strategy mentioned in the previous section was applied to one batch only. 
After finding the most significant parameters and determining the model 
coefficients for each parameter by multiple linear regression, the model was 
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applied to the remaining batch for validation. This strategy was successfully 
applied to viability models but resulted in significant overfitting for viable cell 
concentration due to the significant differences in the variable ranges 
between the two batches. As such, an alternative LOBO strategy was used, 
in which parameter selection was performed using the reference data from 
both batches, followed by training of each batch separately. The obtained 
model was then used for predicting the remaining batch for validation 
purposes.  
For 3CV, the significant parameters were identified applying forward stepwise 
regression to the reference data from both batches, followed by multiple linear 
regression for model fitting using both batches. Model validation was 
performed by dividing the dataset (37 timepoints) into three random partitions, 
using two for model training with the selected parameters and predicting the 
third partition. The process was repeated for the two remaining partitions. 
The contribution of each parameter to the final model was calculated dividing 
the logworth value for each parameter by the sum of the logworth for all 
parameters (logworth is defined as -log10(p-value)). 
RMSEs for calibration (RMSEC) and validation (RMSEV) were calculated for 
all models (equation 1). In equation 1, ?̂?  represents a vector of 
model-predicted values and y represents the corresponding reference data; 
ncal and nval represent the number of samples in the calibration or validation 
set, respectively; max(y) and min(y) refer to the maximum and minimum 
values for the reference data, respectively. Normalized RMSE (nRMSE) was 
obtained by dividing the RMSE by the variable range.  
The correlation coefficients of calibration and validation were calculated 
according to equation 2 using calibration (R2) or validation (Q2) data. R2 is a 
measure of how well the chosen model fits the calibration data while Q2 
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measures how the obtained model fits the validation dataset, which is not 
used to fit the model, being indicative of the model predictive power for new 
data. σ2 represents sample variance. 
 
𝑅𝑀𝑆𝐸𝐶 = √
∑ (?̂? − 𝑦)2𝑛𝑐𝑎𝑙𝑖=1
𝑛𝑐𝑎𝑙
     𝑅𝑀𝑆𝐸𝑉 = √
∑ (?̂? − 𝑦)2𝑛𝑣𝑎𝑙𝑖=1
𝑛𝑣𝑎𝑙
      𝑛𝑅𝑀𝑆𝐸 =
𝑅𝑀𝑆𝐸
max(𝑦) − min(𝑦)
     (1) 
 
𝑅2 = 1 −
𝑅𝑀𝑆𝐸𝐶2
𝜎2
.                                                     𝑄2 = 1 −
𝑅𝑀𝑆𝐸𝑉2
𝜎2
.                                           (2) 
 
3. Results  
3.1. Digital holographic microscopy can be used for monitoring 
viable cell concentration and viability 
In this chapter, we study applicability of iLine F system for online monitoring 
of critical process variables in the insect cell-baculovirus system, for 
production of recombinant adeno associated viral vectors (rAAV). The critical 
process variables under analysis were viable cell concentration, cell viability 
and intra and extracellular rAAV titers.  
Models were trained using two batches, one infected (rAAV production) and 
one uninfected (cell growth). These have similar viability profiles (Figure 
III.1 A), differing only in the time to onset of viability decrease, but are distinct 
in the viable cell concentration ranges achieved (Figure III.1 B), as well as the 
rAAV production profiles (Figure III.2).  
The preferential validation strategy consisted in using one batch for model 
calibration and the other one as validation set (leave one batch out, LOBO). 
The high Q2 obtained for viability (0.72 and 0.92 for validation with growth and 
infected batches, Figure III.1 B) support the feasibility of using iLine F for 
monitoring viability in this process, even using only one batch for model 
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calibration. The lower Q2 score obtained for growth batch is mainly due to an 
underestimation of viability in the growth phase, but the prediction profiles for 
the death phase (more relevant for this system) are accurate for both runs. 
For viable cell concentration, the large range difference between runs causes 
the model to overfit the calibration batch, therefore severely underestimating 
viable cell concentration when predicting the growth batch, although with the 
correct profile (Q2=0.66) and failing to capture the correct viable cell 
concentration trend for the infected batch (Q2=0.34) (Figure III.1 B). 
The second validation strategy tested for viability and viable cell 
concentration was the 3-fold cross-validation (3CV) (Figure III.1 C and D). 
Models were built using data from both batches, and a 3CV strategy was 
applied to measure the model predictive power and confirm these are not 
overfitting, while simultaneously allowing identification of the DDHM attributes 
more important for variable prediction. Applying the 3CV model to iLine F 
real-time data, as expected, yields greatly improved predictions when 
compared with LOBO models (Figure III.1, Q2=0.98 for viability and Q2=0.93 
for viable cell concentration). Although less robust, this strategy was 
necessary so that model coefficients could account for the differences in the 
variable range between the two batches. The final model parameters and 
coefficients are presented in Supplementary Table III.1. For comparison 
purposes, the predictions for viable cell concentration and viability using 
Ovizio proprietary models are shown in Supplementary Figure III.2. Except 
for the viable cell concentration LOBO model calibrated in the infected batch, 
no models consider parameter interactions, since the models containing only 
the main effects possess an equal or better predictive score than the ones 
considering interactions and quadratics. 
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Figure III.1 - Viability (left) and viable cell concentration (VCC, right) predictions using leave one batch out (LOBO, top) and 3-fold 
cross-validation (3CV, bottom) models. Growth batch is represented in black and infected batch is colored in grey. Lines represent 
model-predicted values; filled circles represent reference data; empty circles were considered outliers and excluded from modeling. For LOBO 
models, only the model prediction is shown (i.e. when the growth batch was used for model calibration, the calibration model is not shown, only 
the prediction for the infected batch). For 3CV models, the model shown was built using data from both batches. (A) Observed and predicted 
values for viability using LOBO for model validation. (B) Observed and predicted values for VCC using LOBO for model validation. (C) Observed 
and predicted values for viability using 3CV for model validation. (D) Observed and predicted values for VCC using 3CV for model validation. 
Model parameters and coefficients are presented in Supplementary Table III.1. 
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3.2. Prediction of rAAV titers using digital holographic microscopy 
Given that the used dataset consists of two batches, from which only one is 
expressing rAAV, the LOBO strategy cannot be used for modeling 
rAAV-related variables. As such, the 3-fold cross-validation (3CV) strategy 
described in the previous section was used to calibrate prediction models for 
extracellular volumetric rAAV titer (Q2 = 0.97) and intracellular specific rAAV 
titer (Q2 = 0.99) (Figure III.2). rAAV production trend is captured with our 
modeling strategy, highlighting the potential of using multiple linear 
regression for identification of the most important optical attributes measured 
with DDHM and monitoring rAAV production profiles in this biological system. 
To confirm the obtained models are not overfitting the data, the coefficients 
of correlation for the calibration and validation set for every partition were 
calculated, for the four variables under study (Supplementary Table III.2). For 
each variable, the nRMSE for each partition are comparable in magnitude. 
Moreover, for each partition the nRMSE values obtained for validation are on 
average 1.8 % higher than the ones obtained for calibration, confirming the 
3CV models are not overfitting the data. 
The high adjusted coefficients of correlation for calibration and validation for 
the models shown in Figure III.1 and Figure III.2 indicate that good prediction 
models were obtained, with the exception of the LOBO viable cell 
concentration model (Figure III.3, Supplementary Table III.3). The feasibility 
of using DDHM for bioprocessing monitoring is demonstrated by the 
acceptable Q2 (0.74) using LOBO for viability prediction, and by the high 
cross-validation Q2 for all variables (0.93 to 0.98). For LOBO viable cell 
concentration models, the negative value is obtained when considering the 
Q2 for both batches simultaneously, due to the high discrepancy in the 
variable range and the overfitting in each calibration model. Individual Q2 are 
0.66 for prediction of growth batch and 0.34 for prediction of infected batch. 
The Q2 values for 3CV models are very close to the corresponding R2, 
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demonstrating that the chosen model is appropriate to describe both the 
calibration data and new datapoints. Altogether, this demonstrates that using 
only two batches with different rAAV production profiles is enough to find the 
DDHM attributes likely relevant for rAAV production. 
 
 
Figure III.2 – rAAV titer predictions for both batches. Growth batch is represented in black and 
infected batch is colored in grey. Lines represent model-predicted values; filled circles 
represent reference data; empty circles represent datapoints considered outliers and excluded 
from modeling. Models were calibrated using the reference data for both batches (filled circles). 
The prediction data represented by the smooth lines was obtained by applying the model to 
the real-time differential digital holographic microscopy data. (A) Observed and predicted 
values for extracellular rAAV titer; (B) Observed and predicted values for intracellular specific 
rAAV titer. Model parameters and coefficients are presented in Supplementary Table III.1. 
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Figure III.3 – Quality characteristics overview for the models presented in Figure III.1 and 2. 
R2 and Q2 are the correlation coefficients of calibration and validation, respectively. Also 
depicted are the normalized root mean squared errors (nRMSE) for calibration and validation 
which are scaled by the variable range. For the LOBO VCC models, the difference in the cell 
concentration ranges and the fact that the prediction models overfit the calibration batch result 
in a negative Q2 (-0.69) when data from both batches is considered. As such, we chose to 
depict the Q2 for each batch separately (0.66 for prediction of growth batch and 0.34 for 
prediction of infected batch). 3CV – 3-fold cross-validation; LOBO – leave one batch out; 
R2 -correlation coefficient of calibration; nRMSE - normalized root mean squared error; 
Q2 -correlation coefficient of validation; VCC – viable cell concentration. Raw data is provided 
in Supplementary Table III.3. 
 
3.3. Time-course profiles of morphological and optical parameters 
measured with DDHM 
One of the advantages of using DDHM for monitoring biological systems in 
real-time is the number of cell and image attributes that are calculated and 
the possibility to analyze the attribute evolution profile over culture time. 
These attributes are related with the cell morphology and with image optical 
characteristics, such as intensity of the light and light phase differences. While 
some of these attributes have an obvious biological meaning (for instance 
“Cell Radius”), most of them do not have a direct biological meaning per se. 
Still, some of the attributes clearly show an evolution over culture progression, 
and some are clearly correlated with the critical process variables studied in 
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this work, such as culture viability (Figure III.4 C, E and F), viable cell 
concentration (Figure III.4 C and G) and extracellular rAAV titer profiles 
(Figure III.4 A, B and D). These attributes were included in the final multiple 
linear regression prediction models with varying contributions for the overall 
model (Figure III.5 and Supplementary Table III.1). Our final models have 
between 5 and 12 parameters, excluding the intercept term (Figure III.5 and 
Supplementary Table III.2). 
  
 
 
Figure III.4 – Time-course profiles for selected DDHM attributes. Growth batch is represented 
in black, while infection batch is colored in grey. Measurements are obtained every 30 minutes. 
(A) Intensity Average Contrast; (B) Intensity Average Entropy; (C) Intensity Average Intensity; 
(D) Phase Skewness; (E) Phase Correlation; (F) Intensity Correlation; (G) Optical Height 
Minimum; (H) Optical Volume; (I) Peak Area Normalized; (J) Peak Height.  
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3.4. Model parameters have biological significance 
With iLine F, more than 60 attributes are calculated per cell. These are related 
with the cell morphology (e.g. “circularity”), the light optical characteristics 
(e.g. “maximum intensity”), the light phase texture (e.g. “phase skewness”) or 
the light intensity texture (e.g. “intensity correlation”). Overall, the parameters 
with a larger contribution for the obtained models are related with light 
intensity and phase characteristics (Figure III.5).  
 
 
 
Figure III.5 - Relative contribution of each parameter to the final models. For leave one batch 
out (LOBO) models, the batch used for model calibration is indicated (gr – growth; 
inf - infected). For 3CV models, the coefficients presented are related to the model using both 
batches. Relative importance was calculated using the logworth for each parameter 
(Supplementary Table III.1). 
  
Regardless of their relative contribution, some parameters are present in 
most of the models. Examples include “optical height maximum”, “phase 
average uniformity”, “intensity correlation”, “intensity average intensity” and 
“phase skewness”. Parameters present in the predictive models for viability, 
VCC and rAAV extracellular titer are specially interesting because the 
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respective variables are also correlated: viability is the quantitative 
measurement of the decrease in viable cell concentration, and rAAV 
extracellular titer increase is mostly due to cell lysis (Meghrous et al., 2005).  
Another important consideration is the presence of highly correlated 
attributes, which may confound biological interpretation of the model 
contributions. For instance, “phase average uniformity”, a measure of the 
uniformity of the light phase in each cell, is strongly correlated (R2=0.91) with 
“radius variance”, the variance of the cell radius, which is inversely correlated 
with circularity (R2=-0.97). In conclusion, a cell with an increased “phase 
average uniformity” has a less spherical shape (R2=-0.88). The pairwise 
Pearson correlations for every pair of attributes are shown in Supplementary 
Figure III.3. 
 
4. Discussion 
The aim of this study was to demonstrate the applicability of differential digital 
holographic microscopy (DDHM) to monitor important process parameters in 
the insect cell-baculovirus system, including the rAAV production kinetics. 
Specifically, Ovizio iLine F system was used. A forward stepwise regression 
technique combined with multiple linear regression was applied to the 
morphological and physiological attributes quantified by DDHM, successfully 
identifying attributes relevant for viable cell concentration, viability and intra 
and extracellular rAAV titer.  
Currently there is a lack of methods available for online monitoring of viral 
particles production during cell culture (Petiot et al., 2016). Existing methods 
explore chemometrics approaches, by measuring process variables related 
with the viral production kinetics (Pais et al., 2019), or changes in the 
morphological and physiological alterations of the cells (Grein et al., 2018; 
Petiot et al., 2016). In particular for the baculovirus system, these methods 
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are mostly based on the known increase of cell diameter upon baculovirus 
infection (Janakiraman et al., 2006; Laasfeld et al., 2017; Palomares et al., 
2001), although they were used as an assay rather than for in-culture 
determination. 
Viability is one of the most important process variables to consider in many 
viral-based systems, being related with product quality and influencing 
harvest decision (Grein et al., 2018; Nikolay et al., 2018; Pais et al., 2019). In 
both batches cell viability decreases in the end of the culture. However, the 
onset of viability decrease occurs at different process times (150 h for growth 
and 60 h for infected batch) and with different biological triggers: while in the 
infected batch cell viability decreases due to baculovirus-induced cell lysis, in 
the growth batch cells died by nutrient starvation. This validates the 
applicability of DDHM, but also provides a possible explanation to why the 
parameters present in each LOBO viability model are different (Figure III.5), 
since the biological reason for the cell death was different. While some of the 
identified model parameters have a clear similarity with viability profiles (e.g. 
Figure III.4 C, E and F), in general these are not the most important for the 
viability prediction models. Given the small dataset used, the parameters 
more important for the models may be in fact distinguishing between infected 
and growth batch (e.g. Figure III.4 J, “peak height”) followed by fine-tuning 
using the attributes with the similar viability profile. While addition of more 
calibration batches would be essential for determination of the parameters 
associated with viability, the prediction profiles using LOBO (Figure III.1 A) 
show DDHM possess enough predictive power for prediction of viability using 
only one batch for calibration, and additional batches are expected to further 
improve the prediction accuracy.  
Although the lack of an independent testing set for VCC and rAAV predictions 
prevents assessment of model validation for new batches, our aim was to 
explore iLine F applicability to study this system. Furthermore, the 
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identification and analysis of the parameters correlated with the modeled 
variables provides valuable biological insights for rAAV production in this 
system.  
Most of the attributes calculated with DDHM have no biological meaning per 
se, but can be used to characterize a dynamic phenotype, indicative of the 
cell adaptation to different biological situations (Feng et al., 2009; Kasprowicz 
et al., 2017). However, some of these parameters may have a possible 
biological explanation. For instance, “phase correlation”, a measure of how 
neighboring pixels are correlated, has a time-profile very similar to the culture 
viability profiles (Figure III.4 E). A possible explanation may be related with 
the increase in intracellular complexity during baculovirus infection. The 
cellular phenotype alterations occurring throughout baculovirus infection and 
the release of intracellular compounds to the culture supernatant during lysis 
will increase the entropy inside the cell, consequently resulting in less 
correlation of each pixel with its neighbors and a decrease in the phase 
correlation profiles. For viable cell concentration, it is expected that the 
attributes more predictive for viable cell concentration are related to light 
intensity, due to light dispersion caused by suspension cells, analogous to 
turbidimetry-based measurements. In fact, one of the parameters common to 
all three viable cell concentration models is “intensity correlation” (Figure III.4 
F), a measure of how correlated the intensity of one pixel is to the intensity of 
its neighbours over the cell surface.  
One of the aims of this work was to find image attributes associated with rAAV 
production. Some parameters are common for extracellular rAAV and viability 
models (Figure III.5), which is expected since rAAV release into the culture 
supernatant is mostly due to cell lysis (Galibert and Merten, 2011; Meghrous 
et al., 2005). Common parameters include “intensity average intensity”, “peak 
height normalized”, “phase skewness” and “optical height maximum”. 
Interestingly, “phase skewness” has a time-course profile very similar with 
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extracellular rAAV production (Figure III.4 D) for both batches. We believe 
this increase in “phase skewness” concomitant with AAV production is due to 
a combination of several factors: The cell nucleus and nucleolus possess a 
higher molecular density than surrounding regions, and are likely the cell 
organelles better detected using QPI due to their higher phase contrast 
(Kemper et al., 2010). Additionally, rAAV capsid assembly takes place in the 
nucleolus (Bennett et al., 2017). We hypothesize that AAV production in the 
nucleolus of infected cells increases the phase contrast of that nuclear region 
but not in the surrounding regions, creating an asymmetry. The attribute 
“phase skewness” measures the lack of symmetry for the phase histogram of 
the cell and would therefore increase. A similar explanation can be derived 
for baculovirus, which also assembles in the nucleus (Ohkawa et al., 2010). 
Moreover, infection at low baculovirus multiplicity of infection (MOI) yields a 
first round of baculovirus release from infected cells, approximately 24 hours 
after infection. The released baculovirus will then infect more insect cells, 
originating a second round of infection. In the phase skewness profiles shown 
in Figure III.4 D all these phases can be observed, likely validating our 
hypothesis: first baculovirus infection cycle from 24 h (infection time) to 48 h; 
and second infection from 48 to 72 hours. The fact that baculovirus and rAAV 
induce a different phase skewness profile (decrease for baculovirus and 
increase for rAAV) may be due to their different shape (rod vs icosahedral, 
respectively), and the fact that baculovirus nucleocapsid is assembled in 
another nucleus region, the virogenic stroma (Zhao et al., 2019), among other 
factors. 
“Phase skewness” was considered significant for both rAAV models, with a 
total contribution for the overall model of 15 % for extracellular rAAV and 5 % 
for specific rAAV (Figure III.5). Although a much higher contribution for the 
intracellular specific rAAV model was expected, the fact that “phase 
skewness” is also present in some viability models may explain its high 
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contribution for extracellular rAAV. As expected, this parameter has negative 
coefficients for viability models and positive for the extracellular rAAV 
prediction model (Supplementary Table III.1).  
Finally, it is important to consider the influence of biological factors such as 
cell passage or similar. Since we have a small dataset, we cannot be sure 
whether some of the model parameters are accounting with biological 
variability between the two runs. 
Comparison of the number of parameters in the 3CV models allows to have 
a sense of the difficulty in measuring the rAAV signals when compared to 
VCC and viability, which have a more “macroscopic” change. More simple 
models (with 5 and 7 terms) were enough to describe VCC and viability, 
respectively, while for rAAV, models with 10 and 12 parameters were needed 
(for extracellular rAAV and intracellular specific rAAV, respectively). This is 
also expected due to the complexity of measuring viral-induced cell changes, 
in which a combination of methods (measuring nucleus, diameter, cell 
intracellular complexity) is needed. Another possibility relies in the very 
different ranges and time profiles for VCC in the two batches, while for rAAV 
only one range is available. Higher range variations allow to better 
discriminate between significant and non-significant attributes. We expect 
these models to be refined with more batches, excluding parameters which 
are less relevant and clearly highlighting the attributes relevant for each 
variable. 
Other authors have monitored the IC-BEVS using real-time monitoring tools, 
mainly using dielectric spectroscopy (Mena et al., 2010; Negrete et al., 2007; 
Pais et al., 2019; Petiot et al., 2016; Zeiser et al., 2000, 1999). Compared with 
other published reports using RTM in this system, DHM provides a simpler 
workflow: First, iLine F assembly in the bioreactor is straightforward and no 
preliminary calibrations are needed; data analysis is in real-time (every 
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30 minutes) and immediate (no pre-processing needed) and, in OsOne, there 
is a beta-version algorithm to estimate the percentage of baculovirus-infected 
cells, which we tried for the infected batch (Supplementary Figure III.2). 
Further optimization of this algorithm could be helpful to monitor the 
baculovirus replication kinetics and optimize the production conditions, such 
as the overall MOI to use, and contribute to understanding how this parameter 
correlates with infection progression. Moreover, the attribute stepwise 
selection coupled with MLR methodology presented in this work has the 
advantage of generating more interpretable models, when compared with 
partial least squares (PLS) or other projection-based methods: MLR models 
are easier to interpret regarding the biological meaning of each parameter, 
enabling process understanding under the PAT initiative. This is because in 
MLR the coefficients of the parameters itself are analyzed, differing from PLS 
in which the focus is on the principal components, which are linear 
combinations of several parameters. 
In future experiments using this modeling approach, more “perturbation” 
batches will be useful to determine an rAAV-related “label-free dynamic 
phenotype” (Kasprowicz et al., 2017), identifying the attributes related with 
rAAV production and gaining insights on their biological meaning. Batches 
that would strengthen the VCC model calculations include more “growth only” 
runs, at different cell seeding densities. For rAAV models, examples include 
runs allowing to decouple rAAV production signals from other signals which 
may be correlated with VCC or baculovirus production. For instance, infection 
with empty baculovirus (a baculovirus vector which is devoid of any 
transgene, but still can infect and replicate in insect cells, and thus generate 
the normal cytopathic effects expected in this system) or only with the 
rep-encoding baculovirus. Infection with only the cap-encoding baculovirus 
would possibly be useful for finding attributes associated with empty or full 
rAAV capsid formation, which together with the infectivity profile, is one of the 
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most important quality attributes for AAV vectors (Merten, 2016). Regarding 
the empty to full ratio, runs using other rAAV production systems can also be 
performed, particularly using systems known by their high full particle ratio, 
as is the case of the herpes simplex production system (Merten and Gaillet, 
2016). Exploring the application of DHM to other AAV-producing systems, 
such as the HEK293 transfection system, could elucidate the differences for 
AAV production in transfection and infection processes and between different 
producer cells. Moreover, DHM could provide further insights on the reason 
why suspension-based transfection is less efficient than 
adherent-transfection. An alternative DHM device with equivalent image 
processing capabilities, the QMod (also by Ovizio Imaging Systems), could 
be used to enable a similar approach in adherent cell culture. Finally, 
combining the DDHM attributes with process data (e.g., DO profiles, total 
oxygen flow) may further increase prediction capabilities due to the increase 
of complementary information available (Bayer et al., 2019).  
Finally, one of the most promising functionalities of OsOne is the ability to 
analyze individual cells and the values of their attributes. Once the attributes 
correlated with rAAV production are found, clone screening can be performed 
to identify high and low producing cells, or at least allow a deeper 
understanding of why some cells produce more rAAV than others. This would 
be feasible combining one of the other available Ovizio systems, the qMod, a 
camera equipped with DDHM technology, with omics technologies for 
determination of rAAV-associated transcriptomics and proteomics profiles 
(Kasprowicz et al., 2017). 
 
5. Conclusions  
Overall, we demonstrate the suitability of this methodology and DDHM 
technology for monitoring two of the most important variables for this 
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biological system, cell concentration and viability, with potential for the 
development of feeding strategies schemes for rAAV production. The 
approach described in this chapter enables model interpretability, increasing 
process understanding and allowing to draw conclusions regarding the 
biological state of the cell at each infection stage.  
Moreover, models for determination of rAAV production were developed, and 
correlations between DHM attributes and rAAV measurements were 
determined, identifying for the first-time attributes related with rAAV 
production detectable using phase microscopy. 
For future work, it would be relevant to employ the same strategy for 
identification of the DDHM attributes relevant for prediction of AAV infectivity 
and full to empty ratio, in order to fully explore the potential of this method to 
optimize AAV titer and quality, in line with the PAT initiative. 
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8. Supplementary Data 
Supplementary Table III.1 - Estimates, corresponding standard error, t-ratio and logworth / p-value for all the models shown in Figure III.1 and III.2. For leave 
one batch out (LOBO) models, the batch used for model calibration is indicated between brackets. Logworth is defined as -log10(p-value). 
 
Model Parameter Estimate Std Error t-Ratio Logworth p-value 
Extracellular rAAV titer - 3CV 
Intensity Average Intensity -2.5E+11 1.7E+10 -14.4 12.6 2.5E-13 
Phase Skewness 3.9E+09 2.9E+08 13.6 12.0 9.7E-13 
Peak Height Normalized -3.3E+10 2.5E+09 -12.9 11.6 2.8E-12 
Optical Height Maximum 4.5E+09 3.7E+08 12.3 11.2 7.0E-12 
Intensity Average Contrast 2.8E+11 2.4E+10 12.0 10.9 1.3E-11 
Intensity Average Entropy -4.1E+10 3.6E+09 -11.4 10.4 3.7E-11 
Hu Moment 6 -1.7E+15 4.0E+14 -4.3 3.6 2.4E-04 
Hu Moment 5 3.9E+16 1.0E+16 3.8 3.1 8.7E-04 
Intensity Geometric Mean 1.2E+10 4.3E+09 2.7 1.9 1.1E-02 
Center of Mass Vertical 
Position 
3.4E+07 1.5E+07 2.2 1.5 3.5E-02 
Intercept 2.0E+11 1.4E+10 14.2     
Specific rAAV titer - 3CV 
Peak Height -3.2E+03 1.5E+02 -21.4 14.0 9.2E-15 
Optical Volume 3.2E+03 1.7E+02 19.4 13.3 5.3E-14 
Peak Area Normalized -5.0E+05 3.4E+04 -14.7 11.1 8.1E-12 
Cell Area -6.2E+02 4.8E+01 -13.1 10.2 5.8E-11 
Best Depth 2.8E+03 4.8E+02 5.9 4.9 1.1E-05 
Hu Moment 5 1.7E+11 3.3E+10 5.2 4.2 5.6E-05 
Intensity Average Intensity 4.3E+05 8.6E+04 5.0 4.1 8.4E-05 
Phase Skewness 9.4E+03 2.0E+03 4.7 3.8 1.6E-04 
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Supplementary Table III.1 (cont.) 
Model Term Estimate Std Error t-Ratio Logworth p-value 
Specific rAAV titer - 3CV 
Hu Moment 6 -6.4E+09 1.5E+09 -4.2 3.3 4.7E-04 
Intensity Maximum -3.5E+04 9.1E+03 -3.8 2.9 1.3E-03 
Phase Average Uniformity -5.0E+05 1.6E+05 -3.2 2.3 5.0E-03 
Hu Moment 4 -2.5E+08 1.1E+08 -2.3 1.5 3.1E-02 
Intercept 9.1E+04 3.5E+04 2.6     
Viable cell 
concentration - 3CV 
Intensity Geometric Mean -6.4E+07 4.0E+06 -16.2 15.7 2.2E-16 
Intensity Correlation 5.2E+07 6.3E+06 8.2 8.4 3.7E-09 
Phase Average Uniformity -1.6E+08 2.5E+07 -6.3 6.2 5.8E-07 
Optical Height Maximum -8.9E+05 3.4E+05 -2.6 1.9 1.4E-02 
Optical Height Minimum -9.2E+06 4.0E+06 -2.3 1.6 2.8E-02 
Intercept 9.0E+06 6.2E+06 1.5     
Viability - 3CV 
Peak Height Normalized 1.7E+02 1.3E+01 13.4 13.2 5.7E-14 
Phase Skewness -1.4E+01 1.1E+00 -12.8 12.7 1.8E-13 
Optical Height Maximum -2.5E+01 2.7E+00 -9.3 9.5 3.0E-10 
Hu Moment 3 8.9E+04 1.6E+04 5.7 5.4 3.8E-06 
Phase Correlation 4.8E+02 1.3E+02 3.5 2.8 1.4E-03 
Phase Average Uniformity -1.0E+03 3.9E+02 -2.6 1.8 1.5E-02 
Intercept -4.2E+02 1.4E+02 -3.0     
Intensity Average Intensity 3.3E+02 1.3E+02 2.5 1.7 1.9E-02 
Viable cell 
concentration -LOBO 
(growth) 
Intensity Geometric Mean -6.3E+07 7.7E+06 -8.2 4.4 3.7E-05 
Intensity Correlation 6.2E+07 2.6E+07 2.4 1.4 4.1E-02 
Phase Average Uniformity -1.3E+08 5.9E+07 -2.2 1.3 5.6E-02 
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Supplementary Table III.1 (cont.) 
Model Term Estimate Std Error t-Ratio Logworth p-value 
Viable cell 
concentration -LOBO 
(growth) 
Optical Height Minimum -1.6E+07 3.7E+07 -0.4 0.2 6.8E-01 
Optical Height Maximum -6.7E+04 2.0E+06 0.0 0.0 9.7E-01 
Intercept -2.9E+06 3.0E+07 -0.1     
VCC LOBO (infected) 
Phase Average Uniformity 1.0E+08 4.6E+07 2.2 1.4 4.4E-02 
Optical Height Maximum 7.1E+05 5.0E+05 1.4 0.7 1.8E-01 
Intensity Geometric Mean 1.1E+07 9.2E+06 1.2 0.6 2.6E-01 
Intensity Correlation 6.1E+06 6.1E+06 1.0 0.5 3.4E-01 
Optical Height 
Maximum*Intensity 
Geometric Mean 
9.7E+06 1.0E+07 0.9 0.4 3.7E-01 
Intensity Geometric Mean* 
Intensity Geometric Mean 
-2.1E+08 2.5E+08 -0.8 0.4 4.3E-01 
Phase Average Uniformity 
* Intensity Correlation 
7.1E+08 1.1E+09 0.6 0.3 5.4E-01 
Intercept -1.3E+07 6.3E+06 -2.0     
Viability LOBO (growth) 
Intensity Average Intensity 1.6E+03 1.1E+02 15.0 6.4 3.9E-07 
Peak Height Normalized 8.3E+01 8.8E+00 9.4 4.9 1.4E-05 
Aspect Ratio 7.3E+01 2.4E+01 3.1 1.8 1.6E-02 
Circularity 4.6E+02 1.7E+02 2.7 1.6 2.6E-02 
Peak Area 4.9E-01 2.1E-01 2.3 1.3 4.8E-02 
Intercept -1.3E+03 1.6E+02 -7.7     
Viability LOBO (infected) 
Peak Height 2.1E+00 2.3E-01 9.2 5.5 3.3E-06 
Circularity -7.7E+02 1.1E+02 -6.7 4.3 5.3E-05 
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Supplementary Table III.1 (cont.) 
Model Term Estimate Std Error t-Ratio Logworth p-value 
Viability LOBO (infected) 
Optical Height Maximum -2.8E+01 4.3E+00 -6.4 4.1 7.6E-05 
Aspect Ratio -6.8E+01 1.1E+01 -6.3 4.1 8.8E-05 
Hu Moment 4 2.9E+05 6.3E+04 4.6 3.0 1.1E-03 
Phase Correlation 5.3E+02 1.2E+02 4.5 2.9 1.1E-03 
Optical Height Minimum 7.7E+01 1.8E+01 4.2 2.7 1.8E-03 
Best Depth 3.7E+00 9.0E-01 4.1 2.6 2.3E-03 
Peak Area Normalized 1.4E+02 3.6E+01 3.7 2.4 3.9E-03 
Intensity Correlation 1.6E+02 4.7E+01 3.3 2.1 7.6E-03 
Phase Skewness -5.8E+00 2.0E+00 -2.9 1.8 1.5E-02 
Intensity Average Entropy 2.5E+01 1.0E+01 2.4 1.4 3.9E-02 
Intercept 3.0E+02 8.2E+01 3.6     
 
Chapter III 
134 
 Supplementary Table III.2 - RMSE for calibration and validation models, scaled for the variable range, using the 3-fold cross-validation strategy. The dataset 
was divided in three partitions. Two partitions were used for model calibration, which was used for prediction of the reference data for the third partition. This 
process was repeated for the three partitions. 
 
Model  
Partition 
for 
testing 
 R2 
RMSE 
calibration 
Normalized 
RMSE 
calibration 
Q2 
RMSE 
validation 
Normalized 
RMSE 
validation 
Number of 
model 
datapoints 
Number of 
model 
parameters 
Extracellular 
rAAV titer 
1 0.98 4.5E+08 3.2 0.95 8.8E+08 6.2 23 
10 
 
2 0.99 3.9E+08 2.7 0.98 7.4E+08 5.2 24 
3 0.99 2.8E+08 2.0 0.98 4.9E+08 3.4 23 
Specific 
rAAV titer 
1 1.00 7.5E+02 1.5 1.00 1.0E+03 2.1 22 
12 2 0.99 1.3E+03 2.6 0.98 2.1E+03 4.4 23 
3 1.00 7.2E+02 1.5 0.98 2.2E+03 4.5 20 
Viable cell 
concentration 
1 0.97 4.5E+05 4.5 0.92 7.6E+05 7.7 23 
5 2 0.94 7.2E+05 7.3 0.93 7.7E+05 7.8 26 
3 0.98 4.4E+05 4.5 0.94 7.0E+05 7.1 23 
Viability 
1 0.99 2.6E+00 3.7 0.98 3.6E+00 5.2 24 
7 2 0.99 1.9E+00 2.8 0.99 2.1E+00 3.1 26 
3 0.98 2.1E+00 3.1 0.98 2.6E+00 3.7 24 
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Supplementary Table III.3 - Quality characteristics overview for the models presented in Figure III.1 and 
2. R2 and Q2 are the correlation coefficients of calibration and validation, respectively. Also shown are the 
root mean squared errors (RMSE) for calibration and validation and the RMSE scaled by the variable 
range. 
 
Variable 
Validation 
Method 
R2 
RMSE 
calibration 
Normalized 
RMSE 
calibration 
(%) 
Q2 
RMSE 
validation 
Normalized 
RMSE 
validation 
(%) 
Viability LOBO 1.00 6.8×10-1 1.0 0.74 1.1×101 15.8 
Viable cell 
concentration 
LOBO 0.97 4.7×105 4.8 -0.69 3.6×106 36 
Viability 3CV 0.99 2.2 3.2 0.98 2.9 4.1 
Viable cell 
concentration 
3CV 0.96 5.4×105 5.4 0.93 7.1×105 7.2 
Intracellular 
specific rAAV 
titer 
3CV 1.00 9.1×102 1.9 0.99 1.9×103 3.8 
Extracellular 
rAAV titer 
3CV 0.99 3.8×108 2.7 0.97 7.2×108 5.0 
LOBO – leave one batch out; 3CV – 3-fold cross-validation; R2 –correlation coefficient of calibration; 
RMSE - Root Mean Squared Error; Q2 –correlation coefficient of validation. 
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Supplementary Figure III.1 - Overview of the cell culture evolution profile over time, as captured by 
OsOne software. Phase images are presented in top row; middle row shows OsOne identification of each 
cell, with indication of the cell viability by a coloured circle in the middle of each cell: green - viable cells, 
red - non-viable, yellow - cell cluster; the corresponding calculated holograms are shown in bottom row. 
Each column represents different image types from the same culture timepoint, indicated in the bottom 
of the column. Abbreviations: t – culture time (h); c - viable cell concentration (106cells/mL); v: viability 
(%). 
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Supplementary Figure III.2 - Evolution of the predicted process variables using Ovizio proprietary models. 
Growth batch is represented in black, while infection batch is colored in grey. A) Viable cell concentration. 
B) Viability. C) Percentage of transfected cells. Dashed line indicates the time when controller setpoints 
were changed, with noticeable alterations in the iLine F profiles.
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Supplementary Figure III.3 – Pearson correlation coefficients for all attributes. A heatmap representation is shown, with blue colors indicating positive correlation and red colors 
indicating negative correlations.  
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the insect cell-baculovirus system: 
optimization of infection timing and 
robustness in rAAV manufacturing 
 
 
 
 
 
 
This chapter is adapted from the manuscript: 
Pais, DAM, Brown, C, Grewal, H, Isidro, IA, Alves, PM, Slade, PG. 2020. “Dielectric 
spectroscopy as a PAT tool in the insect cell-baculovirus system: optimization of 
infection timing and robustness in rAAV manufacturing” (in preparation). 
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Abstract 
The insect cell – baculovirus expression vector system is established as one 
of the preferred methods for large scale recombinant adeno-associated virus 
(rAAV) production, largely due to its scalability potential and the high 
volumetric productivities achieved. However, rAAV production and infectious 
titers can be affected by several process parameters, of which Sf9 cell 
concentration at infection and cell viability at harvest are the most critical. 
Furthermore, these parameters are dependent on the rAAV serotype, and as 
such are pipeline dependent.  
Herein we demonstrate the use of dielectric spectroscopy as a process 
analytical technology (PAT) tool to continuously monitor Sf9 cell growth in 2 L 
stirred tank bioreactors and accurately predict the infection time up to 
24 hours in advance. Furthermore, we developed prediction models for 
important process variables based on the dielectric measurements of the 
culture. These multiple linear regression-based models resulted in correlation 
coefficients (Q2) of 0.89 for viable cell concentration, 0.97 for viability, 0.92 for 
diameter and 0.77 for intracellular rAAV titer in an independent testing set. 
These models provide the capability to distinguish between high and low 
production batches and reliably estimate the time of harvest, avoiding 
unnecessary prolonged exposure of viral vector to protease activity due to 
baculovirus-induced cell lysis. 
We show dielectric spectroscopy can be used for narrowing the range for the 
infection window, consequently ensuring process robustness and reasonable 
rAAV prediction ability, while decreasing the probability of contamination due 
to reduced sampling needs. Dielectric spectroscopy proves useful for 
real-time monitoring of rAAV-production, and its FDA compliance renders it 
readily available for use in existing processes.  
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1. Introduction 
Recombinant adeno-associated viruses (rAAV) are an ideal candidate gene 
therapy vector for many rare diseases, due to their ability to transduce 
non-dividing cells from several tissues maintaining a long-term gene 
expression. Besides, rAAV possess low immunogenicity compared to other 
viral vectors, and are physical resistant to harsh conditions, making it resilient 
to industry manufacturing methodologies, long-time storage, and in vivo 
administration (Galibert and Merten, 2011; Xu et al., 2014). 
While several biological systems have been adapted for rAAV production, the 
insect cell - baculovirus expression vector system (IC-BEVS) is the system 
more amenable for large scale rAAV production. Insect cells possess 
scalable and GMP-compatible characteristics, since they can grow in 
suspension to high cell densities in serum-free conditions (Penaud-Budloo et 
al., 2017); as for the baculovirus, its use as a vector relies on the high 
recombinant protein production yields achieved and the absence of 
mammalian-derived products (Yee et al., 2018). This combination resulted in 
several approved products, targeting Influenza (Flublok®), cancer (Cervarix® 
and Provenge®) and at least one rAAV-based gene therapy (Glybera™) 
(Monteiro, 2015; Shahryari et al., 2019). 
Since 2004, with the introduction of the PAT initiative (FDA, 2004), regulatory 
entities have become increasingly more stringent regarding the end product 
quality attributes of biopharmaceutical products (Pais et al., 2014). By 
encouraging the pharmaceutical industry to develop tools to characterize the 
pharmaceutical product and manufacturing process, in the end yielding 
biological products with consistent quality, the PAT initiative facilitates 
regulatory approval of new drugs. With that aim, the use of real-time 
monitoring tools for process characterization and product monitoring is 
strongly encouraged (Guerra et al., 2019; Pais et al., 2014).  
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The ability to monitor in real-time the insect cell-baculovirus system can 
support the time of harvest decision, an important process variable to 
consider giving the lytic nature of the baculovirus and consequential release 
of proteases, which can compromise the quality of the end-product (Grein et 
al., 2018; M Lecina et al., 2006; Nikolay et al., 2018; Pais et al., 2019). 
Moreover, the ability to estimate the rAAV titer in real-time is also desirable 
to harvest rAAV when its concentration is higher.  
Several types of sensors have been applied for monitoring of cell culture 
processes. Substantial work has been developed using spectroscopy tools, 
mainly infrared (mid and near), Raman and fluorescence (Marison et al., 
2013; Mercier et al., 2016; Pais et al., 2019; Qiu et al., 2014; Riley et al., 
1997).  
Another spectroscopy tool with proven applications for monitoring cell size 
and biovolume is dielectric spectroscopy (Justice et al., 2011; Mercier et al., 
2016; Moore et al., 2019; Opel et al., 2010), with several authors reporting its 
application for monitoring insect cells in suspension (Ansorge et al., 2007; 
Elias et al., 2000; Negrete et al., 2007; Petiot et al., 2016; Zeiser et al., 2000, 
1999). This technique is based on the detection of the cell dielectric potential, 
which is dependent on the intracellular composition. As such, dielectric 
spectroscopy is ideal for monitoring infection-based processes, because of 
the effect that virus formation and release have in the cell membrane (Petiot 
et al., 2016; Petiot and Kamen, 2012).  
The application of dielectric spectroscopy to monitor the production of viral 
vector production processes is reported in several other works: Zeiser and 
coworkers correlated permittivity measurements with cell swelling due to 
intracellular baculovirus production (Zeiser et al., 1999); Ansorge et al. 
followed lentivirus budding process by monitoring physiological changes in 
infected producer cells (Ansorge et al., 2011); Petiot et al. identified critical 
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infection phases in enveloped and non-enveloped viruses, produced using 
transfection and infection methods (Petiot et al., 2016); Grein and coworkers 
used the culture permittivity measurements to detect the optimal harvest time 
in a oncolytic virus (Grein et al., 2018); and Negrete et al. correlated Sf9 cell 
diameter with rAAV production yield, decreasing the optimal harvest time by 
24 hours (Negrete et al., 2007). However, so far there is a lack of real-time 
monitoring solutions to monitor the accumulation of viral vectors in real-time 
(Petiot et al., 2016), which was not addressed in the cited works.  
Herein, we explored the capabilities of dielectric spectroscopy to monitor the 
cell physiological state to build prediction models for viable cell concentration, 
viability, diameter and intracellular rAAV for the insect cell-baculovirus 
system. We used a commercially available permittivity and conductivity probe 
to monitor in situ the dielectric properties of the culture. By combining the 
permittivity readings at 18 different frequencies with the beta-dispersion 
parameters determined for the system, we built a permittivity-based soft 
sensor for accurate prediction of the infection timing and for estimation of 
intracellular rAAV titers in real-time. 
 
2. Materials and Methods 
2.1. Cell line and culture medium 
Spodoptera frugiperda Sf9 cells were routinely cultivated in 5 L Corning shake 
flasks with 3 L working volume of ESF-AF medium (Expression SystemsTM), 
at 27 °C with an agitation rate of 80 rpm in an Innova 44R incubator (orbital 
motion diameter = 2.54 cm, Eppendorf). Cell concentration and viability were 
determined using a Vi-Cell XR Cell Counter (Beckman Coulter). 
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2.2.  Viruses, infection and titration 
Three recombinant Autographa californica nucleopolyhedrovirus were used 
as expression vector, which due to confidentiality reasons will not be fully 
described. For the standard rAAV production process, cells were infected with 
a “transgene” and “repcap” baculovirus as described in the following section. 
These batches are referred as “standard” throughout this chapter. The 
“transgene” baculovirus encodes an interference RNA gene to selectively 
knock down, or reduce, the mRNA levels of a specific neurodegenerative 
disease. This gene is flanked by the AAV inverted terminal repeats (ITRs). 
The “repcap” baculovirus encodes for the expression of an AAV1 serotype. 
The third recombinant baculovirus vector used in some experiments did not 
encode for any recombinant transgene (hence named “empty Bac”), but it is 
still able to infect and replicate in Sf9 cells.  
After generation of the bacmids for the above mentioned baculoviruses, those 
were used to transfect Sf9 suspension cells. As described elsewhere 
(Wasilko et al., 2009), infected cells were grown until the diameter increased, 
indicating successful baculovirus infection and replication, but before the 
viability started to decrease. At that culture time, cells were frozen and 
cryopreserved as baculovirus-infected insect cells (BIICs), which were 
subsequently used as the viral inoculum for bioreactor experiments.  
Recombinant adeno-associated virus (rAAV) intracellular titer was estimated 
by an in-house qPCR assay.  
2.3.  Bioreactor cultures and sample processing 
Bioreactor cultures were performed in benchtop Finesse 3 L bioreactors with 
1.6 L culture volume, equipped with one turbine with three blades tilted at 
45 ° angle (“elephant ear” turbine). Temperature control (27 °C) was achieved 
using a heating jacket. Dissolved oxygen (DO) concentration was kept at 
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40 % by continuous flow of air over the headspace and on-demand supply of 
air and O2 mixtures using a L-shaped sparger in the bottom of the vessel. The 
stirring rate was kept at 200 rpm. All controller action was ensured by Finesse 
Controllers and DeltaV software.  
Bioreactors were seeded at 1.1x106 Sf9 cells/mL. Infection was performed at 
different cell densities: 3x106 cells/mL for “standard”, “empty” and “blend” 
batches and 5x106 cells/mL for “cell density effect” batches (see Figure IV.1 
for details on each type of batch). All batch types except “empty” were 
infected using both “repcap” and “transgene” BIICs at specific volume of 
culture to BIIC volume ratios. For “empty” runs, “empty” BIICs (“empty” 
baculovirus cryopreserved in infected Sf9 cells) were added to the Sf9 
cultures at a total volume to volume ratio as both the “repcap” and “transgene” 
BIICs. For “blend” batches, both “standard” and “empty” infections were 
performed in separate bioreactors. On day 2 post-infection, cells from both 
reactors were transferred to another bioreactor, with the following ratios of 
“standard” to “empty” (100:0; 65:35; 40:60; 10:90), in a total of 1.3 L working 
volume. The multiplicity of infection (MOI) was kept constant for every batch. 
The Incyte sensor (Hamilton) was inserted in a standard 19 mm bioreactor 
top port, to perform in situ permittivity and conductivity measurements. After 
sterilization, sensor readings were zeroed with culture medium, after allowing 
enough time for the permittivity and conductivity signals to stabilize at 27 °C. 
Permittivity and conductivity measurements were performed every six 
minutes, with permittivity measurements obtained in a range of 18 
frequencies between 300 to 10000 kHz. Measurements were recorded using 
the ArcView instrument (Hamilton). In the “blend” experiments, only the 
“blend” bioreactors were monitored with Incyte, this being the reason why 
there are no permittivity measurements before day 2 post-infection. 
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Sampling for determination of reference variables was done three times per 
day before infection and four times per day after infection. At each sampling 
point, cell concentration and viability were measured using Vi-cell Counter. 
For rAAV determination, 10 mL of culture supernatant were subjected to a 
clarification step (1000 g, 10 min) to separate intra and extracellular rAAV. 
Supernatant was discarded, and the pellet resuspended in an equal volume 
of fresh medium, to which a 1.3 mL of lysis solution was added. Samples 
were left agitating at 27 °C, 200 rpm, for approximately 24 hours, centrifuged 
(4000 g, 5 minutes), filtrated through a 0.2 µm syringe filter and stored at 4 
°C until analysis. 
2.4.  Process-to-target script 
The process-to-target (PTT) is an in-house script which runs in the JMP (SAS 
Institute) programming language. The PTT script predicts the infection timing 
based on all the measured permittivity values for the 1000 kHz frequency, 
considering timepoints from cell seeding to the moment the script is run. It is 
based in a time-weighted linear model of permittivity. Briefly, the script plots 
the permittivity values from the Incyte probe and the corresponding time in 
hours since the beginning of the run. Each data point is given a weight 
(Time7), with later timepoints having a significantly higher weight when 
compared to earlier time points, avoiding the inherent non-linearity of the 
initial portion of the permittivity curve (corresponding to the lag phase). A 
weighted linear model is then fit to the data and the model values are saved. 
Using the target permittivity, the model values are used to calculate the time 
in hours at which the culture will reach infection density. The time remaining 
to infection is also calculated using the current time. The script outputs the 
graphical results as demonstrated in the results section.  
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2.5. Modeling strategy and software 
2.5.1. Dataset 
A total of 14 bioreactors were run in different conditions: 6 “standard” runs, 2 
“cell density effect” runs, 2 “empty” runs and 4 “blend” runs (Figure IV.1).  
All analysis and modeling were performed in JMP v14 (SAS institute). 
The Incyte data consists of 22 variables: permittivity measured at 18 different 
frequencies, medium conductivity and 3 beta-dispersion curve parameters 
(alpha, characteristic frequency and Δε). All these variables are automatically 
calculated by the Incyte sensor. After run completion, the Incyte data was 
smoothed using a 30-minute (5 datapoints) moving average filter. This data 
was time-aligned with the corresponding sampling points (reference data). 
Biovolume was calculated based on the viable cell concentration and the cell 
diameter measurements, considering cells as perfect spheres.  
2.5.2. Model calibration and testing 
For calibrating the models, the offline reference data and corresponding 
online averages were used. The dataset was divided in calibration and testing 
set, with two “standard” batches (numbered 5 and 7) as testing set and the 
remaining belonging to calibration set. For the “empty” runs, random rAAV 
titers were generated, with a normal distribution of rAAV titers below the 
qPCR limit of detection. These random datapoints were divided by the real 
cell concentration to calculate the specific rAAV titers for “empty” batches. 
For modeling rAAV data, only the data after 2.5 days post-infection was used, 
when rAAV titer was above the limit of detection of the assay.  
JMP “Fit model” platform was used. Briefly the 22 parameters were subjected 
to forward and backwards stepwise regression to find the most significant 
parameters to each of the reference variables. 
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Figure IV.1 - Overview of the different batches used for model calibration. “Standard” runs 
represent a normal infection process, with co-infection with repcap- and transgene-Baculovirus 
Infected Insect Cells (BIICs). “Empty” runs were infected with an empty-BIIC, a BIIC which was 
infected with a baculovirus vector devoid of any transgene, but still able to replicate and induce 
cytopathic effects in infected cells. Cell density effect (CDE) runs are like “standard” runs, 
except that infection was performed at 5x106 cells/mL instead of 3x106. “Blend” runs consisted 
of separate “standard” and “empty” batches. 2 days after infection, cells from both reactors 
were transferred to new bioreactors, with the indicated proportions of each batch. Hpi – Hours 
post-infection.  
 
In a forward stepwise regression method, the most significant attribute is 
identified and added to the model, followed by identification and inclusion in 
the model of the second most significant attribute and so on. In a backwards 
stepwise regression method, all parameters are added to the model in the 
beginning and are stepwise removed according to their lack of significance to 
the model. The significance level considered was p-value = 0.05. For the most 
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significant attributes, their two-level interactions and quadratics were also 
considered, using the same combination of forward and backwards stepwise 
regression.  
RMSEs for calibration (RMSEC) and testing (RMSET) were calculated for all 
models (equation 1). The correlation coefficients of calibration and testing 
were calculated according to equation 2 using calibration (R2) or testing (Q2) 
data.  
In equation 1, ?̂?  represents a vector of model-predicted values and y 
represents the corresponding reference data; ncal and ntest represent the 
number of samples in the calibration or testing set, respectively. σ2 represents 
sample variance. 
𝑅𝑀𝑆𝐸𝐶 = √
∑ (?̂? − 𝑦)2𝑛𝑐𝑎𝑙𝑖=1
𝑛𝑐𝑎𝑙
                            𝑅𝑀𝑆𝐸𝑇 = √
∑ (?̂? − 𝑦)2𝑛𝑣𝑎𝑙𝑖=1
𝑛𝑡𝑒𝑠𝑡
              (1) 
𝑅2 = 1 −
𝑅𝑀𝑆𝐸𝐶2
𝜎2
                                                          𝑄2 = 1 −
𝑅𝑀𝑆𝐸𝑇2
𝜎2
               (2) 
 
 
3. Results  
3.1. Accurate prediction of infection timing using continuous 
permittivity monitoring  
Our target cell concentration at infection (CCI) is pipeline dependent. For this 
specific vector, the infection target is 3x106 cells/mL. However, inter-batch 
differences of up to 24 hours can occur for the cells to reach the target 
concentration (Figure IV.2 A). In order to accurately predict infection timing, 
an operator-independent strategy was developed. This strategy, entitled 
“process-to-target”, is based on the real-time continuous availability of 
permittivity measurements provided by the Incyte sensor. The first step was 
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then to determine the correlation between permittivity and viable cell 
concentration, which is linear during the exponential growth stage. As such, 
the permittivity corresponding to the target cell concentration was determined 
to be 2.2 pF/cm (2.18-2.34 pF/cm, 95 % confidence interval, Figure IV.2 B). 
 
 
Figure IV.2 - Process variability and correlation between permittivity and viable cell 
concentration. A) Viable cell concentration time-course profiles for the “standard” batches, with 
co-infection with repcap and transgene BIICs. The time when the cells reached the target cell 
concentration at infection can vary up to 24 hours. B) Correlation between viable cell 
concentration measured by Vi-cell and permittivity values measured by the Incyte sensor. The 
target value of VCC=3x106 cells is represented by a target, corresponding to a permittivity 
value of 2.2 (95% CI = 2.18-2.34). R2adjs=0.94. 
 
The obtained permittivity target was used as input for the “process-to- target” 
script. The other inputs are the permittivity time-profile data until the present 
time. The PTT script will then return the estimated predicted time when cells 
will be at the desired permittivity value (Figure IV.3).  
Prediction accuracy improves significantly with the availability of more 
datapoints, but accurate predictions are obtained as early as 24 hours after 
seeding (Table IV.1). 
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Figure IV.3 – Outputs of the process-to-target (PTT). The script was run at different times after 
inoculation, and the infection timing predictions are indicated below each image. For this figure, 
batch 5 was used, in which the target was reached at 50.8 h. Permittivity data is represented 
in black, the blue line represents model predictions and the red lines are the target (y axis) and 
the predicted time the target will be reached (x axis). A) PTT script run 12 hours after seeding. 
B) PTT script run 24 hours after seeding C) PTT script run 36 hours after seeding. 
 
 
 
 
Table IV.1 – Application of the PTT script to each of ten batches monitored using the Incyte 
probe at several process timepoints after seeding. The numbers in the prediction columns 
represent the predicted infection time (in hours post seeding). Actual time indicates the time in 
hours that the permittivity equaled the nominal target of 2.2 pF/cm. “N/A” indicates a timepoint 
that was past the point where the target was reached. CDE = Cell density effect. The data 
presented in this table was calculated after batch completion. 
 
Batch 
number 
Batch 
type 
Prediction Actual 
time 6 h 12 h 24 h 36 h 48 h 
1 Standard -648 129 53 78 54 55 
2 Standard -299 73 59 67 59 59 
3 Empty 458 95 64 56 53 52 
4 Standard 196 114 59 57 56 55 
5 Standard 213 95 53 52 50 51 
6 Standard 136 56 37 N/A N/A 36 
7 Standard -92 108 53 55 57 52 
8 CDE -120 156 65 73 65 61 
9 Empty -746 112 50 52 N/A 48 
10 CDE 553 107 56 60 55 54 
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3.2. Dielectric spectroscopy can be used for monitoring the 
progress of baculovirus infection  
Analysis of the variables measured by the Incyte probe allows to find 
similarities between those variables and the critical process variables of this 
system, such as cell concentration, viability and virus production (Figure 
IV.4). The first observation is that the culture conductivity increases 
simultaneously with the onset of baculovirus-induced cell lysis, suggesting 
that conductivity can be used for prediction of viability decrease (Figure 
IV.4 A). Incyte measurements of permittivity over a wide range of frequencies 
allows to plot the beta-dispersion curve, and the subsequent calculation of 
the curve parameters: Δε, α and characteristic frequency, which indicate 
changes in the cell state during the production process (Petiot et al., 2016) 
(Figure IV.4 B).  
Specifically for the IC-BEVS system, permittivity measurements allow to 
follow the progress of the culture and baculovirus infection in real-time, due 
to the correlation between permittivity and the cell biovolume (Ansorge et al., 
2007; Petiot et al., 2016). This way, this technology is suited to follow a 
complete IC-BEVS infection process: cell seeding and growth until the 
infection density, baculovirus-induced cell diameter increase and cell growth 
arrest and finally cell death phase (Figure IV.4 C). Baculovirus budding from 
infected cells has been postulated before to be detectable in the characteristic 
frequency signal (Petiot et al., 2016). In this work, the previous-reported 
“v-shaped” profile can also be observed (Figure IV.4 D) (Petiot et al., 2016). 
Figure IV.4 has a two-fold purpose: to provide an overview of the parameters 
measured with Incyte, and prove those parameters have a close 
interconnection with critical process variables in this system and are thus 
suitable for building prediction models for those variables.  
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Figure IV.4 - Incyte measurements can be correlated with the progress of baculovirus infection 
in insect cells. A) The onset of baculovirus-induced cell lysis (viability, represented with circles) 
can be detected by the simultaneous onset of conductivity increase (smooth lines, measured 
by Incyte). B) Beta-dispersion curve 24 hours after seeding, for batch number 1. The 
beta-dispersion allows calculation of variables such as Δε, α and characteristic frequency, 
which are indicative of the cell state during the infection process. C) Visual inspection of the 
permittivity profile allows to follow the three phases of the production process (separated by 
the shaded area): cell growth, cell diameter increase due to baculovirus infection and 
baculovirus-induced cell lysis. Circles represent biovolume calculations based on the 
measured diameter and considering cells as perfect spheres, and smooth lines the Incyte 
permittivity measurements at 1000 kHz. D) The characteristic frequency (frequency 
corresponding to the beta-dispersion curve inflection point) time profile is shown. The “v 
shaped” profile after 2 days post infection has been postulated to be correlated with baculovirus 
release from cells elsewhere (Petiot et al., 2016). 
 
 
As such, prediction models for viable cell concentration (Figure IV.5), viability 
(Figure IV.6) and diameter (Figure IV.7) were built based on the Incyte data. 
Regarding viable cell concentration, the observed vs predicted values for the 
calibration set (Figure IV.5 A) are shown. To complement the information, the 
viable cell concentration time-course profiles for the two batches used as 
testing set are compared with the corresponding time-course predictions 
(Figure IV.5 B). The obtained models are very accurate (Q2=0.89), with only 
a slight underestimation of the viable cell concentration.  
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Figure IV.5 - Calibration and testing data for viable cell concentration. A) Observed and 
predicted values for the dataset used for model calibration, R2=0.96. Batches are represented 
by different colors, with filled triangles representing “cell density effect” batches, empty 
triangles representing “empty” batches and filled circles representing “standard” and “blend” 
batches. B) Viable cell concentration time-course profiles for the testing set, Q2=0.89. 
Reference data is represented by open circles and corresponding model-predicted values are 
shown as filled circles. 
 
For the viability models (Figure IV.6), the prediction profiles are remarkably 
accurate (Q2=0.98), for both culture phases, demonstrating the same 
prediction model can be deployed for the whole cultivation.  
The increase in cell diameter induced by baculovirus infection can be used 
as indicator of the progress of baculovirus infection. Similar to the viability 
models, the models created for prediction of cell diameter are accurate during 
all phases of the infection process (Figure IV.7).  
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Figure IV.6 - Calibration and testing data for viability. Batches are represented by different 
colors. A) Observed and predicted values for the dataset used for model calibration, R2=0.98. 
Batches are represented by different colors, with filled triangles representing “cell density 
effect” batches, empty triangles representing “empty” batches and filled circles representing 
“standard” and “blend” batches. B) Viability time-course profiles for the testing set, Q2=0.97. 
Reference data is represented by open circles and corresponding model-predicted values are 
shown as filled circles. 
 
 
 
Figure IV.7 - Calibration and testing data for diameter. Batches are represented by different 
colors. A) Observed and predicted values for the dataset used for model calibration, R2=0.94. 
Batches are represented by different colors, with filled triangles representing “cell density 
effect” batches, empty triangles representing “empty” batches and filled circles representing 
“standard” and “blend” batches. B) Diameter time-course profiles for the testing set, Q2=0.92. 
Reference data is represented by open circles and corresponding model-predicted values are 
shown as filled circles. 
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3.3. rAAV production kinetics in the insect cell – baculovirus system 
The same modeling strategy used for the process variables was employed 
for developing prediction models for intracellular rAAV production. 
Supernatant rAAV concentrations were not considered on the assumption 
that dielectric spectroscopy measures variations in the intracellular 
composition of the cell. The chosen bioreactor dataset translated into 
desirable and intended variability (Figure IV.8). Both the intracellular rAAV 
titer (rAAV quantified in the supernatant of the lysed pellet solution, Figure 
IV.8 A) and the specific rAAV titer are presented (Figure IV.8 B, intracellular 
titer normalized by viable cell concentration).  
In particular, the effect of infecting cells at high cell density in the specific 
rAAV production titer can be observed (Figure IV.8 B, blue and green 
triangles). The “blend batch” strategy (depicted in Figure IV.1) also has the 
desired effect of providing rAAV concentration profiles at different ranges 
(Figure IV.8, open circles).  
3.4. Detection of rAAV-induced signals using multiple linear 
regression 
The same modeling strategy used for the critical process variables was 
applied to the specific rAAV data from Figure IV.8 B. The model predictions 
obtained (Figure IV.9) demonstrate this strategy yields acceptable predictions 
for the testing set (Q2=0.77).  
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Figure IV.8 - rAAV intracellular production profiles. The datapoints represent vector genomes 
quantification. Filled circles represent “standard” batches, triangles represent “cell density 
effect” batches, empty diamonds represent “empty batches” and the empty circles represent 
“blend batches”. For the details on batch nomenclature, the reader is referred to Figure IV.1. 
Lines represent a smooth of the reference data, unrelated with model predictions. A) rAAV 
intracellular titer, the rAAV concentration after lysing pellet from 10 mL of culture. B) Specific 
rAAV titer. Same data as A normalized by the number of viable cells at the corresponding 
sampling time. 
 
 
Figure IV.9 - Calibration and testing data for intracellular specific rAAV. Batches are 
represented by different colors. A) Observed and predicted values for the dataset used for 
model calibration, R2=0.71. Batches are represented by different colors, with filled triangles 
representing “cell density effect” batches, empty triangles representing “empty” batches, filled 
circles representing “standard” batches and empty circles representing “blend” batches. B) 
Intracellular specific rAAV time-course profiles for the testing set, Q2=0.77. Reference data is 
represented by open circles and corresponding model-predicted values are shown as filled 
circles. 
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4. Discussion 
In this work we employed dielectric spectroscopy for accurate prediction of 
infection timing in the insect cell-baculovirus system. Moreover, we 
developed predictive models for cell concentration, viability, diameter and 
rAAV production, which can be used to follow the progress of baculovirus 
infection and recombinant AAV production in real-time.  
The time of infection is one of the most important process parameters that 
need optimization in the insect cell system, with direct implication on the 
overall process results (Druzinec et al., 2013; M. Lecina et al., 2006). Current 
methods for infection timing require frequent, offline cell-counting, subjected 
to equipment variability and operator dependency, frequently resulting in 
more than 10 % variability. Additionally, frequent sampling increases the 
changes for contamination. Real-time, continuous monitoring of viable cell 
concentration can alleviate this issue. One of the real-time monitoring tools 
extensively applied to monitor cell concentration in cell culture processes is 
dielectric spectroscopy (Kroll et al., 2017; Mercier et al., 2016; Nikolay et al., 
2018). In particular for the insect-cell system, dielectric spectroscopy has 
been extensively used (Ansorge et al., 2007; Elias et al., 2000; Negrete et al., 
2007; Petiot et al., 2016; Zeiser et al., 2000, 1999) owing to the scalable 
properties of the system and the increase in cell diameter induced by 
baculovirus infection. Taking advantage of the frequent Incyte permittivity 
measurements and the high correlation between permittivity and cell 
concentration (before the cells increase diameter due to baculovirus infection, 
Figure IV.2), we applied dielectric spectroscopy to predict infection timing 
(Figure IV.3). An in-house JMP script (PTT – “process-to-target”) was 
developed, which uses the current batch historical permittivity data to 
accurately predict infection timing. As expected, the more historical data is 
available for the current batch, the better the predictions (Table IV.1). This 
tool was able to predict infection timing within 10 % of the actual infection time 
Dielectric spectroscopy as PAT tool in the IC-BEVS 
165 
as early as 24 hours post-inoculation. This amount of prior notice would allow 
for more accurate infection timing and could help alleviating resources in 
manufacturing facilities. Additionally, the PTT script is operator independent, 
allowing for easy transfer to Contract Manufacturing Organizations. Currently 
the script relies on a weighted linear regression, and the occasional 
permittivity spikes or the initial cell lag phase can impact prediction accuracy 
(Table IV.1, predictions at 36 h and 6 h, respectively). Although for our current 
process the weighted linear regression model used in the PTT allow accurate 
enough predictions, the script can be adjusted for using other prediction 
models. 
Our script relies on the target permittivity value as an input. This target is 
obtained by a simple linear regression between viable cell concentration and 
permittivity for all the dataset. Since permittivity values are correlated with the 
culture biovolume, rather than cell concentration, this linear relationship is 
maintained until the cell diameter starts increasing. However, cell permittivity 
can be indicative not only of the cell biovolume, but more importantly of the 
overall cell state (Ansorge et al., 2007; Petiot et al., 2016). As such, we 
envision to move from a cell concentration-based infection process, to a 
permittivity-based infection. Further experiments with cells infected at 
different permittivity values is ongoing.  
Moreover, and taking into account the inverse linear correlation between the 
onset of viability decrease and the onset of conductivity increase (Figure 
IV.4 A and Supplementary Figure IV.1), we are conducting experiments to 
switch from a “by day”-based harvest into a viability-based harvest, adapting 
the PTT to the conductivity measurements to accurately predict harvest time. 
The choice of the best viability to harvest is dependent not only on the final 
rAAV titer but also the vector potency and the overall downstream yield (Grein 
et al., 2018; M Lecina et al., 2006; Nikolay et al., 2018). 
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The PTT relies only in current data historical profiles, since for any current 
batch and during exponential growth phase, a linear correlation can be 
obtained between permittivity and cell concentration and viability and 
conductivity (Supplementary Figure IV.2). However, the correlation obtained 
for one batch cannot be used directly in another batch. We even detected a 
significant difference in the obtained linear regression slope for permittivity 
and cell concentration in different cell banks (results not shown). Moreover, 
even though the same medium was used in parallel bioreactors and the Incyte 
probe is zeroed in the medium, the conductivity measurements have a 
baseline reading which is different between batches (Figure IV.4 A). For 
manufacturing purposes, it is useful to have robust prediction models which 
are less sensitive of the small variations in probe measurements and the cell 
biological variations. As such, conductivity or permittivity-only based models 
cannot be used for the development of robust process prediction models, and 
consequently the beta-dispersion curve was considered for modeling the 
critical process variables in this process. This curve changes during the 
culture progression, being indicative of the cell physiological alterations 
during the overall growth and infection progress (Supplementary Figure IV.3). 
These changes can be quantified by calculating the beta-dispersion curve 
parameters along time: the difference between the low and high frequency 
plateaus (Δε), the Cole-Cole α (α) and the curve inflexion point (characteristic 
frequency, fc). These parameters have been shown to be useful for 
characterizing the culture. For instance, α is related with the distribution of the 
dielectric properties in the population and the cell shape and size (Ansorge et 
al., 2007; Dabros et al., 2009); Δε is proportional to cell concentration and 
biovolume (Petiot et al., 2016) and fc has been demonstrated to be correlated 
with the cell death phase and virus budding (Ansorge et al., 2011; Petiot et 
al., 2016). For a more in-depth review of the biological meaning of each 
parameter, the reader is referred to the work of Dabros (Dabros et al., 2009). 
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The models shown in Figure IV.5 to Figure IV.9 were built using the calibration 
dataset introduced before and the above mentioned beta-dispersion 
parameters and frequency measurements. Besides multiple linear 
regression, we also tested partial least squares (PLS) regression and artificial 
neural networks. Multiple linear regression models combined simplicity with 
accurate predictions, and thus it was the strategy followed for developing 
predictive models. The high Q2 obtained (0.78-0.97) show that dielectric 
spectroscopy signals can be used to predict critical process variables for this 
system and highlight the importance of a variable dataset.  
Although not explored in this work, dielectric spectroscopy can be used to 
monitor baculovirus release kinetics from infected cells. Petiot and coworkers 
found a characteristic “V-shape” profile in the characteristic frequency 
time-course profile, and associated that signal with viral budding from the 
infected cells (Petiot et al., 2016). In Figure IV.4 D, we also observed a 
significant drop in the permittivity around day 2 post-infection. Given that our 
infection process takes place at a very low MOI, it takes two days to infect a 
significant proportion of the Sf9 population and the baculovirus release from 
the cells be detectable. As a control group, the two cell density effect batches 
do not show the decrease in the fc value on day 2, but instead on day 4, since 
the higher cell concentration at infection is able to delay detection of the cell 
growth arrest induced by baculovirus. Moreover, we developed good 
prediction models for the cell diameter, a good indicator of the progress of 
baculovirus infection (Janakiraman et al., 2006; Laasfeld et al., 2017). 
Altogether, this knowledge may be useful for characterizing the baculovirus 
release kinetics for each baculovirus, developing dielectric 
spectroscopy-based models for prediction of baculovirus release from 
infected cells and possibly for baculovirus and BIIC titration.  
The permittivity-based models were expanded to prediction of intracellular 
specific rAAV titer (Figure IV.9). rAAV extracellular titer was excluded from 
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the models because our hypothesis was that most rAAV-induced alterations 
in the cell state would be detected through variations in the intracellular 
composition of the cell. However, as mentioned in previous chapters, 
increase of rAAV concentration in the medium is mostly due to cell lysis. As 
good viability prediction models were developed using dielectric 
spectroscopy, we believe building extracellular rAAV prediction models would 
also be feasible, as demonstrated in Chapter III with digital holographic 
microscopy.  
Still, measuring intracellular rAAV data contributed to an increase in 
understanding of our production process (Figure IV.8). For instance, rAAV 
production per cell seems to halt around day 5 post-infection. As such, we 
may be able to harvest our process one day earlier, although this decision is 
also dependent on the rAAV quality profiles. As culture progresses and cell 
lysis starts to occur, the number of viable cells producing rAAV decreases. 
However, since the rAAV profiles plateau around day 5 and the viability 
decrease starts around day 2.5, there are probably other factors related other 
than cell viability.  
We clearly show the impact of baculovirus infection at high cell density for 
specific rAAV production (Figure IV.8). The addition of cultures infected at 
higher cell density was intended to introduce variability in the model, based 
on the well-known cell density effect, a drop in cell specific productivities when 
infecting high cell density cultures (Bernal et al., 2009; Ferreira et al., 2009; 
Merten, 2016). Similarly, the “blend” batch strategy intended to decouple 
rAAV permittivity signals from cell and baculovirus-induced permittivity 
changes. This strategy was successful in generating batches with decreasing 
rAAV concentration, keeping the cell concentration and baculovirus 
production at similar levels (Figure IV.8). However, even though infection was 
performed at 3x106 cells/mL, these runs have a similar rAAV production 
profile with the “cell density effect” batches (Supplementary Figure IV.4). The 
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existence of a “blend” batch with 0 % “empty” (theoretically, a “standard” 
production run) but still with low rAAV production titers seem to indicate there 
was an unknown problem in the “blend” batch runs. Regardless, the positive 
impact of the “blend” strategy in the overall model is incontestable.  
 
5. Conclusions  
The work developed clearly shows dielectric spectroscopy can be used as 
PAT tool for this system, not only by allowing accurate infection time 
determination, but also for rAAV production monitoring. The ability to estimate 
the time of infection more than 24 hours before is invaluable for GMP settings, 
proving the usefulness of the PTT approach. The predictive models 
developed for critical process variables demonstrate accurate predictions for 
all variables in an independent testing set, validating the chosen strategy, and 
can be used for developing viability-based harvest methods. The determined 
intracellular rAAV production profiles, together with the developed rAAV 
prediction models, allow to increase process knowledge regarding this 
process, and to possibly unveil new factors influencing rAAV production by 
conducting process alterations and supplements administration and assess 
their impact on rAAV production in real-time. Future studies will address the 
possibility of applying this tool for determination of rAAV quality 
characteristics, such as potency or ratio of empty to full particles.  
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7. Supplementary Data 
 
 
Supplementary Figure IV.1 - Viability reference data and corresponding predictions using only the 
conductivity data. For each run, a linear fit was obtained between conductivity and viability, considering 
only the data after viability started to decrease. This simple fit can be applied in the PTT. 
 
 
 
Supplementary Figure IV.2 – Linear correlation between permittivity and viable cell concentration (A) and 
conductivity and viability (B). For viable cell concentration, only data until day two post infection is shown, 
since after day 2 cell diameter increases. For viability, only data after day two post-infection is shown, 
corresponding to the timepoints of viability decrease.  
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Supplementary Figure IV.3 – Representative beta-dispersion curve evolution profiles for different culture 
phases, here shown for batch number 1. Each curve is colored according to the culture time (the darker 
the color, the closer the timepoint is to the harvest time).  
 
 
Supplementary Figure IV.4 – Scores for the two first principal components for all runs. The 22 
permittivity-related variables were utilized to calculate the principal components. Filled circles represent 
“standard” batches, filled triangles represent “cell density effect” batches, empty triangles represent “empty 
batches” and the empty circles represent “blend batches”. As it can be observed, even though “blend” 
batches were infected at the same cell concentration as the “standard” batches, their permittivity data is 
more similar to the “cell density effect” ones, similar to what was observed in the specific rAAV titers (Figure 
IV.8) 
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1. Introduction 
The biotechnology industry is largely contributing to the global economy. Its 
growth is mainly attributed to an in-depth understanding of biological systems, 
fostered by developments in ‘omics’ technologies (Lee et al., 2005) and to an 
ever-increasing demand for biotech-derived products, such as 
biopharmaceuticals, food and feed products or biofuels (Matasci et al., 2009; 
Rude and Schirmer, 2009). Despite the large amount of research conducted 
in the last few years, process control has played a minor role in the industrial 
practice, with the majority of established industrial processes still manually 
following empirical state trajectories obtained after a significant experimental 
effort (Henson, 2006). Nevertheless, the economic interest in process control 
is increasing as a mean to effectively compete in the marketplace, especially 
against cheaper generic alternatives due to expiration of blockbuster drugs 
patents (Kresse, 2009) and also due to the process analytical technology 
(PAT) guidance introduced by the Food and Drug Administration (FDA) in 
2004 (Munson et al., 2008), encouraging pharmaceutical and 
biopharmaceutical companies to implement advanced control strategies to 
achieve operational excellence. 
Well established control technologies apply classical 
proportional-integral-derivative (PID) feedback loops to easily measurable 
physicochemical variables, such as dissolved oxygen (DO), temperature, and 
pH. The control of these variables, although important, is not enough to 
guarantee optimal operation. The success of PID control schemes is primarily 
founded on the reliability of the measurement technologies.  
Currently, key bioprocess variables like biomass concentration, nutrient 
uptake rates and product titer cannot be measured directly and online. In fact, 
this is one of the main limitations preventing wider adoption of classical online 
control in bioprocesses. Process control approaches based on online sensors 
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that are able to estimate key variables indirectly are becoming more common 
in biomanufacturing, based on recent developments in bioprocess monitoring 
technologies (Zhao et al., 2015). 
State-of-the-art bioprocess control schemes rely on more sophisticated 
approaches, which find still limited acceptance in the industry due to their 
complexity in implementation, maintenance and use and the need for 
accurate bioprocess models to achieve reliable performance. 
For any bioreactor operation mode (batch, fed-batch, or continuous), the goal 
in process control is most often to maximize total production of the desired 
product, while assuring consistent quality. The choice of specific control 
objective may vary from maximization of cell concentration, maximization of 
product titer or specific productivity, by-product minimization, improvement of 
a quality attribute or reproducing an established process trajectory. 
Continuous operation involves control of the nutritional environment at an 
operating point that maximizes the steady-state productivity. Zhao and 
Skogestad (Zhao and Skogestad, 1997) compare various control 
configurations for continuous bioreactors. The most common control 
structures employ the dilution rate or the feed concentration of the 
rate-limiting substrate as manipulated variables. When a sufficiently accurate 
mathematical model is available, the optimal operating state can be 
determined offline through computer simulation and optimization (the optimal 
control problem), and then implemented in the process in the form of either 
an open-loop operating protocol or a closed-loop control system that forces 
the measured process state to track the optimal state. 
Process control of batch and fed-batch operations is more challenging, as the 
optimization is a dynamic programming problem. The fed-batch operation 
mode is the most employed, as it often avoids substrate inhibition and 
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overflow metabolism while still allowing some operational flexibility. A 
comprehensive review of fed-batch control strategies was published by Lee 
and coworkers (Lee et al., 1999). The most frequently addressed process 
control problem in fed-batch reactors is designing substrate-feeding 
strategies to maximize product quantity at the end of the culture. If a reliable 
dynamic model of the process is available, dynamic programming is adopted 
to solve the control problem (Li and Biegler, 1988). In general, the biotech 
industry prefers the open-loop implementation as it does not rely on complex 
instrumentation; still this method is often suboptimal due to the unavoidable 
process-model mismatch. 
Apart from the theory-practice gap, the choice of adequate control theory for 
biotechnological applications is still surprisingly challenging due to the 
nonlinear and time-varying nature of bioprocesses and their poorly 
understood kinetics (van Impe and Bastin, 1995). Nonetheless, by using the 
available bioprocess information together with tools from control theory, it is 
possible to develop control strategies that overrule some of the empiricism 
associated with the operation of bioreactors.  
Process control is a rich field in the literature with many different strategies, 
methods and algorithms that can be combined in multiple ways to address a 
control problem. Consequently, specific implementations can be classified 
according to different criteria. Here we attempt to highlight common and 
defining attributes of different approaches to bioprocess control, but these 
approaches inherently have conceptual and method overlaps. The examples 
presented focus on upstream processing. A recent review by Hong and 
coworkers (Hong et al., 2018) highlights how process control can be used in 
different steps of biopharmaceutical manufacturing. 
The objective of this article is to review some of the strategies that have been 
developed to design bioprocess control systems. The first part summarizes 
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several works employing classical control strategies, while the second part is 
focused on applications of advanced control strategies. Here, we focus on 
the techniques that we think are closer to practice and thus with higher 
industrial potential. 
 
2. Current Practice of Bioprocess Control 
Simple semiautomatic control strategies developed based on extensive 
experimental testing are the current industrial practice to control 
bioprocesses, employing either open- or closed-loop protocols (Gnoth et al., 
2008). Process control based on open-loop operation is well accepted in the 
biotechnology industry because of its simple technological implementation 
and quasi-guaranteed reproducibility of manipulated variables; these factors 
are concomitant with a safe operation strategy, which is highly valued by 
industry. In open-loop control, the optimization of the process is performed 
offline, and then the resulting policy is implemented online. This type of 
control is applied when a good prediction model exists but information about 
the process state is not enough to be used for online feedback actions when 
deviations from the desired behavior occur. The weaknesses of an open-loop 
protocol when model-process mismatches exist are illustrated in the work by 
Vanichsriratana and coworkers (Vanichsriratana et al., 1996) through 
simulations. They introduced a 10 % error in the parameters of the 
mathematical model for the process and then used this model to calculate the 
optimal substrate concentration that maximized biomass production. The 
performance of the open-loop control was much poorer than that of a 
closed-loop control using model predictive control (MPC), since the modeling 
error could be compensated by a feedback control action in the latter case. 
The variables usually monitored in industrial bioreactors are temperature, pH, 
DO concentration, bioreactor head pressure, and, often, the oxygen and 
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carbon dioxide composition in the off gas. Relying on these basic 
measurements and, sometimes, on more sophisticated determinations of 
rate-limiting substrates, toxic metabolites, and cell biomass, simple 
closed-loop algorithms have been developed for bioreactor control. Normally, 
an optimal policy is derived based on empirical biochemical knowledge or 
simplistic models representing the cellular biochemical reactions. This 
solution is then implemented online with likely deviations corrected whenever 
new measurements are available. 
2.1. Manual Control Based on Infrequent Measurements  
A predictive control configuration based on infrequent measurements of 
glucose was applied by Dowd et al. (Dowd et al., 2001), to keep the 
concentration of this substrate at a defined set point in a perfusion culture of 
Chinese hamster ovary (CHO) cells. Glucose concentration in the culture bulk 
was analyzed off-line every 24 h, from which a consumption rate was 
predicted and used to adjust the feeding rate for the next 24 h. Despite the 
infrequent sampling, glucose deviation from the set point was less than 
0.4 mM. A similar strategy was followed by Cruz and coworkers (Cruz et al., 
2000) to control both glucose and glutamine concentrations at extremely low 
levels to reduce byproduct formation during fed-batch cultures of recombinant 
baby hamster kidney (BHK) cells. Feeding rates were adjusted daily after 
offline analysis of both the nutrients. This empirical way of controlling key 
state variables is still very common in industrial practice. 
2.2. Closed-loop Control Based on At- or Online Measurements  
There are many examples in literature of standard closed-loop controllers 
based on variables that are measured in real-time employing sophisticated 
measurement technologies. An example of this type of control is given in the 
work by Turner et al. (Turner et al., 1994), in which a fully automated system 
for the online monitoring of acetate and closed-loop control of a fed-batch 
fermentation of recombinant Escherichia coli is developed to prevent acetate 
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formation. Samples from the bioreactor are collected through an aseptic 
sampling device, then the supernatant is separated from biomass in a 
microcentrifuge and injected into a high-performance liquid chromatography 
for acetate analysis. The results were used by a control algorithm that 
determined the feeding strategy to limit acetate concentration to a low level 
throughout the fermentation. 
Ozturk and coworkers (Ozturk et al., 1997) employed a similar strategy, in 
which a simple algorithm was derived to maintain glucose and lactate levels 
at their set points during hybridoma perfusion cultures. In their study, every 
60 min, a cell-free sample was drawn from the bioreactor to quantify glucose 
and lactate concentrations using a biochemical analyzer YSI2700 upgraded 
with an aseptic sampling module. Then, the perfusion rate was adjusted 
according to a simple model, which accounted with the specific 
consumption/secretion rates previously observed. 
2.3. Inferential Control Methods 
In this type of control, unmeasured control variables are estimated from other 
more easily measured variables and then feedback control is applied to 
maintain the estimated control variable at the desired set point. This enables 
real-time control of variables for which direct measurements are only 
available offline. The combination of hardware sensors with a software-based 
estimator is known as a soft sensor, and their current applications in 
bioprocessing have been reviewed in Luttman et al. (Luttmann et al., 2012). 
For example, Zhou and coworkers (Zhou et al., 1995) established a 
closed-loop scheme to control glucose concentration at a desired set point in 
high cell density cultures of mammalian cells by measuring oxygen uptake 
rates (OUR) and assuming a constant stoichiometric ratio between glucose 
and oxygen uptake. Using the same principle, Konstantinov et al. 
(Konstantinov et al., 1990) estimated the glucose consumption rate from 
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real-time measurements of the exit gas composition in an E. coli fed-batch 
culture. The control objective was to keep the specific glucose feed rate below 
a critical limit to prevent acetate formation. This controller allowed negligible 
acetic acid accumulation and improved phenylalanine synthesis. Hiller et al. 
(Hiller et al., 2017) demonstrated a simple but interesting strategy to control 
perfusion rate in CHO cell cultures based on pH measurements. CHO cells 
will produce lactate if glucose concentration is high and will consume lactate 
when glucose drops to limiting levels, leading to variations in pH. By keeping 
the pH to a specific set point by turning perfusion on and off, the authors were 
able to ensure adequate glucose supply.  
Spectroscopic probes are commonly used in inferential control methods, 
often in combination with soft sensors. Raman spectroscopy, for example, 
allows simultaneous estimation of multiple metabolite concentrations and has 
been increasingly used in bioprocess monitoring practice (Esmonde-White et 
al., 2016). In Matthews et al. (Matthews et al., 2016), the authors used Raman 
spectroscopy and partial least squares (PLS) regression to control glucose 
feeding and minimize lactate accumulation in mammalian fed-batch cultures.  
Dielectric spectroscopy sensors, or biocapacitance probes, are a promising 
solution to monitor viable cells. Zhang and coworkers (Zhang et al., 2015) 
showed that dielectric spectroscopy can be used with an online feedback loop 
to adjust nutrient feeding in a CHO fed-batch, as long as the viability is high. 
In this study, the control loop kept the feeding proportional to the cumulative 
integral of cell growth.   
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3. Advanced Process Control Strategies 
Model-based control strategies based on well-established control theory have 
been effectively employed in the chemical industry for decades. Their 
application to biotechnological processes has also received considerable 
attention in academia over the last few years. Examples include adaptive 
control, linearization-based control, iterative learning control (ILC), and MPC. 
These are described below, and their block diagrams represented in 
Figure V.1. In many of the published studies, the additional benefits of these 
strategies in relation to classical control are demonstrated, laying primarily on 
the possibility of correcting not only the manipulated variables, but also the 
underlying model parameters as fresh process data become available. 
Nevertheless, only a small number of published works provide the proof of 
concept in real process conditions; the majority presents simulation results, 
assuming that the required state variables are accurately measured or 
estimated, which many times is technically unfeasible. In practice, the 
estimation of unmeasured state variables is not trivial, particularly if unknown 
parameters also have to be estimated (Bequette, 1991). The lack of online 
sensors providing high-quality data for key bioprocess variables is one of the 
main factors hindering the industrial implementation of advanced control 
algorithms. A recent review (Portner et al., 2017) covers monitoring and 
modelling considerations for the implementation of advanced bioprocess 
control strategies. 
3.1. Adaptive Control 
In adaptive control, controller parameters are updated to reflect variability in 
the process or uncertainty in initial parameter estimation. Adaptive control has 
been widely used as a way to cope with process-model mismatch (Bastin and 
Dochain, 1990); the controller structure can be designed on the basis of a 
simple model, and then one or more feedback actions compensate for both 
model uncertainties and major disturbances. Three main classes of adaptive 
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control, differing on the way parameter adaptation is implemented, are gain 
scheduling, model reference adaptive control, and self-tuning control.  
 
 
 
Figure V.1 - Block diagram of advanced control strategies: A) gain-scheduling controller; B) 
self-tuning controller; C) model reference adaptive controller; D) iterative learning control; and 
E) model predictive controller. 
  
3.1.1. Gain scheduling 
Gain scheduling, the simplest version of an adaptive control system, adjusts 
the controller gain, or the strength of the response, of proportional-integral 
(PI) or PID controllers to obtain a good performance at different operating 
regions. It is convenient especially if the process dynamics have good 
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correlation with easily measurable variables that can be used as scheduling 
variables. 
This type of control has been mainly used to improve performance of DO 
concentration control in batch and fed-batch processes. Several authors have 
reported tuning problems when PID controllers with fixed parameters are 
used to control DO concentration during the whole process; a controller tuned 
at one operating condition may not maintain a satisfactory response at 
different operating conditions. One of the main disturbances in DO control is 
the change in OUR over culture time. Cardello and San (Cardello and San, 
1988) applied the OUR as the auxiliary variable to fine-tune the parameters 
of the PID controller for DO in a batch reactor. Also Kuprijanov and coworkers 
(Kuprijanov et al., 2009) based the update of the parameters of a PI controller 
on changes in OUR. These authors developed a linear relationship between 
the controller parameters and OUR, which was then used to adapt online 
those parameters and guarantee a good performance of the DO controller. 
The performance of the controller was further improved by using the 
information from the substrate feeding rate (the variable that mostly 
influences the DO) in a feed-forward fashion. This part of the controller is 
important for a quick response when the substrate feed rate or the mass 
transfer coefficient changes rapidly. 
In the Åkesson and Hagander (Akesson and Hagander, 1999) study, a 
gain-scheduling PID controller for DO concentration was developed using the 
stirrer speed as manipulated variable. The working range for the stirrer speed 
was divided into different operating regions and then for each region the 
controller parameters were obtained using auto-tuning experiments. The 
controller was applied to a recombinant E. coli cultivation and good 
disturbance rejection was achieved. 
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Despite the simplicity of implementation and the quick response provided, the 
design of gain scheduling controllers presents two main drawbacks: it is 
time-consuming since the parameters have to be determined for many 
operating conditions, and, because the schedule is defined a priori, it provides 
no feedback to compensate for incorrect schedules. 
3.1.2. Self-tuning controller  
In a self-tuning controller, the algorithm learns from experience and 
self-adjusts the parameters to improve closed-loop control performance after 
process variations. Often, this learning process builds up a mathematical 
model based on experimental input/output data. It has been used to tune 
classical PID controllers and more complex control laws. Machine learning 
methods, such as fuzzy logic and artificial neural networks (ANN), have been 
used for the adaptation mechanism of controller parameters. 
Ramkumar and Chidambaram (Ramkumar and Chidambaram, 1995) 
employed an online fuzzy logic mechanism to self-tune a PI controller 
designed to maintain cellular concentration at the optimal steady-state in a 
continuous bioreactor. The controller parameters were determined based on 
the Ziegler-Nichols tuning formula. This fuzzy self-tuning method takes the 
process output error as input and the tuning parameters as outputs. 
Simulation studies showed that the controller is robust to the uncertainty and 
disturbances in the model parameters, giving improved responses in relation 
to a PI controller with fixed parameters. On the other hand, in the Mohseni et 
al. study (Mohseni et al., 2008), an ANN was designed to tune online the 
parameters of a PI controller, the weights of the ANN being updated at each 
sampling time by means of the error between the desired output and the 
actual output of the system. This self-tuning controller was employed to follow 
a desired reference trajectory for the cellular growth rate by manipulating the 
substrate feed rate in a fed-batch culture of recombinant E. coli. It 
demonstrated improved performance in relation to the classical PI controller 
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tracking the growth rate and could reject large disturbances and parameter 
variations. 
Radhakrishnan et al. (Radhakrishnan et al., 1999) adopted a nonlinear 
self-tuning controller based on the NARMAX approach (nonlinear 
autoregressive moving average with exogenous inputs) to regulate a 
continuous bioreactor near its optimum productivity. The dilution was the 
manipulated input and cell concentration was the controlled variable. 
Simulation studies showed a smooth response of the controller when 
changes in both load and set point occurred, and a better control performance 
when compared to a classical PI controller. 
3.1.3. Model reference adaptive control  
Model reference adaptive control (MRAC) systems aim at updating the 
parameters of the control law such that the behavior of the resulting 
closed-loop system becomes as close as possible to that of a given reference 
model. The controller parameters are adapted in a way such that the plant 
response matches the response of the reference model. 
In Oliveira et al. (Oliveira et al., 2005), a high cell density Pichia pastoris 
culture was operated near maximum oxygen transfer capacity by 
manipulating glycerol feeding (limiting substrate). Two adaptive control 
algorithms, a MRAC controller, based on the known stoichiometry between 
glycerol and oxygen consumption, and a PI feedback controller with adaptive 
gain, were designed and tested in a pilot plant bioreactor with online 
measurements of DO and off-gas composition. Both controllers proved to be 
robust and accurate, but the MRAC was more sensitive to errors in the 
measurements of oxygen transfer rate since it relies on the exact mass 
balance of oxygen. Nevertheless, the MRAC has the advantage of being 
easily tuned by choosing a first-order time constant for the convergence to 
the set point (the reference model). 
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Maher et al. (Maher et al., 1995) developed a different MRAC to follow a 
predetermined trajectory for the substrate concentration by manipulating the 
dilution rate in a continuous culture of S. cerevisiae. They compared the 
proposed controller to a classical PI controller in terms of regulation, tracking, 
and overshooting after set point changes, demonstrating improved 
performance of the MRAC controller with less overshoot and the absence of 
oscillatory phenomena.  
As adaptive controllers cannot guarantee optimality of the results obtained, 
Smets et al. (Smets et al., 2004) proposed optimal adaptive control, which 
consists of first deriving and carefully analyzing a nearly optimal solution 
based on biochemical knowledge, which is then implemented in an adaptive 
way. 
3.2. Linearization-based Control 
Given the inherently nonlinear nature of bioprocesses, an increasing interest 
is directed to the application of nonlinear control theory (Mailleret et al., 2004). 
However, when nonlinear models are used in a model-based control 
structure, the control law cannot be analytically obtained. The computational 
effort increases considerably, and numerical stability is not guaranteed. To 
circumvent these problems, exact linearization control theory became a 
concept of paramount importance (Wang et al., 1993). This strategy consists 
of finding a feedback control law and a state variable transformation such that 
the closed-loop system model becomes linear in the new coordinate 
variables; the input-output nonlinearities are canceled under the assumption 
of a perfect knowledge of the kinetics. 
Exact linearization has been mainly used to control continuous bioreactors. 
With the objective of keeping the bioreactor near the optimal productivity, 
Henson and Seborg (Henson and Seborg, 1992) showed that exact 
input-output linearizing control provides good control behavior when the 
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manipulated variable is the dilution rate, but not when it is the feed substrate 
concentration. Wang et al. (Wang et al., 1993) also emphasized the 
importance of the control structure selection in the application of exact 
linearization control to continuous bioreactors. 
In general, however, the nonlinear terms are not fully known, making 
impossible their cancelation and leading to a poor performance of the 
linearized controller. In the case of uncertainty in kinetic rates, parameter 
adaptation appears as an attractive way to improve feedback-linearizing 
control. This is called adaptive feedback-linearization control; the nonlinear 
problem is solved by linearizing the process model as the process moves into 
different operating regions (Guardabassi and Savaresi, 2001). The majority 
of reported studies on adaptive linearizing control employs the MRAC 
methodology to define the update law for estimation of parameters for the 
input-output linearization (McLain and Henson, 2000). 
In the Ignatova et al. (Ignatova et al., 2008) study, an indirect adaptive 
linearizing control was evaluated by simulations of the gluconic acid 
production process in a continuous culture of Aspergillus niger. The kinetics 
were considered as fully unknown and treated as time-varying parameters to 
be estimated online. The results of the stability and convergence analysis of 
the closed-loop system confirmed a good global performance. 
3.3. Iterative Learning Control  
ILC has been used to improve process performance from batch-to-batch. The 
basic idea of ILC is to update the control trajectory of the next run using the 
information from previous runs so that the output trajectory converges 
asymptotically to the desired reference trajectory (Lee and Lee, 2007). The 
parameter values used in the process model are updated at the end of the 
batch based on the progression of the previous runs and then an optimization 
is carried out to determine the new optimal policy for the next batch. This 
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strategy exhibits the limitations of open-loop control with respect to the current 
run, without feedback correction for disturbances, but generates useful data 
variability for optimizing subsequent runs (Srinivasan and Bonvin, 2007). 
Xiong et al. (Xiong et al., 2008) presented an ILC scheme based on a 
feed-forward ANN to gradually improve the endpoint product quality of 
fed-batch processes. The performance of the controller was illustrated on a 
simulated fed-batch ethanol fermentation process, where convergence to the 
desired product quality was achieved after six runs. In the Teixeira et al. 
(Teixeira et al., 2006) study, a methodology for fast bioprocess optimization 
employing iterative batch-to-batch dynamic programming was developed and 
applied to three simulation case studies widely reported in the literature. The 
relationship between process performance and control inputs was 
established by means of hybrid models combining parametric and 
nonparametric structures. The main features of this iterative procedure 
include the supervision of model reliability during the optimization step, crucial 
to increase the speed of convergence, and sampling schedule optimization 
to explore new input domains, minimizing overlapping measurements, 
thereby reducing experimental effort. 
3.4. Model Predictive Control  
In the control strategies described before, the desired output trajectory is 
given a priori. The control objective is to track the predetermined output 
trajectory by either one or repetitive cultures. Since the mathematical models 
used to support the optimization studies approximate the process behavior, 
the obtained output trajectories are suboptimal. Online optimizing control or 
MPC strategies represent a way to overcome this problem. 
In MPC, the control policy is obtained by solving online (at each sampling 
point) a finite horizon open-loop optimal control problem, using the current 
state of the process as the initial state (Henson, 1998). Upon the current 
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computation of the optimal trajectories, the values of the manipulated 
variables are updated. This procedure is repeated at each sampling point 
when direct or indirect measurements of the controlled variables are 
available. The objective of applying MPC is to keep pursuing the optimal 
state.  
MPC has been widely used in industrial applications as it can guarantee 
closed-loop stability. Its implementation is particularly well suited for slow 
response processes such as mammalian cultivations since the calculations 
are complex and time-consuming. If a nonlinear model is used, a nonlinear 
optimization problem needs to be solved at every time step. Nonlinear model 
predictive control (NLMPC) is computationally demanding and the solution of 
the optimization problem may not converge to global minima or it may take a 
long time to converge. This makes the online implementation of NLMPC a 
nontrivial task. The numerical solution of NLMPC optimal control problems is 
typically based on direct methods using Newton-type optimization schemes. 
Sommeregger and coworkers (Sommeregger et al., 2017) provide an 
overview of enabling technologies and current issues for the implementation 
of MPC in biopharmaceutical manufacturing. 
In the Frahm et al. (Frahm et al., 2003) study, a model-based controller was 
developed and applied to a fed-batch of NS0 cells expressing an antibody. 
Using this strategy, the performance of the process model could be improved 
by optimizing the model parameters when new data became available. The 
same control strategy was followed by our group (Teixeira et al., 2007) to 
control glucose and glutamine feeding rates over fed-batch cultures of BHK 
cells expressing a fusion antibody. In this case, a hybrid structure including 
knowledge from active metabolic pathways was employed to establish the 
relationship between state variables and process performance. 
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Soni and Parker (Soni and Parker, 2004) applied an MPC algorithm to 
fed-batch cultures of S. cerevisiae with the goal of re-optimizing the glucose 
feeding at each sampling time to maximize ethanol concentration at the end 
of the fermentation. Closed-loop MPC showed an equivalent performance to 
that of the open-loop strategy optimized offline, but simulation tests pointed 
to a better performance in the presence of disturbances. Saha et al. (Saha et 
al., 1999) developed an MPC strategy to control a continuous bioreactor at 
its optimum operating state employing a nonlinear model to describe the 
process. The efficiency of the proposed algorithm was demonstrated by 
simulating shifts in the optimum state as a response to changes in the 
maximum specific growth rate. The algorithm was able to track the optimum 
in the presence of measurement noise and allowed a considerable 
improvement in productivity. Zhu and coworkers (Zhu et al., 2000) employed 
a segregated unstructured model to describe oscillations that adversely 
affected the stability and productivity of a continuous culture of budding yeast. 
Then, a linear model obtained by linearizing and temporally discretizing the 
NL ordinary differential equation was used to develop MPC formulations, 
which were further evaluated via simulation. The best results were obtained 
when a subset of the cell number distribution is employed as the control 
variable. 
Using Raman spectroscopy to monitor glucose levels online, Craven et al. 
(Craven et al., 2014) implemented NLMPC for closed-loop control of the feed 
rate in a CHO fed-batch process. The bioprocess model used classical 
ordinary differential equations to describe cell growth, death and 
consumption/production of main metabolites, and provided the controller with 
an estimation of future changes in glucose consumption at each point. The 
strategy was implemented in a 15 L bioreactor with glucose concentration 
successfully maintained at a fixed set point. Aehle et al. (Aehle et al., 2012) 
used a similar kinetic model to control the growth rate of EPO-producing CHO 
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cultures to an optimum level known to lead to higher productivity and product 
quality. The growth rate was controlled indirectly by changing oxygen supply 
based on model predictions and OUR was calculated online from in- and 
off-gas composition. This approach demonstrated high batch-to-batch 
consistency in cell profiles, as well as product titer and quality. 
 
4. Concluding remarks 
The importance of process control to maintain an extracellular environment 
promoting cell growth and product synthesis is well recognized, in view of the 
extensive literature on the application of simple and advanced control 
strategies to biotechnological processes. However, few experimental 
applications have been reported using these strategies, most works reporting 
results on simulation studies. The lack of compelling published evidence of 
such algorithms significantly increasing bioprocess performance, together 
with higher implementation costs has hampered their widespread adoption 
by industry. 
Because advanced control strategies are usually based on a dynamic model 
of the process, the accuracy of the model is another key concern; it should 
properly describe the relationship between intracellular metabolic pathways 
and extracellular parameters, including all process aspects relevant to 
achieve the control objectives. First-principle models are preferred, although 
for many bioprocesses these not readily available. Purely data-driven models 
are a useful alternative when there is little process knowledge available and 
time/cost constraints, but they do not contribute much to process 
understanding and have limited generalizability. Consequently, there has 
been a considerable interest in developing hybrid models for process 
identification, combining first-principle knowledge with nonparametric 
functions, to describe the unknown parts of the process. Due to their inherent 
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capacity to mimic any nonlinear function after proper training, artificial neural 
networks (ANNs) have been used for a variety of applications in bioprocess 
control, including developing dynamic models, self-tuning controllers, and 
assisting batch-to-batch optimization. 
Choosing a control strategy for a specific process is a non-trivial task that 
must consider the process objective, sources of variation, availability of a 
process model and/or previous data, availability of reliable sensors for critical 
variables, as well as cost and development time considerations.  
The availability of monitoring techniques to reliably estimate key process 
variables is a hard constraint when developing a control strategy. Further 
advances in this area will also contribute to the increased industrial 
application of advanced process control in biotechnology. In this regard, the 
development of noninvasive methods based on in situ spectroscopic 
techniques has been an active area of research in recent years (Teixeira et 
al., 2009). These tools provide series of spectra from which online information 
on multiple key bioprocess and/or metabolic variables can be extracted using 
data-mining techniques. Once the potential of applying such techniques for 
process control is clearly demonstrated, they will progressively become 
routine at the industrial environment.  
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6. Glossary 
Open-loop control - The optimal trajectory is computed off-line and then 
implemented online. No feedback loop is employed, thus eventual deviations 
of the controlled variable from the desired value are not corrected. 
Closed-loop or feedback control - The controlled variable is measured, and 
its value is sent to the controller where it is compared with a desired value or 
set point. Then, the controller adjusts the manipulated variable as necessary 
to minimize the error.  
Feed-forward control - Detects disturbances in an input variable and applies 
corrective action to prevent or minimize impact on the process. Because 
process outputs are not measured, this cannot correct for disturbances in the 
process itself.  
Inferential or indirect control - Uses easy to measure process variables to 
infer variables that are more difficult to measure.  
Adaptive control - A class of control algorithms that deal with system 
uncertainties by continuously adapting the control law to compensate for 
those uncertainties.  
Model predictive control - A class of control algorithms that apply an explicit 
model of the process to predict the future response of the process. At each 
sampling instant, the future process behavior is optimized by computing a 
sequence of adjustments to the manipulated variable.  
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1. General discussion 
Gene therapies are now finding their path into the clinic and the market, as 
confirmed by the 454 clinical trials currently active (clinicaltrials.gov, 
accessed on February 2019) and the recent increase in product approvals. 
Although substantially improving the life of patients suffering from devastating 
diseases, gene therapy product manufacturing is complex and costly, 
translating into a high selling cost, and starting the debate on the 
reimbursement strategies. Zolgensma, an rAAV-based gene therapy, is 
currently the most expensive drug in the world, with an one-time 
administration price tag of €1.92 M (Shahryari et al., 2019). At the current rate 
of Investigational New Drug (IND) applications submitted to the FDA (1000 in 
2019), it is projected that 70-90 gene therapy products will be approved by 
2025 (Puri, 2019) and that the demand for viral vector manufacturing will 
exceed the contract manufacturing organization capacity by March 2020 
(Rininger et al., 2019). As such, it is paramount to increase the production 
titers and decrease the manufacturing costs of the current manufacturing 
systems.  
AAV-derived vectors are one of the most commonly used gene therapy 
vectors, mainly targeting monogenic diseases. In the specific case of rAAV 
production, strategies for increasing the vector yield include the development 
of high productive cell lines (Martin et al., 2013), production process 
improvements (Aucoin et al., 2007; Joshi et al., 2019; Mena et al., 2010) and 
increasing rAAV recovery yields in the downstream process (Qu et al., 2015).  
This PhD aimed at contributing for the decrease of gene therapy 
manufacturing costs. First, by assessing applicability of different real-time 
monitoring techniques for prediction of important process variables for the 
insect cell-baculovirus system, including the prediction of rAAV titers; second, 
by increasing process understanding in this system, by elucidating possible 
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rAAV production pathways (Chapter II, fluorescence spectroscopy) and 
rAAV-associated cell attributes (Chapter III, digital holographic microscopy 
and Chapter IV, dielectric spectroscopy) and supporting the decision on the 
optimal harvest time according to the intra and extracellular rAAV profiles. 
The major achievements obtained for each chapter are depicted in Figure 
VI.1. 
The first step for this PhD was the implementation of the rAAV production 
process, with the assessment of the optimal infection and harvest conditions 
and the establishment of the analytical methodologies for rAAV quantification. 
Only with this process knowledge the implementation of real-time monitoring 
tools of Chapters II-IV could be studied.  
Implementation of real-time monitoring tools in the biopharmaceutical 
manufacturing processes is one of the main drives of the Process Analytical 
Technology (PAT) initiative, but its application is still lagging behind the 
chemical industry (Guerra et al., 2019). In particular, for recombinant viral 
vector production processes, application of real-time monitoring tools is still 
limited to few works (Grein et al., 2018; Negrete et al., 2007; Petiot et al., 
2016). However, these publications do not explore the predictive model 
generation, being mainly based in correlations between the monitored signals 
and the viral production phases. The ability to clearly identify the onset of 
rAAV production and the rAAV titer during the culture is critical to identify the 
best harvest time and predict the batch productivity even before its end. 
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Figure VI.1 - Schematic representation of the work developed in this thesis. Each pillar 
represents the main achievements for each real-time monitoring chapter, culminating in the 
generation of predictive models for rAAV titer, viable cell concentration and viability. Online 
control strategies are the next step towards implementation of PAT systems for viral vector 
monitoring and control. rAAV – recombinant adeno-associated virus; IC-BEVS - Insect 
cell - baculovirus expression vector system; ANN – Artificial neural networks.  
 
1.1. Comparison of real-time monitoring strategies  
The suitability of three real-time monitoring tools for the IC-BEVS was 
assessed: fluorescence spectroscopy (Chapter II), digital differential 
holographic microscopy (Chapter III) and dielectric spectroscopy (Chapter 
IV). For each technique, predictive models for cell concentration, viability, 
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extracellular rAAV titer and intracellular specific rAAV titer were developed, 
either based on direct or indirect (soft sensor) measurements.  
Fluorescence spectroscopy detects the fluorescent compounds present in the 
media or incorporated into the cells or recombinant product. These 
fluorescent compounds are mostly metabolic-related: amino acids, metabolic 
co-factors and vitamins (Teixeira et al., 2009). In Chapter II, we identified 
fluorescence regions corresponding to NAD(P)H, riboflavin, tryptophan and 
tyrosine as being possibly correlated with metabolic pathways for rAAV 
production or amino acid incorporation into viral particles. To further elucidate 
the metabolic pathways relevant for rAAV production, fluorescence 
spectroscopy can be combined with deeper metabolic studies, using carbon 
tracers and metabolic flux analysis. Importantly, the influence of the 
baculovirus in infected cell metabolism, extensively studied by our group 
(Bernal et al., 2009; Carinhas et al., 2010; Monteiro et al., 2016, 2014), needs 
to be considered in the experimental design to decouple metabolic signatures 
from rAAV production from the ones caused by baculovirus replication. 
Although direct detection of cell and product concentration is possible, for 
bioprocessing monitoring most authors use fluorescence spectroscopy as a 
soft sensor, relying in chemometric analysis for correlating fluorescence 
spectra dynamics with the critical process variables (Bayer et al., 2019; 
Chopda et al., 2017; Faassen and Hitzmann, 2015; Kroll et al., 2017; Zabadaj 
et al., 2017). Consequently, the choice and application of the right spectra 
pre-treatment is critical (Glassey, 2013), as demonstrated in Chapter II.  
Digital differential holographic microscopy (Chapter III) relies on cell 
detection and quantification, followed by calculation of the light phase 
characteristics for every cell. These quantitative parameters can then be 
correlated with the desired critical process variables and product 
characteristics using data analysis techniques. Compared with traditional soft 
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sensors, DDHM models have the advantage of providing important biologic 
insights regarding the changes induced by the recombinant product 
formation. However, in contrast with spectroscopic techniques, DHM does not 
allow metabolite quantification, and consequently it cannot be used to find 
metabolic correlations. 
Dielectric spectroscopy (Chapter IV) is the technique explored in this thesis 
that provides more information regarding the cell physiological state, although 
with less interpretability than DDHM. The main advantage of the probe used 
is the ability to measure permittivity at 18 different frequencies, which can be 
used to calculate the beta-dispersion curve parameters and infer information 
regarding the cell state throughout the infection process. 
Throughout the thesis we demonstrate that the techniques utilized in each 
chapter can work independently as a PAT tool. Still, combination of at least 
two probes would significantly increase the process information obtained and 
improve the model-prediction capabilities, as well as reducing the 
pre-processing and modeling necessary. Since viral vector production 
induces metabolic and physiological alterations in the producer cells 
(Monteiro et al., 2012), a good two-probe approach should combine these two 
types of information. Metabolic insights could be obtained using fluorescence, 
Raman or MIR/NIR, while digital holographic microscopy or dielectric 
spectroscopy could provide the information regarding the cell physiological 
state. This is even more useful if metabolic or cell-related viral-induced 
changes are known, such as the high alanine secretion of infected Sf9 cells 
(Bernal et al., 2009) or the increase of the cell diameter upon baculovirus 
infection (Palomares et al., 2001).  
When calibrating prediction models for real-time monitoring, one important 
consideration is the choice of the calibration dataset. The experiment design 
space needs to include a considerable distribution of the range of the process 
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variables, to assure variations in the process variable and product attribute 
can be detected using the real-time monitoring tool. This was done in Chapter 
II by building a dataset with fluorescence data from two spectrofluorometers 
and from bioreactors infected at different MOIs; in Chapter III using one 
infected and one uninfected batch; and in Chapter IV with the addition of 
perturbation batches to decouple physiological parameters associated with 
rAAV production from the ones associated with baculovirus infection or cell 
growth. 
The predictive power of the data-driven models developed in this thesis can 
be improved by adding data from the process controllers, since the controller 
inputs and outputs are recorded throughout the culture. This improvement in 
model predictions by adding process data such as accumulated added 
compounds, temperature data or total inlet air is demonstrated in other works 
(Bayer et al., 2019; Guerra et al., 2019). In the case of the insect 
cell-baculovirus system, in which the O2 uptake increases significantly during 
baculovirus infection, oxygen uptake rate calculations have been applied for 
process improvement (Hidalgo et al., 2017; Kioukia et al., 1995; Lecina et al., 
2006). Finally, the available biological process knowledge, such as rAAV 
metabolic requirements or degradation kinetics can be combined with the 
real-time probe outputs to yield hybrid models with improved prediction 
accuracy (Bayer et al., 2019; von Stosch et al., 2016). 
1.2. Manufacturing challenges for rAAV production in the insect cell 
system 
In rAAV manufacturing, the critical quality attributes more important are the 
vector transducing potential and the ratio of empty to full capsids (Merten, 
2016). This is especially relevant in the IC-BEVS, with low vector infectivity 
being the most important issue reported (Kondratov et al., 2017; Le et al., 
2019; Merten, 2016; Wang et al., 2011). The low infectivity is mostly due to 
the release of intracellular proteases upon baculovirus-induced cell lysis 
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(Berry and Asokan, 2017; Horowitz et al., 2013; Nam et al., 2011; Rayaprolu 
et al., 2013) and due to pH alterations during the manufacturing and 
purification process (Mitchell and Samulski, 2013; Salganik et al., 2012), 
which can affect rAAV specific domains. Recombinant AAV infectivity is 
mostly related with the phospholipase A2 domain in the VP1 N-terminus 
(Brown et al., 2017; Galibert and Merten, 2011; Kondratov et al., 2017). 
Online monitoring of the highly variable and process dependent quality 
characteristics of these vectors is one of the challenges ahead for the field. 
One possible approach is to find surrogate markers that correlate well with 
the desired quality characteristics, an approach that would even deepen the 
interplay between vector quality and the measured surrogate (Zhang et al., 
2015). Consequently, the phospholipase A2 domain could work as the 
surrogate marker for detecting rAAV infectivity, for instance by fusing a 
fluorescence marker to the VP1 protein, similar to the SpyTag approach 
(Hatlem et al., 2019), and using fluorescence spectroscopy to measure the 
presence of those proteins during culture time. A similar approach has 
already been used for monitoring intracellular AAV trafficking (Zhang et al., 
2018). 
The empty to full rAAV particle ratio is dependent on the expression system 
(Merten and Gaillet, 2016) and it can be affected by process conditions, such 
as temperature modulation after infection (Aucoin et al., 2007). To monitor 
this CQA, DHM would probably be the chosen technique. A possible strategy 
is to build a dataset consisting of reactors infected only with repcap 
baculovirus and reactors infected with the dual baculovirus strategy, together 
with blend batches as exemplified in Chapter IV. This approach can be 
further explored by adding to the dataset bioreactor runs using other 
production systems known by their high full particle ratio, as the herpes 
simplex production system (Merten and Gaillet, 2016). After identification of 
the relevant attributes, it would be interesting to assess how those attributes 
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would change for other production systems, rAAV serotypes or packaged 
transgenes. 
The quality of rAAV vectors is a highly debatable concern in the industry. 
Although the titer of infectious vectors is universally accepted as a critical 
quality attribute, the mindset towards the presence of empty capsids in the 
final product is switching. Initially, the presence of empty capsids was 
considered detrimental, due to their possible immunogenic potential (Wright, 
2014; Schnödt and Büning, 2017) and evidence of reduced inflammation 
when total capsid content was reduced by empty capsid removal (Timmers 
et al., 2019). However, some authors consider the presence of empty capsids 
as desirable, since empty capsids may work as a decoy for the presence of 
rAAV neutralizing antibodies in the patient (Flotte, 2017; Wright, 2014; 
Mingozzi and High, 2013). Moreover, the administration route and site also 
has relevance when deciding the presence of empty capsids or not, since 
immune privileged sites such as the retina benefit from an increase in 
genome-containing particles, while systemic administration may benefit from 
the presence of empty capsids (Flotte, 2017). As such, after identification of 
the process parameters affecting the empty to full ratio, we envision rAAV 
production processes to tailor the ratio of full and empty capsids as desired, 
through the implementation of real-time monitoring and control systems. 
Still, more importantly than the discussion over rAAV quality is the ability to 
detect such quality attributes. The lack of standardized methods in academia 
and industry is a concern, which led to a consortium taking action to develop 
rAAV reference standard materials (Ayuso et al., 2014; Lock et al., 2010; 
Penaud-Budloo et al., 2019). The physical and biological properties of the 
reference material were measured in different labs using standardized 
protocols, but the standard deviation of the measured quality characteristics 
among the different lab consortiums clearly shows the lack of standardization 
in this field.  
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As such, the development of real-time monitoring methods to track rAAV 
quality characteristics is hindered not only because of the difficulty and 
time-consuming nature of the current quality characterization methods, but 
also because of the lack of standardization, which may prevent models 
developed in one lab to be used in another lab. Still, we strongly believe on 
the potential for monitoring rAAV quality attributes of some of the approaches 
developed in this thesis, in particular DHM (Chapter III), as referred above. 
Real-time monitoring of the infectious vectors is, to the best of our knowledge, 
the more challenging approach, also because rAAV potency is largely 
dependent on the cell type and rAAV serotype used (Ellis et al., 2013) and 
the “definition” of potency is dependent on the therapeutic application and 
mechanism of action (protein expression or gene knockdown).  
Another concern on the use of the IC-BEVS for rAAV production is the fact 
that baculovirus induces cell growth arrest and ultimately cell apoptosis, and 
consequently rAAV production is limited in time. Strategies to prevent 
generation of contaminating baculovirus virions (Marek et al., 2017) or 
increase the time viable insect cells are expressing the recombinant product 
(Fath-goodin et al., 2009; Steele et al., 2017; Weidner et al., 2017) are a 
possible way to increase the rAAV-production time of insect cells, while 
keeping the high volumetric productivities achieved with this system.  
In line with the PAT initiative, after establishing tools for real-time monitoring 
of rAAV quality attributes, the implementation of real-time control systems for 
keeping the CQAs in the desired range would follow. Although there are 
feeding schemes that increase the viral vector production titers (Carinhas et 
al., 2010; Huang et al., 2014; Lee et al., 2003; Liu et al., 2010; Mena et al., 
2010; Monteiro et al., 2016), a de facto control mechanism that would act 
upon the process when the viral titers detour from the desired profile is, to our 
knowledge, not available. However, when therapeutic monoclonal antibody 
research started, the scientific community was far from imagining that it would 
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be possible to tailor the glycosylation profile of the produced antibodies 
(reviewed in Sha et al., 2016). With the current rAAV research focused on 
understanding metabolic and process limitations to increase rAAV titers, it is 
certain that AAV future use as gene therapy vector is “bright and impacting” 
(Hastie and Samulski, 2015). 
 
2. Contributions to the field and future directions 
This PhD thesis main contribution is to the field of bioprocess engineering, 
with the development and implementation of real-time monitoring tools for 
rAAV production in the insect cell system, and the data analysis and modeling 
tools used. The genetic algorithm-based “toolbox” for fluorescence spectra 
pre-processing presented in Chapter II can be applied to any spectroscopic 
technique, by adjusting the available pre-processing and multivariate data 
analysis methods. This is critical since spectroscopic tools always require 
spectra pre-processing before data analysis, and the spectra pre-processing 
step has a strong influence in the final data analysis interpretation and model 
development (Bayer et al., 2019; Glassey, 2013). Additionally, we 
demonstrated the applicability of stepwise forward/backward attribute 
selection combined with multiple linear regression as a simple yet powerful 
way to develop interpretable and robust predictive models (Chapters III and 
IV). 
The tools and strategies developed in this thesis were developed with the aim 
of being as universal as possible and can be applied to other 
biopharmaceuticals produced in the IC-BEVS, such as virus-like particles and 
vaccines, and possibly to other viral vector production systems as well. 
Specifically, the methods developed can be readily applied for following the 
baculovirus infection progress. Although in low MOI infections multiple 
baculovirus replication cycles take place, with consequent several phases of 
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baculovirus entry and release from the host cells, in general the progress of 
baculovirus infection can be estimated through the increase in the mean cell 
diameter of the population. This was briefly addressed in Chapter IV, relying 
on the correlation between culture permittivity and cell biovolume, and it is 
reported in other works using either dielectric spectroscopy (Ansorge et al., 
2007; Negrete et al., 2007; Petiot et al., 2016; Zeiser et al., 2000, 1999) and 
imaging microscopy (Janakiraman et al., 2006; Laasfeld et al., 2017; 
Palomares et al., 2001).  
The other main contribution of this thesis is the improvement of the 
understanding of rAAV production kinetics. In all chapters, intracellular rAAV 
titer was quantified and the rAAV production kinetics described. This 
knowledge is important in order to improve the production process by 
determining the time when intracellular rAAV concentration is maximized. 
Moreover, the identification of possibly rAAV-related signals is translational 
to other AAV research topics. These signals include the DDHM attribute 
known as “phase skewness” (Chapter III) or the fluorescence region between 
270-300 nm excitation and 310-370 nm emission (Chapter II), validated in 
the work of Fu and coworkers (Fu et al., 2019). 
The work developed in this thesis, in particular the models for viable cell 
concentration, viability and the “process-to-target” script, can be used for 
developing predictive models of infection timing and harvest and feed starting 
times, as well as to develop feedback control mechanisms to keep the cell 
concentration and viability at the desired setpoints. Once other process 
parameters impacting rAAV quality attributes are known, the same models 
can be used to develop feedback control mechanisms to keep the desired 
product profile and minimize the global production costs.  
Overall, this thesis will contribute to the advance of Process Analytical 
Technology implementation in the IC-BEVS.  
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